PharmGKB ID	Name	Source	Biomarker Flag	Testing Level	Has Prescribing Info	Has Dosing Info	Has Alternate Drug	Has Other Prescribing Guidance	Cancer Genome	Prescribing	Chemicals	Genes	Variants/Haplotypes	Latest History Date (YYYY-MM-DD)
PA166269401	Annotation of EMA Label for nateglinide and CYP2C9	EMA									nateglinide	CYP2C9		2023-11-21
PA166269701	Annotation of EMA Label for glycerol phenylbutyrate and ARG1, ASL, ASS1, CPS1, OTC	EMA		Testing Required							glycerol phenylbutyrate	ARG1; ASL; ASS1; CPS1; OTC		2024-08-07
PA166340141	Annotation of HCSC Label for amphetamine and CYP2D6	HCSC		Informative PGx							amphetamine	CYP2D6		2025-03-23
PA166273281	Annotation of EMA Label for nusinersen and SMN2	EMA									nusinersen	SMN2		2023-08-17
PA166273261	Annotation of EMA Label for ospemifene and CYP2B6, CYP2C9	EMA									ospemifene	CYP2B6; CYP2C9		2024-12-13
PA166271261	Annotation of EMA Label for tegafur / gimeracil / oteracil and DPYD	EMA		Testing Recommended	Prescribing Info		Alternate Drug			Prescribing	tegafur / gimeracil / oteracil	DPYD	DPYD c.1129-5923C>G, c.1236G>A (HapB3); DPYD c.1679T>G (*13); DPYD c.1905+1G>A (*2A); DPYD c.2846A>T	
PA166273521	Annotation of EMA Label for ipilimumab and ALK, CD274, EGFR	EMA		Testing Required					Cancer Genome		ipilimumab	ALK; CD274; EGFR		2025-01-09
PA166273501	Annotation of EMA Label for ipilimumab and HLA-A	EMA		No Clinical PGx							ipilimumab	HLA-A	HLA-A*02:01	2025-01-09
PA166273423	Annotation of EMA Label for lutetium (177Lu) dotatate and SSTR1, SSTR2, SSTR3, SSTR4, SSTR5	EMA		Testing Required					Cancer Genome		lutetium (177Lu) dotatate	SSTR1; SSTR2; SSTR3; SSTR4; SSTR5		2024-08-08
PA166272241	Annotation of HCSC Label for upadacitinib and CYP2D6	HCSC		No Clinical PGx							upadacitinib	CYP2D6		
PA166272321	Annotation of HCSC Label for tipiracil / trifluridine and ERBB2, KRAS	HCSC							Cancer Genome		tipiracil / trifluridine	ERBB2; KRAS		2023-08-27
PA166271361	Annotation of HCSC Label for capmatinib and MET	HCSC		Testing Required					Cancer Genome		capmatinib	MET		2024-04-16
PA166272581	Annotation of HCSC Label for sotorasib and KRAS	HCSC		Testing Required					Cancer Genome		sotorasib	KRAS	rs121913530	2024-08-13
PA166272601	Annotation of EMA Label for sotorasib and KRAS	EMA		Testing Required					Cancer Genome		sotorasib	KRAS	rs121913530	2024-08-13
PA166271481	Annotation of HCSC Label for escitalopram and CYP2C19	HCSC		Actionable PGx	Prescribing Info	Dosing Info				Prescribing	escitalopram	CYP2C19		2024-08-14
PA166184114	Annotation of Swissmedic Label for capecitabine and DPYD	Swissmedic		Actionable PGx	Prescribing Info	Dosing Info	Alternate Drug			Prescribing	capecitabine	DPYD		2023-02-28
PA166184117	Annotation of Swissmedic Label for carbasalate calcium and G6PD	Swissmedic		Actionable PGx							carbasalate calcium	G6PD		2022-09-30
PA166184126	Annotation of Swissmedic Label for codeine and CYP2D6	Swissmedic		Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	codeine	CYP2D6		
PA166184405	Annotation of Swissmedic Label for brexpiprazole and CYP2D6	Swissmedic		Actionable PGx	Prescribing Info	Dosing Info				Prescribing	brexpiprazole	CYP2D6		
PA166184116	Annotation of Swissmedic Label for carbamazepine and HLA-B	Swissmedic		Testing Required	Prescribing Info		Alternate Drug			Prescribing	carbamazepine	HLA-B	HLA-B*15:02	2023-02-28
PA166272701	Annotation of EMA Label for rimegepant and CYP2C9	EMA		No Clinical PGx							rimegepant	CYP2C9		2023-08-24
PA166272721	Annotation of EMA Label for risdiplam and SMN1, SMN2	EMA		Testing Required							risdiplam	SMN1; SMN2		2024-08-13
PA166271541	Annotation of EMA Label for sacituzumab govitecan and UGT1A1	EMA		Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	sacituzumab govitecan	UGT1A1	UGT1A1*28	2024-08-13
PA166184506	Annotation of Swissmedic Label for dolutegravir / abacavir / lamivudine and HLA-B	Swissmedic		Testing Required	Prescribing Info					Prescribing	dolutegravir / abacavir / lamivudine	HLA-B	HLA-B*57:01	2023-02-28
PA166184122	Annotation of Swissmedic Label for ciprofloxacin and G6PD	Swissmedic		Actionable PGx							ciprofloxacin	G6PD		
PA166184124	Annotation of Swissmedic Label for clomipramine and CYP2D6	Swissmedic		Actionable PGx							clomipramine	CYP2D6		
PA166184133	Annotation of Swissmedic Label for dexlansoprazole and CYP2C19	Swissmedic		Actionable PGx							dexlansoprazole	CYP2C19		
PA166184134	Annotation of Swissmedic Label for dextromethorphan and CYP2D6	Swissmedic		Actionable PGx							dextromethorphan	CYP2D6		
PA166184442	Annotation of Swissmedic Label for duloxetine and CYP2D6	Swissmedic		Actionable PGx							duloxetine	CYP2D6		
PA166184449	Annotation of Swissmedic Label for flucytosine and DPYD	Swissmedic		Testing Recommended							flucytosine	DPYD		
PA166183786	Annotation of Swissmedic Label for amlodipine / atorvastatin / perindopril arginine and G6PD, SLCO1B1	Swissmedic		Actionable PGx							amlodipine / atorvastatin / perindopril arginine	G6PD; SLCO1B1	rs4149056	
PA166274002	Annotation of HCSC Label for blinatumomab and ABL1, BCR	HCSC							Cancer Genome		blinatumomab	ABL1; BCR		2024-10-02
PA166271561	Annotation of HCSC Label for sacituzumab govitecan and UGT1A1	HCSC		Actionable PGx	Prescribing Info		Alternate Drug	Other Prescribing Guidance		Prescribing	sacituzumab govitecan	UGT1A1	UGT1A1*28	2024-08-13
PA166272781	Annotation of EMA Label for selpercatinib and RET	EMA		Testing Required					Cancer Genome		selpercatinib	RET		2024-08-13
PA166272801	Annotation of EMA Label for setmelanotide and LEPR, PCSK1, POMC	EMA		Testing Required							setmelanotide	LEPR; PCSK1; POMC		2024-08-13
PA166272821	Annotation of EMA Label for siponimod and CYP2C9	EMA		Testing Required	Prescribing Info	Dosing Info	Alternate Drug			Prescribing	siponimod	CYP2C9	CYP2C9*1; CYP2C9*11; CYP2C9*2; CYP2C9*3; CYP2C9*5; CYP2C9*6; CYP2C9*8	2024-09-17
PA166272841	Annotation of EMA Label for sodium oxybate and ALDH5A1	EMA		Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	sodium oxybate	ALDH5A1		2024-08-14
PA166273101	Annotation of EMA Label for pitolisant and CYP2D6	EMA		Actionable PGx	Prescribing Info	Dosing Info				Prescribing	pitolisant	CYP2D6		
PA166278442	Annotation of HCSC Label for cemiplimab-rwlc and ALK, CD274, EGFR, ROS1	HCSC		Testing Required					Cancer Genome		cemiplimab-rwlc	ALK; CD274; EGFR; ROS1		2024-04-16
PA166278601	Annotation of HCSC Label for selpercatinib and RET	HCSC		Testing Required					Cancer Genome		selpercatinib	RET		2024-08-13
PA166184157	Annotation of Swissmedic Label for ofloxacin and G6PD	Swissmedic		Actionable PGx	Prescribing Info					Prescribing	ofloxacin	G6PD		2023-02-28
PA166184173	Annotation of Swissmedic Label for oxcarbazepine and HLA-B	Swissmedic		Testing Required	Prescribing Info		Alternate Drug			Prescribing	oxcarbazepine	HLA-B	HLA-B*15:02	2023-02-28
PA166184120	Annotation of Swissmedic Label for quinine and G6PD	Swissmedic		Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	quinine	G6PD		2023-02-28
PA166184403	Annotation of Swissmedic Label for rasburicase and G6PD	Swissmedic		Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	rasburicase	G6PD		2023-02-28
PA166184450	Annotation of Swissmedic Label for fluorouracil and DPYD	Swissmedic		Testing Required							fluorouracil	DPYD		
PA166184452	Annotation of Swissmedic Label for fluoxetine and CYP2D6	Swissmedic		Informative PGx							fluoxetine	CYP2D6		
PA166184461	Annotation of Swissmedic Label for hydroxychloroquine and G6PD	Swissmedic		Actionable PGx							hydroxychloroquine	G6PD		
PA166183900	Annotation of Swissmedic Label for moclobemide and CYP2C19	Swissmedic		Actionable PGx							moclobemide	CYP2C19		
PA166183910	Annotation of Swissmedic Label for nebivolol and CYP2D6	Swissmedic		Informative PGx							nebivolol	CYP2D6		
PA166184221	Annotation of Swissmedic Label for palonosetron and CYP2D6	Swissmedic		Informative PGx							palonosetron	CYP2D6		
PA166184268	Annotation of Swissmedic Label for pazopanib and HLA-B	Swissmedic		Actionable PGx							pazopanib	HLA-B	HLA-B*15:02	
PA166184395	Annotation of Swissmedic Label for propafenone and CYP2D6	Swissmedic		Actionable PGx							propafenone	CYP2D6		
PA166184388	Annotation of Swissmedic Label for losartan and CYP2C9, CYP3A4	Swissmedic		Actionable PGx							losartan	CYP2C9; CYP3A4		
PA166184390	Annotation of Swissmedic Label for sulfamethoxazole / trimethoprim and G6PD	Swissmedic		Actionable PGx							sulfamethoxazole / trimethoprim	G6PD		
PA166281081	Annotation of EMA Label for eculizumab and AQP4, CHRNA1, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNB1, CHRNE	EMA									eculizumab	AQP4; CHRNA1; CHRNA3; CHRNA4; CHRNA5; CHRNA6; CHRNA7; CHRNB1; CHRNE		2023-09-28
PA166129525	Annotation of HCSC Label for carglumic acid and NAGS	HCSC									carglumic acid	NAGS		2024-08-05
PA166129527	Annotation of HCSC Label for ponatinib and ABL1, BCR	HCSC		Testing Required					Cancer Genome		ponatinib	ABL1; BCR		2024-09-17
PA166129526	Annotation of HCSC Label for ceritinib and ALK	HCSC		Testing Required					Cancer Genome		ceritinib	ALK		2024-12-02
PA166329401	Annotation of HCSC Label for zilucoplan and CHRNA1, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNB1, CHRNE	HCSC									zilucoplan	CHRNA1; CHRNA3; CHRNA4; CHRNA5; CHRNA6; CHRNA7; CHRNB1; CHRNE		2025-04-08
PA166396961	Annotation of HCSC Label for chloroprocaine and BCHE	HCSC		Informative PGx							chloroprocaine	BCHE		
PA166281722	Annotation of HCSC Label for pralsetinib and RET	HCSC		Testing Required					Cancer Genome		pralsetinib	RET	rs74799832; rs77709286	2024-08-13
PA166281761	Annotation of HCSC Label for paliperidone and CYP2D6	HCSC		No Clinical PGx							paliperidone	CYP2D6		2024-12-04
PA166283221	Annotation of HCSC Label for lumasiran and AGXT	HCSC									lumasiran	AGXT		2024-08-08
PA166284541	Annotation of EMA Label for encorafenib and HRAS, KRAS, NRAS	EMA		Actionable PGx	Prescribing Info		Alternate Drug	Other Prescribing Guidance	Cancer Genome	Prescribing	encorafenib	HRAS; KRAS; NRAS		2024-08-14
PA166283241	Annotation of HCSC Label for lenvatinib	HCSC		Testing Required					Cancer Genome		lenvatinib			2024-09-12
PA166397721	Annotation of FDA Label for relugolix / estradiol / norethindrone acetate and F5, PROC, PROS1, SERPINC1	FDA		Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	relugolix / estradiol / norethindrone acetate	F5; PROC; PROS1; SERPINC1	rs6025	
PA166284681	Annotation of EMA Label for pembrolizumab and BRAF	EMA							Cancer Genome		pembrolizumab	BRAF	rs113488022	2023-11-21
PA166283161	Annotation of HCSC Label for niraparib and BRCA1, BRCA2	HCSC		Informative PGx					Cancer Genome		niraparib	BRCA1; BRCA2		2024-07-24
PA166397701	Annotation of HCSC Label for relugolix / estradiol / norethindrone acetate and F5, PROC, PROS1, SERPINC1	HCSC		Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	relugolix / estradiol / norethindrone acetate	F5; PROC; PROS1; SERPINC1	rs6025	
PA166284761	Annotation of HCSC Label for cabotegravir / rilpivirine and UGT1A1	HCSC		No Clinical PGx							cabotegravir / rilpivirine	UGT1A1		2023-08-14
PA166398041	Annotation of HCSC Label for cariprazine and CYP2D6	HCSC		No Clinical PGx							cariprazine	CYP2D6		
PA166284241	Annotation of HCSC Label for fosphenytoin and HLA-B	HCSC		Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	fosphenytoin	HLA-B	HLA-B*15:02	2024-08-14
PA166224081	Annotation of HCSC Label for oxcarbazepine and HLA-A	HCSC		Informative PGx							oxcarbazepine	HLA-A	HLA-A*31:01	2024-07-26
PA166284561	Annotation of HCSC Label for encorafenib and HRAS, KRAS, NRAS	HCSC		Actionable PGx	Prescribing Info		Alternate Drug	Other Prescribing Guidance	Cancer Genome	Prescribing	encorafenib	HRAS; KRAS; NRAS		2024-08-14
PA166283802	Annotation of HCSC Label for givosiran and CPOX, HMBS, PPOX	HCSC									givosiran	CPOX; HMBS; PPOX		2024-12-12
PA166272361	Annotation of HCSC Label for tafamidis and TTR	HCSC									tafamidis	TTR		2023-08-24
PA166278561	Annotation of HCSC Label for sodium oxybate and ALDH5A1	HCSC		Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	sodium oxybate	ALDH5A1		2024-07-21
PA166284721	Annotation of HCSC Label for nivolumab and ALK, CD274, EGFR, ERBB2	HCSC		Testing Required					Cancer Genome		nivolumab	ALK; CD274; EGFR; ERBB2		2024-08-09
PA166283821	Annotation of HCSC Label for ipilimumab and ALK, CD274, EGFR	HCSC		Testing Required					Cancer Genome		ipilimumab	ALK; CD274; EGFR		2025-01-09
PA166272341	Annotation of HCSC Label for tepotinib and MET	HCSC		Testing Required					Cancer Genome		tepotinib	MET		2024-08-14
PA166273302	Annotation of EMA Label for nivolumab and BRAF	EMA							Cancer Genome		nivolumab	BRAF	rs113488022	2023-08-17
PA166281741	Annotation of HCSC Label for pitolisant and CYP2D6	HCSC		Actionable PGx	Prescribing Info	Dosing Info		Other Prescribing Guidance		Prescribing	pitolisant	CYP2D6		2024-09-19
PA166283961	Annotation of EMA Label for fosdenopterin and MOCS1	EMA		Testing Required							fosdenopterin	MOCS1		2024-08-06
PA166283941	Annotation of EMA Label for trastuzumab deruxtecan and ERBB2	EMA		Testing Required					Cancer Genome		trastuzumab deruxtecan	ERBB2		2024-08-05
PA166273481	Annotation of EMA Label for isatuximab and CD38	EMA							Cancer Genome		isatuximab	CD38		2023-08-18
PA166283981	Annotation of EMA Label for evinacumab and LDLR	EMA									evinacumab	LDLR		2024-08-20
PA166284001	Annotation of EMA Label for enfortumab vedotin and NECTIN4	EMA							Cancer Genome		enfortumab vedotin	NECTIN4		2023-11-21
PA166284021	Annotation of HCSC Label for enfortumab vedotin and NECTIN4	HCSC							Cancer Genome		enfortumab vedotin	NECTIN4		2024-12-12
PA166277761	Annotation of FDA Label for tebentafusp and HLA-A	FDA	On FDA Biomarker List	Testing Required							tebentafusp	HLA-A	HLA-A*02:01	2023-08-21
PA166229941	Annotation of HCSC Label for atezolizumab and ALK, CD274, EGFR	HCSC		Testing Required					Cancer Genome		atezolizumab	ALK; CD274; EGFR		2024-04-15
PA166272641	Annotation of EMA Label for tepotinib and MET	EMA		Testing Required					Cancer Genome		tepotinib	MET		2024-08-14
PA166284062	Annotation of HCSC Label for entrectinib and NTRK1, NTRK2, NTRK3, ROS1	HCSC		Testing Required					Cancer Genome		entrectinib	NTRK1; NTRK2; NTRK3; ROS1		2024-09-10
PA166284261	Annotation of HCSC Label for fosphenytoin and CYP2C9	HCSC		Informative PGx							fosphenytoin	CYP2C9		2024-12-02
PA166278202	Annotation of EMA Label for azacitidine and KRAS, NRAS, PTPN11	EMA							Cancer Genome		azacitidine	KRAS; NRAS; PTPN11		2023-08-14
PA166229921	Annotation of HCSC Label for amifampridine and NAT2	HCSC		Actionable PGx	Prescribing Info	Dosing Info				Prescribing	amifampridine	NAT2		
PA166283901	Annotation of HCSC Label for inclisiran and APOB, LDLR, PCSK9	HCSC									inclisiran	APOB; LDLR; PCSK9		2024-07-23
PA166273462	Annotation of EMA Label for lenvatinib	EMA							Cancer Genome		lenvatinib			2023-08-18
PA166184172	Annotation of Swissmedic Label for Opium derivatives and expectorants and CYP2D6	Swissmedic		Actionable PGx							Opium derivatives and expectorants	CYP2D6		
PA166184112	Annotation of Swissmedic Label for azathioprine and NUDT15, TPMT	Swissmedic		Actionable PGx	Prescribing Info	Dosing Info				Prescribing	azathioprine	NUDT15; TPMT		
PA166184125	Annotation of Swissmedic Label for clopidogrel and CYP2C19	Swissmedic		Actionable PGx	Prescribing Info	Dosing Info				Prescribing	clopidogrel	CYP2C19	CYP2C19*1; CYP2C19*2; CYP2C19*3; CYP2C19*4; CYP2C19*5; CYP2C19*6; CYP2C19*7; CYP2C19*8	2019-11-05
PA166182948	Annotation of EMA Label for encorafenib and BRAF	EMA		Testing Required					Cancer Genome		encorafenib	BRAF	rs113488022	2024-04-16
PA166182952	Annotation of EMA Label for irinotecan and UGT1A1	EMA		Actionable PGx	Prescribing Info	Dosing Info				Prescribing	irinotecan	UGT1A1	UGT1A1*28	2024-05-31
PA166183181	Annotation of EMA Label for lesinurad and CYP2C9	EMA		Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	lesinurad	CYP2C9	CYP2C9*1; CYP2C9*3	2024-11-08
PA166184121	Annotation of Swissmedic Label for chloroquine and G6PD	Swissmedic		Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	chloroquine	G6PD		2023-02-28
PA166184429	Annotation of Swissmedic Label for ezetimibe / simvastatin and SLCO1B1	Swissmedic		Testing Recommended	Prescribing Info	Dosing Info				Prescribing	ezetimibe / simvastatin	SLCO1B1	rs4149056	2023-02-28
PA166184502	Annotation of Swissmedic Label for lamivudine / abacavir and HLA-B	Swissmedic		Testing Required	Prescribing Info					Prescribing	lamivudine / abacavir	HLA-B	HLA-B*57:01	2023-02-28
PA166184113	Annotation of Swissmedic Label for bisoprolol fumarate / perindopril arginine and G6PD	Swissmedic		Actionable PGx							bisoprolol fumarate / perindopril arginine	G6PD		
PA166184132	Annotation of Swissmedic Label for dasabuvir and IFNL3	Swissmedic		Actionable PGx							dasabuvir	IFNL3		
PA166184443	Annotation of Swissmedic Label for efavirenz and CYP2B6	Swissmedic		Actionable PGx							efavirenz	CYP2B6	CYP2B6*1; CYP2B6*6; rs3745274	
PA166184446	Annotation of Swissmedic Label for escitalopram and CYP2D6	Swissmedic		Informative PGx							escitalopram	CYP2D6		
PA166184447	Annotation of Swissmedic Label for fesoterodine and CYP2D6	Swissmedic		Actionable PGx							fesoterodine	CYP2D6		
PA166184451	Annotation of Swissmedic Label for fluorouracil and TYMS	Swissmedic		Actionable PGx							fluorouracil	TYMS	rs45445694	
PA166184455	Annotation of Swissmedic Label for gefitinib and CYP2D6	Swissmedic		Actionable PGx							gefitinib	CYP2D6		
PA166184457	Annotation of Swissmedic Label for gliclazide and G6PD	Swissmedic		Actionable PGx							gliclazide	G6PD		
PA166184374	Annotation of Swissmedic Label for ibrutinib and CYP2D6	Swissmedic		Informative PGx							ibrutinib	CYP2D6		
PA166184383	Annotation of Swissmedic Label for lapatinib and HLA-DQA1, HLA-DRB1	Swissmedic		Actionable PGx							lapatinib	HLA-DQA1; HLA-DRB1	HLA-DQA1*02:01; HLA-DRB1*07:01	
PA166184427	Annotation of Swissmedic Label for ezetimibe / rosuvastatin and ABCG2, SLCO1B1	Swissmedic		Actionable PGx	Prescribing Info	Dosing Info				Prescribing	ezetimibe / rosuvastatin	ABCG2; SLCO1B1	rs2231142; rs4149056	2024-08-13
PA166398581	Annotation of HCSC Label for clomipramine and CYP2C19, CYP2D6	HCSC		Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	clomipramine	CYP2C19; CYP2D6		
PA166184155	Annotation of Swissmedic Label for nitrofurantoin and G6PD	Swissmedic		Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	nitrofurantoin	G6PD		
PA166184500	Annotation of Swissmedic Label for simvastatin and SLCO1B1	Swissmedic		Testing Recommended	Prescribing Info					Prescribing	simvastatin	SLCO1B1	rs4149056	2023-02-28
PA166119827	Annotation of EMA Label for dextromethorphan / quinidine and CYP2D6	EMA		Informative PGx							dextromethorphan / quinidine	CYP2D6		2025-04-16
PA166184160	Annotation of Swissmedic Label for ondansetron and CYP2D6	Swissmedic		Informative PGx							ondansetron	CYP2D6		
PA166184177	Annotation of Swissmedic Label for oxycodone and CYP2D6	Swissmedic		Actionable PGx							oxycodone	CYP2D6		
PA166184220	Annotation of Swissmedic Label for paliperidone and CYP2D6	Swissmedic		Informative PGx							paliperidone	CYP2D6		
PA166184286	Annotation of Swissmedic Label for perindopril and G6PD	Swissmedic		Actionable PGx							perindopril	G6PD		
PA166184393	Annotation of Swissmedic Label for pitavastatin and SLCO1B1	Swissmedic		Actionable PGx							pitavastatin	SLCO1B1		
PA166184396	Annotation of Swissmedic Label for rabeprazole and CYP2C19	Swissmedic		Actionable PGx							rabeprazole	CYP2C19		
PA166184421	Annotation of Swissmedic Label for risperidone and CYP2D6	Swissmedic		Informative PGx							risperidone	CYP2D6		
PA166184389	Annotation of Swissmedic Label for sulfadiazine and G6PD	Swissmedic		Actionable PGx							sulfadiazine	G6PD		
PA166184392	Annotation of Swissmedic Label for tamoxifen and CYP2D6	Swissmedic		Actionable PGx							tamoxifen	CYP2D6		
PA166184391	Annotation of Swissmedic Label for sulfasalazine and G6PD	Swissmedic		Actionable PGx							sulfasalazine	G6PD		
PA166184425	Annotation of Swissmedic Label for tolperisone and CYP2D6	Swissmedic		Actionable PGx							tolperisone	CYP2D6		
PA166184236	Annotation of Swissmedic Label for umeclidinium / vilanterol and CYP2D6	Swissmedic		Informative PGx							umeclidinium / vilanterol	CYP2D6		
PA166184239	Annotation of Swissmedic Label for vortioxetine and CYP2D6	Swissmedic		Actionable PGx							vortioxetine	CYP2D6		
PA166184386	Annotation of Swissmedic Label for letermovir and SLCO1B1, UGT1A1	Swissmedic		Informative PGx							letermovir	SLCO1B1; UGT1A1	rs2306283; rs4148323; rs4149032; rs4149056; UGT1A1*28	
PA166122967	Annotation of EMA Label for fesoterodine and CYP2D6	EMA		Informative PGx							fesoterodine	CYP2D6		2014-08-07
PA166119823	Annotation of EMA Label for afatinib and EGFR	EMA		Testing Required					Cancer Genome		afatinib	EGFR		2024-04-15
PA166286161	Annotation of HCSC Label for allopurinol and HLA-B	HCSC		Testing Recommended	Prescribing Info		Alternate Drug			Prescribing	allopurinol	HLA-B	HLA-B*58:01	2024-06-18
PA166184422	Annotation of Swissmedic Label for tetrabenazine and CYP2D6	Swissmedic		Testing Required	Prescribing Info					Prescribing	tetrabenazine	CYP2D6		
PA166179847	Annotation of FDA Label for ivacaftor / tezacaftor and CFTR	FDA	On FDA Biomarker List	Testing Required							ivacaftor / tezacaftor	CFTR	rs113993958; rs113993960; rs115545701; rs11971167; rs121908752; rs121908753; rs121909020; rs141033578; rs150212784; rs186045772; rs202179988; rs368505753; rs397508256; rs397508288; rs397508387; rs397508442; rs397508513; rs397508537; rs397508759; rs397508761; rs74551128; rs75039782; rs75541969; rs76151804; rs77834169; rs77932196	2025-04-22
PA166182954	Annotation of EMA Label for ivacaftor / tezacaftor and CFTR	EMA		Testing Required							ivacaftor / tezacaftor	CFTR	rs113993960; rs121908752; rs121908753; rs141033578; rs202179988; rs368505753; rs397508288; rs397508442; rs397508761; rs74551128; rs75039782; rs75541969; rs76151804; rs77834169; rs80224560	2025-04-22
PA166398921	Annotation of HCSC Label for ivacaftor / tezacaftor and CFTR	HCSC		Testing Required							ivacaftor / tezacaftor	CFTR		
PA166398941	Annotation of HCSC Label for ivacaftor / lumacaftor and CFTR	HCSC		Testing Required							ivacaftor / lumacaftor	CFTR	rs113993960	
PA166122972	Annotation of FDA Label for fesoterodine and CYP2D6	FDA	On FDA Biomarker List	Informative PGx							fesoterodine	CYP2D6		2025-04-23
PA166117941	Annotation of EMA Label for bosutinib and ABL1, BCR	EMA		Testing Required					Cancer Genome		bosutinib	ABL1; BCR		2024-08-26
PA166104844	Annotation of EMA Label for erlotinib and EGFR	EMA		Testing Required					Cancer Genome		erlotinib	EGFR		2024-04-16
PA166104834	Annotation of FDA Label for lenalidomide	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		lenalidomide			2024-05-02
PA166104841	Annotation of EMA Label for clopidogrel and CYP2C19	EMA		Informative PGx							clopidogrel	CYP2C19	CYP2C19*2; CYP2C19*3; CYP2C19*4; CYP2C19*5; CYP2C19*6; CYP2C19*7; CYP2C19*8	2024-07-17
PA166127706	Annotation of HCSC Label for rabeprazole and CYP2C19	HCSC		Informative PGx							rabeprazole	CYP2C19		2024-07-22
PA166122487	Annotation of EMA Label for propranolol and CYP2D6	EMA		No Clinical PGx							propranolol	CYP2D6		2024-11-15
PA166127634	Annotation of HCSC Label for atorvastatin and LDLR	HCSC									atorvastatin	LDLR		2024-12-12
PA166122547	Annotation of EMA Label for trastuzumab emtansine and ERBB2	EMA		Testing Required					Cancer Genome		trastuzumab emtansine	ERBB2		2024-04-21
PA166127702	Annotation of HCSC Label for primaquine and CYB5R1, CYB5R2, CYB5R3, CYB5R4, CYP2D6	HCSC		Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	primaquine	CYB5R1; CYB5R2; CYB5R3; CYB5R4; CYP2D6		2024-07-25
PA166114481	Annotation of EMA Label for trastuzumab and ERBB2	EMA		Testing Required					Cancer Genome		trastuzumab	ERBB2		2024-04-21
PA166104920	Annotation of FDA Label for trastuzumab and ERBB2	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		trastuzumab	ERBB2		2023-09-01
PA166104902	Annotation of FDA Label for sulfadiazine and G6PD	FDA	On FDA Biomarker List	Informative PGx							sulfadiazine	G6PD		2013-10-25
PA166127707	Annotation of HCSC Label for rasburicase and G6PD	HCSC		Testing Required	Prescribing Info		Alternate Drug			Prescribing	rasburicase	G6PD		2024-09-19
PA166104793	Annotation of FDA Label for risperidone and CYP2D6	FDA	On FDA Biomarker List	No Clinical PGx							risperidone	CYP2D6		2023-08-22
PA166104881	Annotation of FDA Label for glyburide and G6PD	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug	Other Prescribing Guidance		Prescribing	glyburide	G6PD		2024-09-09
PA166127633	Annotation of HCSC Label for atomoxetine and CYP2D6	HCSC		Informative PGx							atomoxetine	CYP2D6		2024-12-02
PA166159707	Annotation of HCSC Label for atazanavir and CYP2C19	HCSC		Informative PGx							atazanavir	CYP2C19		2024-05-30
PA166182931	Annotation of EMA Label for brigatinib and ALK	EMA		Testing Required					Cancer Genome		brigatinib	ALK		2024-04-16
PA166115435	Annotation of EMA Label for timolol and CYP2D6	EMA									timolol	CYP2D6		2023-08-24
PA166114378	Annotation of EMA Label for telaprevir and IFNL3	EMA		Informative PGx							telaprevir	IFNL3		2013-10-28
PA166114913	Annotation of FDA Label for dabrafenib and G6PD	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	dabrafenib	G6PD		2025-01-17
PA166122066	Annotation of EMA Label for pertuzumab and ERBB2	EMA		Testing Required					Cancer Genome		pertuzumab	ERBB2		2024-04-21
PA166122969	Annotation of EMA Label for vardenafil	EMA									vardenafil			2023-08-29
PA166119826	Annotation of EMA Label for dabrafenib and BRAF	EMA		Testing Required					Cancer Genome		dabrafenib	BRAF	rs113488022	2025-01-17
PA166122826	Annotation of EMA Label for voriconazole and CYP2C19	EMA		Informative PGx							voriconazole	CYP2C19		2025-01-24
PA166127704	Annotation of HCSC Label for propafenone and CYP2D6	HCSC		No Clinical PGx							propafenone	CYP2D6		2024-11-15
PA166127701	Annotation of HCSC Label for phenytoin and HLA-B	HCSC		Testing Recommended	Prescribing Info		Alternate Drug			Prescribing	phenytoin	HLA-B	HLA-B*15:02	2024-09-18
PA166127635	Annotation of HCSC Label for azathioprine and TPMT	HCSC		Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	azathioprine	TPMT		2024-07-18
PA166127700	Annotation of HCSC Label for pertuzumab and ERBB2	HCSC		Testing Required					Cancer Genome		pertuzumab	ERBB2		2024-09-12
PA166127647	Annotation of HCSC Label for celecoxib and CYP2C9	HCSC		Actionable PGx	Prescribing Info	Dosing Info				Prescribing	celecoxib	CYP2C9	CYP2C9*3	2024-07-19
PA166127650	Annotation of HCSC Label for citalopram and CYP2C19	HCSC		Actionable PGx	Prescribing Info	Dosing Info				Prescribing	citalopram	CYP2C19		2024-07-19
PA166127705	Annotation of HCSC Label for quinine and G6PD	HCSC		Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	quinine	G6PD		2024-07-22
PA166105321	Annotation of EMA Label for prasugrel and CYP2B6, CYP2C19, CYP2C9, CYP3A5	EMA		No Clinical PGx							prasugrel	CYP2B6; CYP2C19; CYP2C9; CYP3A5		2013-10-27
PA166127646	Annotation of HCSC Label for carvedilol and CYP2D6	HCSC		Informative PGx							carvedilol	CYP2D6		2024-07-19
PA166127708	Annotation of HCSC Label for risperidone and CYP2D6	HCSC		No Clinical PGx							risperidone	CYP2D6		2024-12-04
PA166104786	Annotation of FDA Label for chloroquine and G6PD	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	chloroquine	G6PD		2023-09-27
PA166104887	Annotation of FDA Label for iloperidone and CYP2D6	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info	Dosing Info				Prescribing	iloperidone	CYP2D6		2013-10-25
PA166127709	Annotation of HCSC Label for rosuvastatin and LDLR	HCSC									rosuvastatin	LDLR		2024-07-22
PA166122546	Annotation of EMA Label for rituximab and MS4A1	EMA							Cancer Genome		rituximab	MS4A1		2025-01-10
PA166104785	Annotation of FDA Label for erlotinib and EGFR	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		erlotinib	EGFR	rs121434568	2023-09-01
PA166114903	Annotation of FDA Label for afatinib and EGFR	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		afatinib	EGFR	rs121434568	2024-08-01
PA166104872	Annotation of EMA Label for boceprevir and IFNL3	EMA		No Clinical PGx							boceprevir	IFNL3		2023-08-14
PA166104835	Annotation of FDA Label for fluoxetine and CYP2D6	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info					Prescribing	fluoxetine	CYP2D6		2023-09-07
PA166104880	Annotation of FDA Label for nefazodone and CYP2D6	FDA	On FDA Biomarker List	No Clinical PGx							nefazodone	CYP2D6		2023-08-15
PA166104791	Annotation of FDA Label for lapatinib and ERBB2, ESR1, ESR2, PGR	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		lapatinib	ERBB2; ESR1; ESR2; PGR		2024-08-26
PA166104782	Annotation of FDA Label for azathioprine and NUDT15, TPMT	FDA	On FDA Biomarker List	Testing Recommended	Prescribing Info	Dosing Info	Alternate Drug			Prescribing	azathioprine	NUDT15; TPMT		2023-08-22
PA166104775	Annotation of FDA Label for atorvastatin and LDLR	FDA	Formerly on FDA Biomarker List								atorvastatin	LDLR		2023-12-04
PA166104830	Annotation of FDA Label for tiotropium and CYP2D6	FDA	Formerly on FDA Biomarker List								tiotropium	CYP2D6		2023-08-27
PA166104794	Annotation of FDA Label for sodium benzoate / sodium phenylacetate and ARG1, ASL, ASS1, CPS1, NAGS, OTC	FDA	Formerly on FDA Biomarker List								sodium benzoate / sodium phenylacetate	ARG1; ASL; ASS1; CPS1; NAGS; OTC		2023-09-28
PA166104822	Annotation of FDA Label for terbinafine and CYP2D6	FDA	Formerly on FDA Biomarker List								terbinafine	CYP2D6		2023-08-24
PA166104779	Annotation of EMA Label for indacaterol and UGT1A1	EMA		No Clinical PGx							indacaterol	UGT1A1		2023-08-18
PA166104869	Annotation of FDA Label for galantamine and CYP2D6	FDA	On FDA Biomarker List	No Clinical PGx							galantamine	CYP2D6		2023-08-22
PA166104850	Annotation of FDA Label for isoniazid / pyrazinamide / rifampin and NAT2	FDA	On FDA Biomarker List	Informative PGx							isoniazid / pyrazinamide / rifampin	NAT2		2025-02-05
PA166104896	Annotation of EMA Label for abacavir and HLA-B	EMA		Testing Required	Prescribing Info		Alternate Drug			Prescribing	abacavir	HLA-B	HLA-B*57:01	2013-10-15
PA166104916	Annotation of FDA Label for codeine and CYP2D6	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	codeine	CYP2D6	CYP2D6*1xN; CYP2D6*2xN	2025-04-15
PA166104922	Annotation of FDA Label for flurbiprofen and CYP2C9	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info	Dosing Info				Prescribing	flurbiprofen	CYP2C9		2025-02-03
PA166104825	Annotation of FDA Label for valproic acid and OTC	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	valproic acid	OTC		2023-02-16
PA166104805	Annotation of FDA Label for thioridazine and CYP2D6	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	thioridazine	CYP2D6		2013-10-25
PA166104862	Annotation of FDA Label for desipramine and CYP2D6	FDA	On FDA Biomarker List	Informative PGx							desipramine	CYP2D6		2013-10-25
PA166104890	Annotation of FDA Label for ivacaftor and CFTR	FDA	On FDA Biomarker List	Testing Required							ivacaftor	CFTR	rs113993958; rs115545701; rs11971167; rs121908752; rs121908753; rs121908755; rs121908757; rs121909005; rs121909013; rs121909020; rs121909021; rs121909041; rs121909044; rs140883683; rs141033578; rs142773283; rs144055758; rs144476686; rs145449046; rs149279509; rs150157202; rs150212784; rs151048781; rs1800076; rs1800079; rs1800097; rs1800098; rs1800100; rs1800103; rs1800110; rs1800111; rs1800112; rs1800120; rs186045772; rs186089140; rs193922525; rs200321110; rs201759207; rs201958172; rs202179988; rs2116683801; rs267606723; rs35516286; rs368505753; rs376008630; rs386134230; rs397508153; rs397508256; rs397508288; rs397508300; rs397508378; rs397508387; rs397508440; rs397508442; rs397508513; rs397508537; rs397508556; rs397508572; rs397508573; rs397508602; rs397508616; rs397508621; rs397508678; rs397508721; rs397508744; rs397508748; rs397508758; rs397508761; rs397508783; rs397508784; rs397508785; rs74503330; rs74551128; rs74571530; rs75039782; rs75527207; rs75541969; rs75763344; rs758818611; rs76151804; rs769016520; rs77409459; rs77834169; rs77902683; rs77932196; rs78655421; rs78769542; rs80224560; rs80282562	2025-04-22
PA166104889	Annotation of FDA Label for pertuzumab and ERBB2	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		pertuzumab	ERBB2		2023-09-01
PA166104928	Annotation of EMA Label for ivacaftor and CFTR	EMA		Testing Required							ivacaftor	CFTR	rs121908755; rs121908757; rs121909005; rs121909013; rs121909041; rs193922525; rs267606723; rs74503330; rs75527207; rs78655421; rs80282562	2025-04-22
PA166104814	Annotation of FDA Label for drospirenone / ethinyl estradiol and CYP2C19	FDA	On FDA Biomarker List								drospirenone / ethinyl estradiol	CYP2C19		2023-08-15
PA166104853	Annotation of FDA Label for cisplatin and TPMT	FDA	On FDA Biomarker List	Informative PGx							cisplatin	TPMT		2024-07-26
PA166104905	Annotation of EMA Label for capecitabine and DPYD	EMA		Testing Recommended	Prescribing Info		Alternate Drug			Prescribing	capecitabine	DPYD	DPYD c.1129-5923C>G, c.1236G>A (HapB3); DPYD c.1679T>G (*13); DPYD c.1905+1G>A (*2A); DPYD c.2846A>T	2022-06-03
PA166104870	Annotation of FDA Label for pimozide and CYP2D6	FDA	On FDA Biomarker List	Testing Required	Prescribing Info	Dosing Info				Prescribing	pimozide	CYP2D6		2023-08-28
PA166104883	Annotation of FDA Label for denileukin diftitox and IL2RA	FDA	On FDA Biomarker List						Cancer Genome		denileukin diftitox	IL2RA		2024-08-06
PA166104876	Annotation of FDA Label for primaquine and G6PD	FDA	On FDA Biomarker List	Testing Required	Prescribing Info		Alternate Drug	Other Prescribing Guidance		Prescribing	primaquine	G6PD		2017-11-09
PA166114908	Annotation of FDA Label for carglumic acid and NAGS	FDA	On FDA Biomarker List								carglumic acid	NAGS		2024-08-05
PA166104898	Annotation of FDA Label for lansoprazole and CYP2C19	FDA	On FDA Biomarker List								lansoprazole	CYP2C19		2023-08-18
PA166104899	Annotation of EMA Label for aripiprazole and CYP2D6	EMA		Actionable PGx	Prescribing Info	Dosing Info				Prescribing	aripiprazole	CYP2D6		2023-12-11
PA166104904	Annotation of EMA Label for brentuximab vedotin and TNFRSF8	EMA							Cancer Genome		brentuximab vedotin	TNFRSF8		2024-08-05
PA166123048	Annotation of EMA Label for cabazitaxel and CYP3A4	EMA									cabazitaxel	CYP3A4		2023-08-14
PA166104832	Annotation of FDA Label for carisoprodol and CYP2C19	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	carisoprodol	CYP2C19		2013-10-25
PA166104843	Annotation of FDA Label for celecoxib and CYP2C9	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info	Dosing Info	Alternate Drug			Prescribing	celecoxib	CYP2C9	CYP2C9*3	2021-02-05
PA166104930	Annotation of EMA Label for gefitinib and EGFR	EMA		Testing Required					Cancer Genome		gefitinib	EGFR		2024-04-16
PA166104927	Annotation of EMA Label for lenalidomide	EMA		Testing Required					Cancer Genome		lenalidomide			2024-05-02
PA166104894	Annotation of EMA Label for rasburicase and G6PD	EMA		Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	rasburicase	G6PD		2023-02-22
PA166119824	Annotation of EMA Label for belimumab and TNFSF13B	EMA									belimumab	TNFSF13B		2023-08-14
PA166122488	Annotation of EMA Label for regorafenib and KRAS	EMA		Informative PGx					Cancer Genome		regorafenib	KRAS		2022-07-05
PA166114382	Annotation of EMA Label for ticagrelor and CYP2C19	EMA		Informative PGx							ticagrelor	CYP2C19		2024-07-19
PA166119825	Annotation of EMA Label for carglumic acid and NAGS	EMA									carglumic acid	NAGS		2024-08-05
PA166105240	Annotation of FDA Label for rituximab and MS4A1	FDA	On FDA Biomarker List						Cancer Genome		rituximab	MS4A1		2025-01-10
PA166121251	Annotation of EMA Label for mercaptopurine and NUDT15, TPMT	EMA		Testing Recommended	Prescribing Info	Dosing Info				Prescribing	mercaptopurine	NUDT15; TPMT	rs116855232	2024-07-24
PA166121246	Annotation of EMA Label for ibritumomab and MS4A1	EMA							Cancer Genome		ibritumomab	MS4A1		2025-01-10
PA166151881	Annotation of FDA Label for rasburicase and G6PD	FDA	On FDA Biomarker List	Testing Required	Prescribing Info		Alternate Drug			Prescribing	rasburicase	G6PD		2016-03-21
PA166159064	Annotation of FDA Label for elosulfase alfa and GALNS	FDA	On FDA Biomarker List	Testing Required							elosulfase alfa	GALNS		2023-08-21
PA166185194	Annotation of FDA Label for raloxifene and ESR1, ESR2	FDA	On FDA Biomarker List						Cancer Genome		raloxifene	ESR1; ESR2		2023-09-07
PA166160288	Annotation of HCSC Label for brentuximab vedotin and TNFRSF8	HCSC							Cancer Genome		brentuximab vedotin	TNFRSF8		2024-08-05
PA166160289	Annotation of HCSC Label for brivaracetam and CYP2C19	HCSC		Informative PGx							brivaracetam	CYP2C19		2024-07-15
PA166159938	Annotation of HCSC Label for belimumab and TNFSF13B	HCSC									belimumab	TNFSF13B		2024-12-12
PA166183246	Annotation of EMA Label for osimertinib and EGFR	EMA		Testing Required					Cancer Genome		osimertinib	EGFR	rs121434568; rs121434569	2024-08-12
PA166182744	Annotation of FDA Label for lorlatinib and ALK	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		lorlatinib	ALK		2023-12-05
PA166182727	Annotation of FDA Label for ivosidenib and IDH1	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		ivosidenib	IDH1		2023-08-31
PA166182940	Annotation of EMA Label for cholic acid and AKR1D1, HSD3B7	EMA									cholic acid	AKR1D1; HSD3B7		2024-08-05
PA166182726	Annotation of FDA Label for rivaroxaban and F5	FDA	On FDA Biomarker List								rivaroxaban	F5		2023-08-24
PA166160121	Annotation of FDA Label for nivolumab and BRAF, ERBB2	FDA	On FDA Biomarker List						Cancer Genome		nivolumab	BRAF; ERBB2	rs113488022	2023-12-04
PA166182725	Annotation of FDA Label for eribulin and ERBB2, ESR1, ESR2, PGR	FDA	On FDA Biomarker List						Cancer Genome		eribulin	ERBB2; ESR1; ESR2; PGR		2023-08-17
PA166182750	Annotation of FDA Label for toremifene and ESR1, ESR2	FDA	On FDA Biomarker List						Cancer Genome		toremifene	ESR1; ESR2		2024-08-06
PA166182787	Annotation of FDA Label for tolbutamide and G6PD	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug	Other Prescribing Guidance		Prescribing	tolbutamide	G6PD		2024-10-14
PA166182944	Annotation of EMA Label for duloxetine and CYP2D6	EMA		Informative PGx							duloxetine	CYP2D6		
PA166182941	Annotation of EMA Label for cobimetinib and BRAF	EMA		Testing Required					Cancer Genome		cobimetinib	BRAF	rs113488022	2025-01-17
PA166182943	Annotation of EMA Label for dolutegravir and UGT1A1	EMA		Informative PGx							dolutegravir	UGT1A1		2025-02-18
PA166129528	Annotation of HCSC Label for sodium nitrite and G6PD	HCSC		Actionable PGx	Prescribing Info		Alternate Drug	Other Prescribing Guidance		Prescribing	sodium nitrite	G6PD		2024-07-21
PA166183621	Annotation of Swissmedic Label for mefloquine and G6PD	Swissmedic		Informative PGx							mefloquine	G6PD		
PA166183593	Annotation of Swissmedic Label for acenocoumarol and CYP2C9	Swissmedic		Actionable PGx							acenocoumarol	CYP2C9	CYP2C9*2; CYP2C9*3	
PA166182752	Annotation of FDA Label for talazoparib and ERBB2	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		talazoparib	ERBB2		2024-08-26
PA166160051	Annotation of FDA Label for alectinib and ALK	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		alectinib	ALK		2024-08-19
PA166184238	Annotation of Swissmedic Label for voriconazole and CYP2C19	Swissmedic		Actionable PGx							voriconazole	CYP2C19		
PA166184404	Annotation of Swissmedic Label for tamsulosin and CYP2D6, CYP3A4	Swissmedic		Actionable PGx							tamsulosin	CYP2D6; CYP3A4		
PA166160010	Annotation of FDA Label for dolutegravir and UGT1A1	FDA	On FDA Biomarker List	Informative PGx							dolutegravir	UGT1A1		
PA166151974	Annotation of HCSC Label for nilotinib and UGT1A1	HCSC		Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	nilotinib	UGT1A1	rs8175347	2025-01-15
PA166183590	Annotation of Swissmedic Label for maraviroc and CYP3A5	Swissmedic		Actionable PGx							maraviroc	CYP3A5	CYP3A5*1	
PA166182949	Annotation of EMA Label for erlotinib and UGT1A1	EMA		Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	erlotinib	UGT1A1		2024-08-06
PA166183219	Annotation of EMA Label for mirabegron and CYP2D6	EMA		No Clinical PGx							mirabegron	CYP2D6		2023-08-15
PA166182953	Annotation of EMA Label for ivacaftor / lumacaftor and CFTR	EMA		Testing Required							ivacaftor / lumacaftor	CFTR	rs113993960	2025-04-22
PA166183563	Annotation of Swissmedic Label for abacavir and HLA-B	Swissmedic		Testing Required	Prescribing Info		Alternate Drug			Prescribing	abacavir	HLA-B	HLA-B*57:01	2023-02-28
PA166161536	Annotation of PMDA Label for atazanavir and CYP2C19	PMDA		Actionable PGx							atazanavir	CYP2C19		
PA166183441	Annotation of EMA Label for umeclidinium and CYP2D6	EMA		No Clinical PGx							umeclidinium	CYP2D6		
PA166182928	Annotation of EMA Label for binimetinib and BRAF	EMA		Testing Required					Cancer Genome		binimetinib	BRAF	rs113488022	2024-04-16
PA166177479	Annotation of FDA Label for cariprazine and CYP2D6	FDA	On FDA Biomarker List	No Clinical PGx							cariprazine	CYP2D6		2023-08-15
PA166182942	Annotation of EMA Label for dacomitinib and EGFR	EMA		Testing Required					Cancer Genome		dacomitinib	EGFR		2024-04-16
PA166183423	Annotation of EMA Label for rucaparib and BRCA1, BRCA2	EMA		Testing Required					Cancer Genome		rucaparib	BRCA1; BRCA2		2024-04-21
PA166182934	Annotation of EMA Label for cerliponase alfa and TPP1	EMA									cerliponase alfa	TPP1		2024-08-05
PA166182932	Annotation of EMA Label for brivaracetam and CYP2C19	EMA		Informative PGx							brivaracetam	CYP2C19		2024-07-15
PA166182766	Annotation of FDA Label for fosphenytoin and CYP2C9, HLA-B	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info	Dosing Info	Alternate Drug			Prescribing	fosphenytoin	CYP2C9; HLA-B	CYP2C9*2; CYP2C9*3; HLA-B*15:02	2024-12-02
PA166184917	Annotation of FDA Label for avatrombopag and CYP2C9	FDA	On FDA Biomarker List	Informative PGx							avatrombopag	CYP2C9	CYP2C9*2; CYP2C9*3	2024-07-11
PA166160668	Annotation of PMDA Label for allopurinol and HLA-B	PMDA		Informative PGx							allopurinol	HLA-B	HLA-B*58:01	
PA166170937	Annotation of FDA Label for trametinib and G6PD	FDA	On FDA Biomarker List								trametinib	G6PD		2025-01-21
PA166183200	Annotation of EMA Label for midostaurin and FLT3	EMA		Testing Required					Cancer Genome		midostaurin	FLT3		2024-04-21
PA166183184	Annotation of EMA Label for lorlatinib and ALK	EMA		Testing Required					Cancer Genome		lorlatinib	ALK		2024-05-24
PA166177516	Annotation of FDA Label for neratinib and ERBB2	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		neratinib	ERBB2		2023-08-31
PA166183784	Annotation of Swissmedic Label for amifampridine phosphate and NAT2	Swissmedic		Actionable PGx							amifampridine phosphate	NAT2		
PA166183782	Annotation of Swissmedic Label for aspirin and G6PD	Swissmedic		Actionable PGx							aspirin	G6PD		
PA166184232	Annotation of Swissmedic Label for venlafaxine and CYP2D6	Swissmedic		Actionable PGx							venlafaxine	CYP2D6		
PA166183249	Annotation of EMA Label for pembrolizumab and ALK, CD274, EGFR, ERBB2	EMA		Testing Required					Cancer Genome		pembrolizumab	ALK; CD274; EGFR; ERBB2		2024-04-21
PA166159584	Annotation of HCSC Label for obinutuzumab and MS4A1	HCSC							Cancer Genome		obinutuzumab	MS4A1		2024-12-12
PA166170930	Annotation of FDA Label for dabrafenib and HRAS, KRAS, NRAS	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug	Other Prescribing Guidance	Cancer Genome	Prescribing	dabrafenib	HRAS; KRAS; NRAS		2025-01-17
PA166183251	Annotation of EMA Label for raltegravir and UGT1A1	EMA		No Clinical PGx							raltegravir	UGT1A1		2023-08-23
PA166183248	Annotation of EMA Label for palonosetron and CYP2D6	EMA		No Clinical PGx							palonosetron	CYP2D6		
PA166169877	Annotation of FDA Label for avelumab and CD274	FDA	On FDA Biomarker List						Cancer Genome		avelumab	CD274		2025-01-09
PA166183783	Annotation of Swissmedic Label for allopurinol and HLA-B	Swissmedic		Actionable PGx	Prescribing Info					Prescribing	allopurinol	HLA-B	HLA-B*58:01	2023-02-28
PA166163433	Annotation of FDA Label for eteplirsen and DMD	FDA	On FDA Biomarker List	Testing Required							eteplirsen	DMD		2023-08-21
PA166183172	Annotation of EMA Label for lapatinib and HLA-DQA1, HLA-DRB1	EMA		Informative PGx							lapatinib	HLA-DQA1; HLA-DRB1	HLA-DQA1*02:01; HLA-DRB1*07:01	
PA166353002	Annotation of EMA Label for bempedoic acid / ezetimibe	EMA									bempedoic acid / ezetimibe			
PA166353003	Annotation of HCSC Label for bempedoic acid / ezetimibe	HCSC									bempedoic acid / ezetimibe			
PA166183220	Annotation of EMA Label for neratinib and ERBB2, ESR1, ESR2, PGR	EMA		Testing Required					Cancer Genome		neratinib	ERBB2; ESR1; ESR2; PGR		2024-04-21
PA166353001	Annotation of FDA Label for bempedoic acid / ezetimibe	FDA	On FDA Biomarker List								bempedoic acid / ezetimibe			
PA166353023	Annotation of HCSC Label for mavorixafor	HCSC									mavorixafor			
PA166353022	Annotation of EMA Label for mavorixafor	EMA									mavorixafor			2024-11-11
PA166353021	Annotation of FDA Label for mavorixafor and CXCR4	FDA	On FDA Biomarker List								mavorixafor	CXCR4		
PA166353081	Annotation of HCSC Label for mecasermin and GH1, GHR, IGF1	HCSC									mecasermin	GH1; GHR; IGF1		
PA166353061	Annotation of FDA Label for mecasermin and GH1, IGF1	FDA	On FDA Biomarker List								mecasermin	GH1; IGF1		
PA166353141	Annotation of HCSC Label for medroxyprogesterone	HCSC									medroxyprogesterone			
PA166353121	Annotation of FDA Label for medroxyprogesterone and ESR1, ESR2	FDA	On FDA Biomarker List								medroxyprogesterone	ESR1; ESR2		
PA166353122	Annotation of EMA Label for medroxyprogesterone	EMA									medroxyprogesterone			
PA166353123	Annotation of HCSC Label for pitavastatin	HCSC									pitavastatin			
PA166353101	Annotation of EMA Label for mecasermin and IGF1	EMA		Actionable PGx							mecasermin	IGF1		
PA166160153	Annotation of PMDA Label for celecoxib and CYP2C9	PMDA		Actionable PGx							celecoxib	CYP2C9		
PA166160226	Annotation of PMDA Label for codeine and CYP2D6	PMDA		Actionable PGx							codeine	CYP2D6		
PA166160683	Annotation of PMDA Label for dapsone and G6PD	PMDA		Actionable PGx							dapsone	G6PD		
PA166160162	Annotation of PMDA Label for efavirenz and CYP2B6	PMDA		Actionable PGx							efavirenz	CYP2B6		
PA166160712	Annotation of PMDA Label for fesoterodine and CYP2D6	PMDA		Actionable PGx							fesoterodine	CYP2D6		
PA166160717	Annotation of PMDA Label for letrozole and CYP2A6	PMDA		Actionable PGx							letrozole	CYP2A6		
PA166160719	Annotation of PMDA Label for nalidixic acid and G6PD	PMDA		Actionable PGx							nalidixic acid	G6PD		
PA166160845	Annotation of PMDA Label for perphenazine and CYP2D6	PMDA		Actionable PGx							perphenazine	CYP2D6		
PA166160846	Annotation of PMDA Label for rabeprazole and CYP2C19	PMDA		Actionable PGx							rabeprazole	CYP2C19		
PA166160847	Annotation of PMDA Label for sulfadiazine and G6PD	PMDA		Actionable PGx							sulfadiazine	G6PD		
PA166160848	Annotation of PMDA Label for sulfamethoxazole / trimethoprim and G6PD	PMDA		Actionable PGx							sulfamethoxazole / trimethoprim	G6PD		
PA166160849	Annotation of PMDA Label for sulfasalazine and G6PD	PMDA		Actionable PGx							sulfasalazine	G6PD		
PA166160850	Annotation of PMDA Label for tetrabenazine and CYP2D6	PMDA		Actionable PGx							tetrabenazine	CYP2D6		
PA166160854	Annotation of PMDA Label for moviprep and G6PD	PMDA		Actionable PGx							moviprep	G6PD		
PA166160856	Annotation of PMDA Label for voriconazole and CYP2C19	PMDA		Actionable PGx							voriconazole	CYP2C19		
PA166160709	Annotation of PMDA Label for eliglustat and CYP2D6	PMDA		Testing Required							eliglustat	CYP2D6		
PA166160710	Annotation of PMDA Label for erlotinib and EGFR	PMDA		Testing Required							erlotinib	EGFR		
PA166160851	Annotation of PMDA Label for vemurafenib and BRAF	PMDA		Testing Required							vemurafenib	BRAF		
PA166160669	Annotation of PMDA Label for escitalopram and CYP2C19, CYP2D6	PMDA		Actionable PGx							escitalopram	CYP2C19; CYP2D6		
PA166353161	Annotation of FDA Label for pitavastatin and APOB, LDLR, PCSK9	FDA	On FDA Biomarker List								pitavastatin	APOB; LDLR; PCSK9		
PA166152939	Annotation of FDA Label for ivacaftor / lumacaftor and CFTR	FDA	On FDA Biomarker List	Testing Required							ivacaftor / lumacaftor	CFTR	rs113993960	2025-04-22
PA166353162	Annotation of EMA Label for pitavastatin	EMA									pitavastatin			
PA166179870	Annotation of FDA Label for binimetinib and BRAF	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		binimetinib	BRAF	rs113488022	2023-10-25
PA166183881	Annotation of Swissmedic Label for mivacurium and BCHE	Swissmedic		Actionable PGx							mivacurium	BCHE		2022-11-15
PA166184130	Annotation of Swissmedic Label for dapoxetine and CYP2D6	Swissmedic		Actionable PGx	Prescribing Info	Dosing Info				Prescribing	dapoxetine	CYP2D6		
PA166184115	Annotation of Swissmedic Label for carbamazepine and HLA-A	Swissmedic		Testing Recommended	Prescribing Info		Alternate Drug			Prescribing	carbamazepine	HLA-A	HLA-A*31:01	2023-02-28
PA166184445	Annotation of Swissmedic Label for escitalopram and CYP2C19	Swissmedic		Actionable PGx	Prescribing Info	Dosing Info				Prescribing	escitalopram	CYP2C19		2023-02-28
PA166184378	Annotation of Swissmedic Label for irinotecan and UGT1A1	Swissmedic		Actionable PGx	Prescribing Info	Dosing Info				Prescribing	irinotecan	UGT1A1	UGT1A1*28	2023-02-28
PA166183901	Annotation of Swissmedic Label for moxifloxacin and G6PD	Swissmedic		Actionable PGx	Prescribing Info					Prescribing	moxifloxacin	G6PD		2023-02-28
PA166184082	Annotation of Swissmedic Label for nicorandil and G6PD	Swissmedic		Actionable PGx	Prescribing Info					Prescribing	nicorandil	G6PD		2023-02-28
PA166184128	Annotation of Swissmedic Label for acetaminophen / codeine and G6PD	Swissmedic		Actionable PGx							acetaminophen / codeine	G6PD		
PA166184109	Annotation of Swissmedic Label for aripiprazole and CYP2D6	Swissmedic		Actionable PGx							aripiprazole	CYP2D6		
PA166184119	Annotation of Swissmedic Label for celecoxib and CYP2C9	Swissmedic		Actionable PGx							celecoxib	CYP2C9	CYP2C9*1; CYP2C9*3	
PA166184131	Annotation of Swissmedic Label for darifenacin and CYP2D6	Swissmedic		Actionable PGx							darifenacin	CYP2D6		
PA166184444	Annotation of Swissmedic Label for eletriptan and CYP2D6	Swissmedic		Informative PGx							eletriptan	CYP2D6		
PA166184448	Annotation of Swissmedic Label for flucloxacillin and HLA-B	Swissmedic		Actionable PGx							flucloxacillin	HLA-B	HLA-B*57:01	
PA166184108	Annotation of Swissmedic Label for fluorouracil / salicylic acid and DPYD	Swissmedic		Testing Recommended							fluorouracil / salicylic acid	DPYD		
PA166184453	Annotation of Swissmedic Label for fluvoxamine and CYP2D6	Swissmedic		Actionable PGx							fluvoxamine	CYP2D6		
PA166184458	Annotation of Swissmedic Label for glimepiride and G6PD	Swissmedic		Actionable PGx							glimepiride	G6PD		
PA166184377	Annotation of Swissmedic Label for indacaterol and UGT1A1	Swissmedic		Informative PGx							indacaterol	UGT1A1	UGT1A1*28	
PA166184382	Annotation of Swissmedic Label for lansoprazole and CYP2C19	Swissmedic		Actionable PGx							lansoprazole	CYP2C19		
PA166184385	Annotation of Swissmedic Label for lesinurad and CYP2C9	Swissmedic		Informative PGx							lesinurad	CYP2C9	CYP2C9*1; CYP2C9*3	
PA166183790	Annotation of Swissmedic Label for metoprolol and CYP2D6	Swissmedic		Actionable PGx							metoprolol	CYP2D6		
PA166183810	Annotation of Swissmedic Label for mirabegron and CYP2D6	Swissmedic		Informative PGx							mirabegron	CYP2D6		
PA166184118	Annotation of Swissmedic Label for carvedilol and CYP2D6	Swissmedic		Informative PGx							carvedilol	CYP2D6		2023-08-15
PA166184127	Annotation of Swissmedic Label for acetaminophen / codeine and CYP2D6	Swissmedic		Testing Required	Prescribing Info		Alternate Drug			Prescribing	acetaminophen / codeine	CYP2D6		2024-04-15
PA166182947	Annotation of EMA Label for elosulfase alfa and GALNS	EMA		Testing Required							elosulfase alfa	GALNS		2024-04-16
PA166182929	Annotation of EMA Label for binimetinib and UGT1A1	EMA		No Clinical PGx							binimetinib	UGT1A1		2023-08-14
PA166353202	Annotation of HCSC Label for resmetirom	HCSC									resmetirom			
PA166184156	Annotation of Swissmedic Label for norfloxacin and G6PD	Swissmedic		Actionable PGx							norfloxacin	G6PD		
PA166184459	Annotation of Swissmedic Label for nitroglycerin and G6PD	Swissmedic		Actionable PGx							nitroglycerin	G6PD		
PA166184159	Annotation of Swissmedic Label for omeprazole and CYP2C19	Swissmedic		Actionable PGx							omeprazole	CYP2C19		
PA166184222	Annotation of Swissmedic Label for pantoprazole and CYP2C19	Swissmedic		Informative PGx							pantoprazole	CYP2C19		
PA166182930	Annotation of EMA Label for brexpiprazole and CYP2D6	EMA		Actionable PGx	Prescribing Info	Dosing Info				Prescribing	brexpiprazole	CYP2D6		
PA166182926	Annotation of EMA Label for atezolizumab and ALK, CD274, EGFR	EMA		Testing Required					Cancer Genome		atezolizumab	ALK; CD274; EGFR		2025-01-09
PA166184402	Annotation of Swissmedic Label for ranolazine and CYP2D6	Swissmedic		Actionable PGx	Prescribing Info					Prescribing	ranolazine	CYP2D6		
PA166184373	Annotation of Swissmedic Label for piroxicam and CYP2C9	Swissmedic		Actionable PGx							piroxicam	CYP2C9	CYP2C9*2; CYP2C9*3	
PA166184381	Annotation of Swissmedic Label for prilocaine and G6PD	Swissmedic		Actionable PGx							prilocaine	G6PD		
PA166184234	Annotation of Swissmedic Label for vernakalant and CYP2D6	Swissmedic		Informative PGx							vernakalant	CYP2D6		
PA166184504	Annotation of Swissmedic Label for zidovudine / lamivudine / abacavir and HLA-B	Swissmedic		Testing Required	Prescribing Info					Prescribing	zidovudine / lamivudine / abacavir	HLA-B	HLA-B*57:01	2023-02-28
PA166184110	Annotation of Swissmedic Label for vitamin c and G6PD	Swissmedic		Actionable PGx	Prescribing Info	Dosing Info				Prescribing	vitamin c	G6PD		2023-02-28
PA166184441	Annotation of Swissmedic Label for dolutegravir and CYP3A4, CYP3A5, NR1I2, UGT1A1	Swissmedic		Informative PGx							dolutegravir	CYP3A4; CYP3A5; NR1I2; UGT1A1		2023-08-15
PA166182924	Annotation of EMA Label for alectinib and ALK	EMA		Testing Required					Cancer Genome		alectinib	ALK		2024-04-15
PA166182951	Annotation of EMA Label for glyburide and G6PD	EMA		Actionable PGx	Prescribing Info		Alternate Drug	Other Prescribing Guidance		Prescribing	glyburide	G6PD		2024-07-22
PA166183183	Annotation of EMA Label for lidocaine / prilocaine and CYB5R3, G6PD	EMA		Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	lidocaine / prilocaine	CYB5R3; G6PD		2024-07-23
PA166182950	Annotation of EMA Label for gefitinib and CYP2D6	EMA		Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	gefitinib	CYP2D6		2024-08-07
PA166182945	Annotation of EMA Label for efavirenz and CYP2B6	EMA		Informative PGx							efavirenz	CYP2B6	CYP2B6*1; CYP2B6*6; rs3745274	
PA166183171	Annotation of EMA Label for lacosamide and CYP2C19	EMA		No Clinical PGx							lacosamide	CYP2C19		2025-01-24
PA166353201	Annotation of FDA Label for resmetirom and ABCG2	FDA	On FDA Biomarker List	No Clinical PGx							resmetirom	ABCG2	rs2231137; rs2231142	
PA166353203	Annotation of EMA Label for resmetirom	EMA									resmetirom			
PA166353241	Annotation of FDA Label for tislelizumab and CD274	FDA	On FDA Biomarker List						Cancer Genome		tislelizumab	CD274		
PA166353242	Annotation of HCSC Label for tislelizumab	HCSC									tislelizumab			
PA166353261	Annotation of EMA Label for tislelizumab and CD274	EMA		Testing Required					Cancer Genome		tislelizumab	CD274		
PA166353281	Annotation of EMA Label for tovorafenib	EMA									tovorafenib			
PA166353282	Annotation of HCSC Label for tovorafenib	HCSC									tovorafenib			
PA166353262	Annotation of FDA Label for tovorafenib and BRAF	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		tovorafenib	BRAF	rs113488022	2025-01-17
PA166183247	Annotation of EMA Label for palbociclib and ERBB2, ESR1, ESR2, PGR	EMA		Testing Required					Cancer Genome		palbociclib	ERBB2; ESR1; ESR2; PGR		2024-04-21
PA166105319	Annotation of EMA Label for panitumumab and KRAS, NRAS	EMA		Testing Required					Cancer Genome		panitumumab	KRAS; NRAS		2024-04-21
PA166122067	Annotation of EMA Label for ponatinib and ABL1, BCR	EMA		Testing Required					Cancer Genome		ponatinib	ABL1; BCR	rs121913459	2025-01-16
PA166353741	Annotation of FDA Label for blinatumomab and CD19	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		blinatumomab	CD19		
PA166277781	Annotation of EMA Label for tebentafusp and HLA-A	EMA		Testing Required							tebentafusp	HLA-A	HLA-A*02:01	2024-08-14
PA166353761	Annotation of EMA Label for blinatumomab and CD19	EMA		Testing Required					Cancer Genome		blinatumomab	CD19		
PA166353762	Annotation of HCSC Label for blinatumomab and CD19	HCSC		Testing Required					Cancer Genome		blinatumomab	CD19		
PA166353781	Annotation of EMA Label for dextromethorphan hydrobromide / bupropion hydrochloride	EMA									dextromethorphan hydrobromide / bupropion hydrochloride			
PA166353801	Annotation of HCSC Label for dextromethorphan hydrobromide / bupropion hydrochloride	HCSC									dextromethorphan hydrobromide / bupropion hydrochloride			
PA166353861	Annotation of FDA Label for xanomeline / trospium and CYP2D6	FDA		Informative PGx							xanomeline / trospium	CYP2D6		
PA166284081	Annotation of HCSC Label for erdafitinib and FGFR3	HCSC		Testing Required					Cancer Genome		erdafitinib	FGFR3		2024-10-03
PA166284101	Annotation of HCSC Label for erdafitinib and CYP2C9	HCSC		Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	erdafitinib	CYP2C9	CYP2C9*3	2024-10-03
PA166353901	Annotation of FDA Label for maralixibat and ABCB11, ABCB4, ATP8B1, MYO5B, TJP2	FDA	On FDA Biomarker List								maralixibat	ABCB11; ABCB4; ATP8B1; MYO5B; TJP2		
PA166353921	Annotation of EMA Label for maralixibat and ABCB11, ABCB4, ATP8B1, MYO5B, TJP2	EMA									maralixibat	ABCB11; ABCB4; ATP8B1; MYO5B; TJP2		
PA166353941	Annotation of FDA Label for quinine and G6PD	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	quinine	G6PD		
PA166357541	Annotation of HCSC Label for dronabinol	HCSC									dronabinol			
PA166357561	Annotation of HCSC Label for enasidenib	HCSC									enasidenib			
PA166357681	Annotation of HCSC Label for desipramine	HCSC									desipramine			
PA166357721	Annotation of HCSC Label for doxepin and CYP2C19, CYP2D6	HCSC		Informative PGx							doxepin	CYP2C19; CYP2D6		
PA166357728	Annotation of HCSC Label for fluoxetine and CYP2D6	HCSC		Informative PGx							fluoxetine	CYP2D6		
PA166357732	Annotation of HCSC Label for fluvoxamine and CYP2D6	HCSC		Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	fluvoxamine	CYP2D6		
PA166357726	Annotation of HCSC Label for flibanserin and CYP2C19	HCSC		Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	flibanserin	CYP2C19		
PA166357727	Annotation of HCSC Label for flibanserin and CYP2C9, CYP2D6	HCSC		Informative PGx							flibanserin	CYP2C9; CYP2D6		
PA166357729	Annotation of HCSC Label for flurbiprofen and CYP2C9	HCSC		Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	flurbiprofen	CYP2C9		2025-02-03
PA166357682	Annotation of HCSC Label for desvenlafaxine	HCSC									desvenlafaxine			
PA166357724	Annotation of HCSC Label for estradiol / progesterone	HCSC									estradiol / progesterone			
PA166357730	Annotation of HCSC Label for flutamide	HCSC									flutamide			
PA166357701	Annotation of HCSC Label for diazepam and CYP2C19, CYP3A4	HCSC		Informative PGx							diazepam	CYP2C19; CYP3A4		
PA166357722	Annotation of HCSC Label for efavirenz and CYP2B6	HCSC		Informative PGx							efavirenz	CYP2B6	CYP2B6*6	
PA166357723	Annotation of HCSC Label for elagolix and SLCO1B1	HCSC		No Clinical PGx							elagolix	SLCO1B1	rs4149056	
PA166357741	Annotation of HCSC Label for fulvestrant and ERBB2, ESR1, ESR2	HCSC		Testing Required					Cancer Genome		fulvestrant	ERBB2; ESR1; ESR2		
PA166357761	Annotation of HCSC Label for hydralazine and NAT2	HCSC		Actionable PGx	Prescribing Info	Dosing Info				Prescribing	hydralazine	NAT2		
PA166357781	Annotation of HCSC Label for hydroxychloroquine and G6PD	HCSC		Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	hydroxychloroquine	G6PD		
PA166355241	Annotation of EMA Label for belinostat	EMA									belinostat			
PA166355242	Annotation of HCSC Label for belinostat	HCSC									belinostat			
PA166357801	Annotation of HCSC Label for imipramine and CYP2D6	HCSC		Informative PGx							imipramine	CYP2D6		
PA166355282	Annotation of HCSC Label for brexpiprazole and CYP2D6	HCSC		Actionable PGx	Prescribing Info	Dosing Info				Prescribing	brexpiprazole	CYP2D6		
PA166357821	Annotation of HCSC Label for lacosamide and CYP2C19	HCSC		No Clinical PGx							lacosamide	CYP2C19		
PA166355301	Annotation of HCSC Label for carisoprodol	HCSC									carisoprodol			
PA166357822	Annotation of EMA Label for lecanemab	EMA									lecanemab			2025-01-10
PA166355421	Annotation of HCSC Label for cisplatin	HCSC									cisplatin			
PA166357841	Annotation of HCSC Label for lidocaine / prilocaine and CYB5R3, G6PD	HCSC		Actionable PGx	Prescribing Info		Alternate Drug	Other Prescribing Guidance		Prescribing	lidocaine / prilocaine	CYB5R3; G6PD		
PA166355442	Annotation of HCSC Label for clobazam and CYP2C19	HCSC		Actionable PGx	Prescribing Info	Dosing Info				Prescribing	clobazam	CYP2C19		
PA166357861	Annotation of HCSC Label for lidocaine and tetracaine and CYB5R3, G6PD	HCSC		Actionable PGx	Prescribing Info		Alternate Drug	Other Prescribing Guidance		Prescribing	lidocaine and tetracaine	CYB5R3; G6PD		
PA166104884	Annotation of FDA Label for clobazam and CYP2C19	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info	Dosing Info				Prescribing	clobazam	CYP2C19		2024-10-16
PA166357881	Annotation of EMA Label for lusutrombopag and F2, F5, PROC, PROS1, SERPINC1	EMA		Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	lusutrombopag	F2; F5; PROC; PROS1; SERPINC1	rs1799963; rs6025	
PA166355461	Annotation of HCSC Label for clozapine	HCSC									clozapine			
PA166358001	Annotation of EMA Label for lutetium (177Lu) vipivotide tetraxetan and FOLH1	EMA		Testing Required					Cancer Genome		lutetium (177Lu) vipivotide tetraxetan	FOLH1		
PA166355481	Annotation of HCSC Label for dextromethorphan / quinidine	HCSC									dextromethorphan / quinidine			
PA166358021	Annotation of HCSC Label for lutetium (177Lu) vipivotide tetraxetan and FOLH1	HCSC		Testing Required					Cancer Genome		lutetium (177Lu) vipivotide tetraxetan	FOLH1		
PA166355501	Annotation of HCSC Label for donepezil	HCSC									donepezil			
PA166355801	Annotation of EMA Label for lonafarnib and CYP3A4	EMA		Actionable PGx	Prescribing Info	Dosing Info		Other Prescribing Guidance		Prescribing	lonafarnib	CYP3A4		
PA166355321	Annotation of HCSC Label for ceftriaxone	HCSC									ceftriaxone			
PA166355882	Annotation of HCSC Label for duloxetine	HCSC									duloxetine			
PA166272661	Annotation of HCSC Label for abemaciclib and ERBB2, ESR1, ESR2	HCSC		Testing Required					Cancer Genome		abemaciclib	ERBB2; ESR1; ESR2		2024-08-26
PA166184123	Annotation of Swissmedic Label for citalopram and CYP2C19, CYP2D6	Swissmedic		Actionable PGx	Prescribing Info	Dosing Info				Prescribing	citalopram	CYP2C19; CYP2D6		2023-02-28
PA166184345	Annotation of Swissmedic Label for phenytoin and CYP2C9, HLA-B	Swissmedic		Actionable PGx	Prescribing Info	Dosing Info				Prescribing	phenytoin	CYP2C9; HLA-B	HLA-B*15:02	2023-02-28
PA166184424	Annotation of Swissmedic Label for thioguanine and TPMT	Swissmedic		Actionable PGx	Prescribing Info	Dosing Info				Prescribing	thioguanine	TPMT		2023-02-28
PA166358301	Annotation of HCSC Label for methylene blue and G6PD	HCSC		Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	methylene blue	G6PD		
PA166356321	Annotation of FDA Label for hydralazine and NAT2	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info	Dosing Info				Prescribing	hydralazine	NAT2		
PA166358581	Annotation of HCSC Label for modafinil and CYP2D6	HCSC									modafinil	CYP2D6		
PA166104891	Annotation of FDA Label for nalidixic acid and G6PD	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	nalidixic acid	G6PD		2024-11-13
PA166358601	Annotation of HCSC Label for nateglinide	HCSC									nateglinide			
PA166358621	Annotation of HCSC Label for nebivolol and CYP2D6	HCSC		No Clinical PGx							nebivolol	CYP2D6		
PA166358662	Annotation of HCSC Label for palbociclib and ERBB2, ESR1, ESR2, PGR	HCSC		Testing Required					Cancer Genome		palbociclib	ERBB2; ESR1; ESR2; PGR		
PA166358701	Annotation of HCSC Label for palonosetron and CYP2D6	HCSC		No Clinical PGx							palonosetron	CYP2D6		
PA166358762	Annotation of HCSC Label for pantoprazole	HCSC									pantoprazole			
PA166358781	Annotation of HCSC Label for pazopanib and HLA-B	HCSC		Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	pazopanib	HLA-B	HLA-B*51:01	
PA166358801	Annotation of HCSC Label for pemetrexed	HCSC									pemetrexed			
PA166358821	Annotation of HCSC Label for perphenazine	HCSC									perphenazine			
PA166358841	Annotation of HCSC Label for piroxicam	HCSC									piroxicam			
PA166358861	Annotation of HCSC Label for prasugrel and CYP2B6, CYP2C19, CYP2C9, CYP3A5	HCSC		No Clinical PGx							prasugrel	CYP2B6; CYP2C19; CYP2C9; CYP3A5		
PA166358881	Annotation of HCSC Label for propranolol and CYP2D6	HCSC		No Clinical PGx							propranolol	CYP2D6		
PA166358901	Annotation of HCSC Label for raltegravir and UGT1A1	HCSC		No Clinical PGx							raltegravir	UGT1A1		
PA166358921	Annotation of HCSC Label for ramucirumab	HCSC									ramucirumab			
PA166358941	Annotation of HCSC Label for ribociclib and ERBB2, ESR1, ESR2, PGR	HCSC		Testing Required					Cancer Genome		ribociclib	ERBB2; ESR1; ESR2; PGR		
PA166358961	Annotation of EMA Label for risperidone and CYP2D6	EMA		No Clinical PGx							risperidone	CYP2D6		
PA166358981	Annotation of HCSC Label for ropivacaine	HCSC									ropivacaine			
PA166359101	Annotation of HCSC Label for streptomycin	HCSC									streptomycin			
PA166160039	Annotation of FDA Label for evolocumab	FDA	On FDA Biomarker List								evolocumab			2023-09-07
PA166359201	Annotation of HCSC Label for tamsulosin and CYP2D6	HCSC		Informative PGx							tamsulosin	CYP2D6		
PA166293361	Annotation of FDA Label for desmopressin and F8	FDA	On FDA Biomarker List	Testing Required							desmopressin	F8		2023-08-21
PA166293681	Annotation of FDA Label for trastuzumab deruxtecan and ESR1, ESR2	FDA	On FDA Biomarker List						Cancer Genome		trastuzumab deruxtecan	ESR1; ESR2		2023-09-28
PA166163412	Annotation of FDA Label for ombitasvir / paritaprevir / ritonavir and IFNL3	FDA	On FDA Biomarker List								ombitasvir / paritaprevir / ritonavir	IFNL3		2023-09-07
PA166163435	Annotation of FDA Label for olaratumab and PDGFRA	FDA	On FDA Biomarker List						Cancer Genome		olaratumab	PDGFRA		2023-08-23
PA166359241	Annotation of HCSC Label for ticagrelor and CYP2C19	HCSC		No Clinical PGx							ticagrelor	CYP2C19		
PA166235881	Annotation of FDA Label for margetuximab and ERBB2	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		margetuximab	ERBB2		2023-08-31
PA166293742	Annotation of FDA Label for mirvetuximab soravtansine and FOLR1	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		mirvetuximab soravtansine	FOLR1		2023-08-31
PA166293921	Annotation of FDA Label for olutasidenib and IDH1	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		olutasidenib	IDH1	rs121913499; rs121913500	2023-08-31
PA166294401	Annotation of HCSC Label for evolocumab	HCSC									evolocumab			2024-08-14
PA166293301	Annotation of FDA Label for betaine and CBS, MMADHC, MTHFR	FDA	On FDA Biomarker List								betaine	CBS; MMADHC; MTHFR		2024-08-05
PA166293961	Annotation of HCSC Label for betaine and CBS, MMADHC, MTHFR	HCSC									betaine	CBS; MMADHC; MTHFR		2024-08-05
PA166293981	Annotation of HCSC Label for desmopressin and F8	HCSC		Testing Required							desmopressin	F8		2024-09-10
PA166293941	Annotation of EMA Label for betaine and CBS, MMADHC, MTHFR	EMA									betaine	CBS; MMADHC; MTHFR		2024-08-05
PA166294981	Annotation of EMA Label for pemigatinib and FGFR2	EMA		Testing Required					Cancer Genome		pemigatinib	FGFR2		
PA166295001	Annotation of HCSC Label for pemigatinib and FGFR2	HCSC		Testing Required					Cancer Genome		pemigatinib	FGFR2		
PA166104800	Annotation of FDA Label for indacaterol and UGT1A1	FDA	On FDA Biomarker List	No Clinical PGx							indacaterol	UGT1A1		2024-11-08
PA166104798	Annotation of FDA Label for propranolol and CYP2D6	FDA	On FDA Biomarker List	No Clinical PGx							propranolol	CYP2D6		2024-11-15
PA166104811	Annotation of FDA Label for quinidine and CYP2D6	FDA	On FDA Biomarker List								quinidine	CYP2D6		2023-09-07
PA166104845	Annotation of FDA Label for dapsone and CYB5R3	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	dapsone	CYB5R3		2024-07-19
PA166295822	Annotation of FDA Label for teclistamab	FDA	On FDA Biomarker List						Cancer Genome		teclistamab			2023-08-24
PA166104788	Annotation of FDA Label for fluoxetine / olanzapine and CYP2D6	FDA		Informative PGx							fluoxetine / olanzapine	CYP2D6		2013-12-17
PA166104789	Annotation of FDA Label for gefitinib and EGFR	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		gefitinib	EGFR	rs121434568	2023-09-01
PA166104833	Annotation of FDA Label for abacavir and HLA-B	FDA	On FDA Biomarker List	Testing Required	Prescribing Info		Alternate Drug			Prescribing	abacavir	HLA-B	HLA-B*57:01	2019-05-08
PA166104812	Annotation of FDA Label for protriptyline and CYP2D6	FDA	On FDA Biomarker List	Informative PGx							protriptyline	CYP2D6		2013-10-25
PA166104806	Annotation of FDA Label for tolterodine and CYP2D6	FDA	On FDA Biomarker List	Informative PGx							tolterodine	CYP2D6		2013-10-25
PA166104863	Annotation of FDA Label for dexlansoprazole and CYP2C19	FDA	On FDA Biomarker List	Informative PGx							dexlansoprazole	CYP2C19		2025-01-23
PA166104848	Annotation of FDA Label for rabeprazole and CYP2C19	FDA	On FDA Biomarker List	Informative PGx							rabeprazole	CYP2C19		2025-01-24
PA166104831	Annotation of FDA Label for irinotecan and UGT1A1	FDA	On FDA Biomarker List	Testing Recommended	Prescribing Info	Dosing Info		Other Prescribing Guidance		Prescribing	irinotecan	UGT1A1	UGT1A1*28; UGT1A1*6	2024-08-30
PA166104828	Annotation of FDA Label for hydralazine / isosorbide dinitrate and NAT2	FDA	On FDA Biomarker List	Informative PGx							hydralazine / isosorbide dinitrate	NAT2		2023-09-08
PA166104777	Annotation of FDA Label for clopidogrel and CYP2C19	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	clopidogrel	CYP2C19		2024-07-17
PA166104813	Annotation of FDA Label for carvedilol and CYP2D6	FDA	On FDA Biomarker List	Informative PGx							carvedilol	CYP2D6		2013-10-25
PA166104851	Annotation of FDA Label for ticagrelor and CYP2C19	FDA	On FDA Biomarker List	No Clinical PGx							ticagrelor	CYP2C19		2017-03-16
PA166104842	Annotation of FDA Label for nilotinib and ABL1, BCR	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		nilotinib	ABL1; BCR		2025-01-15
PA166104784	Annotation of FDA Label for diazepam and CYP2C19, CYP3A4	FDA	On FDA Biomarker List	Informative PGx							diazepam	CYP2C19; CYP3A4		2025-01-23
PA166104799	Annotation of FDA Label for tramadol and CYP2D6	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	tramadol	CYP2D6		2017-05-01
PA166104816	Annotation of FDA Label for esomeprazole and CYP2C19	FDA	On FDA Biomarker List	No Clinical PGx							esomeprazole	CYP2C19		2024-12-16
PA166104859	Annotation of FDA Label for crizotinib and ALK, ROS1	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		crizotinib	ALK; ROS1		2023-09-01
PA166104808	Annotation of FDA Label for nelfinavir and CYP2C19, CYP3A4, CYP3A5	FDA	Formerly on FDA Biomarker List								nelfinavir	CYP2C19; CYP3A4; CYP3A5		2024-08-29
PA166104797	Annotation of FDA Label for letrozole and ESR1, ESR2, PGR	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		letrozole	ESR1; ESR2; PGR		2023-09-01
PA166104781	Annotation of FDA Label for dasatinib and ABL1, BCR	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		dasatinib	ABL1; BCR		2024-08-26
PA166104836	Annotation of FDA Label for metoprolol and CYP2D6	FDA	On FDA Biomarker List	Informative PGx							metoprolol	CYP2D6		2023-09-07
PA166104820	Annotation of FDA Label for doxepin and CYP2C19, CYP2D6	FDA	On FDA Biomarker List	Informative PGx							doxepin	CYP2C19; CYP2D6		2013-10-25
PA166104826	Annotation of FDA Label for cetuximab and BRAF, EGFR, KRAS, NRAS	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		cetuximab	BRAF; EGFR; KRAS; NRAS	rs113488022	2025-01-16
PA166104854	Annotation of FDA Label for fluvoxamine and CYP2D6	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	fluvoxamine	CYP2D6		2024-07-22
PA166104858	Annotation of FDA Label for vemurafenib and BRAF	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		vemurafenib	BRAF	rs113488022	2023-09-01
PA166104796	Annotation of FDA Label for trastuzumab emtansine and ERBB2	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		trastuzumab emtansine	ERBB2		2023-09-01
PA166104857	Annotation of FDA Label for trimipramine and CYP2D6	FDA	On FDA Biomarker List	Informative PGx							trimipramine	CYP2D6		2024-07-19
PA166104818	Annotation of FDA Label for voriconazole and CYP2C19	FDA	On FDA Biomarker List	Informative PGx							voriconazole	CYP2C19		2025-01-24
PA166104802	Annotation of FDA Label for capecitabine and DPYD	FDA	On FDA Biomarker List	Testing Recommended	Prescribing Info		Alternate Drug			Prescribing	capecitabine	DPYD		2022-12-19
PA166104815	Annotation of FDA Label for clozapine and CYP2D6	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info	Dosing Info				Prescribing	clozapine	CYP2D6		2023-08-23
PA166104810	Annotation of FDA Label for mercaptopurine and NUDT15, TPMT	FDA	On FDA Biomarker List	Testing Recommended	Prescribing Info	Dosing Info				Prescribing	mercaptopurine	NUDT15; TPMT	NUDT15*2; NUDT15*3; TPMT*2; TPMT*3A; TPMT*3C	2024-06-06
PA166104864	Annotation of FDA Label for paroxetine and CYP2D6	FDA	On FDA Biomarker List								paroxetine	CYP2D6		2023-09-07
PA166104855	Annotation of FDA Label for boceprevir and IFNL3	FDA	On FDA Biomarker List	No Clinical PGx							boceprevir	IFNL3	rs12979860	2024-07-26
PA166104783	Annotation of FDA Label for rasburicase and CYB5R1, CYB5R2, CYB5R3, CYB5R4	FDA	On FDA Biomarker List	No Clinical PGx							rasburicase	CYB5R1; CYB5R2; CYB5R3; CYB5R4		2016-03-21
PA166104803	Annotation of FDA Label for maraviroc and CCR5	FDA	Formerly on FDA Biomarker List								maraviroc	CCR5		2023-08-18
PA166104868	Annotation of FDA Label for modafinil and CYP2D6	FDA	On FDA Biomarker List								modafinil	CYP2D6		2024-11-13
PA166104867	Annotation of FDA Label for telaprevir and IFNL3	FDA	On FDA Biomarker List	Informative PGx							telaprevir	IFNL3	rs12979860	2024-11-18
PA166104906	Annotation of FDA Label for probenecid and G6PD	FDA	On FDA Biomarker List	Informative PGx							probenecid	G6PD		2013-10-25
PA166104877	Annotation of FDA Label for mycophenolic acid and HPRT1	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	mycophenolic acid	HPRT1		2013-10-25
PA166104917	Annotation of FDA Label for prasugrel and CYP2B6, CYP2C19, CYP2C9, CYP3A5	FDA	On FDA Biomarker List	No Clinical PGx							prasugrel	CYP2B6; CYP2C19; CYP2C9; CYP3A5		2013-10-25
PA166104875	Annotation of FDA Label for clomipramine and CYP2D6	FDA	On FDA Biomarker List	Informative PGx							clomipramine	CYP2D6		2013-10-25
PA166105213	Annotation of FDA Label for oxcarbazepine and HLA-B	FDA	On FDA Biomarker List	Testing Recommended	Prescribing Info		Alternate Drug			Prescribing	oxcarbazepine	HLA-B	HLA-B*15:02	2019-04-16
PA166105222	Annotation of FDA Label for piroxicam and CYP2C9	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info	Dosing Info				Prescribing	piroxicam	CYP2C9		2023-08-23
PA166105023	Annotation of FDA Label for rosuvastatin and SLCO1B1	FDA	On FDA Biomarker List	Informative PGx							rosuvastatin	SLCO1B1	rs4149056	2017-03-15
PA166104893	Annotation of FDA Label for perphenazine and CYP2D6	FDA	On FDA Biomarker List	Informative PGx							perphenazine	CYP2D6		2013-10-25
PA166104921	Annotation of FDA Label for omeprazole and CYP2C19	FDA	On FDA Biomarker List	Informative PGx							omeprazole	CYP2C19		2017-03-16
PA166105178	Annotation of FDA Label for lidocaine / prilocaine and CYB5R3, G6PD	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	lidocaine / prilocaine	CYB5R3; G6PD		2024-07-23
PA166105028	Annotation of FDA Label for nebivolol and CYP2D6	FDA	On FDA Biomarker List	No Clinical PGx							nebivolol	CYP2D6		2023-08-15
PA166114907	Annotation of FDA Label for bosutinib and ABL1, BCR	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		bosutinib	ABL1; BCR		2025-01-15
PA166114912	Annotation of FDA Label for dabrafenib and BRAF	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		dabrafenib	BRAF	rs113488022	2025-01-17
PA166104901	Annotation of FDA Label for pantoprazole and CYP2C19	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info	Dosing Info				Prescribing	pantoprazole	CYP2C19	CYP2C19*2	2025-01-24
PA166104913	Annotation of FDA Label for everolimus and ERBB2, ESR1, ESR2	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		everolimus	ERBB2; ESR1; ESR2		2023-09-01
PA166104886	Annotation of FDA Label for dextromethorphan / quinidine and CYP2D6	FDA	On FDA Biomarker List	Testing Recommended	Prescribing Info			Other Prescribing Guidance		Prescribing	dextromethorphan / quinidine	CYP2D6		2023-10-24
PA166104912	Annotation of FDA Label for eltrombopag and F5, SERPINC1	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	eltrombopag	F5; SERPINC1		2024-07-19
PA166114905	Annotation of FDA Label for belimumab and TNFSF13B	FDA	Formerly on FDA Biomarker List								belimumab	TNFSF13B		2023-08-14
PA166104888	Annotation of FDA Label for nortriptyline and CYP2D6	FDA	On FDA Biomarker List	Informative PGx							nortriptyline	CYP2D6		2024-07-23
PA166104866	Annotation of FDA Label for pravastatin and APOE	FDA	Formerly on FDA Biomarker List								pravastatin	APOE		2023-09-07
PA166104892	Annotation of FDA Label for sulfasalazine and G6PD	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	sulfasalazine	G6PD		2024-08-16
PA166131627	Annotation of FDA Label for osimertinib and EGFR	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		osimertinib	EGFR	rs121434568; rs121434569	2024-10-04
PA166114931	Annotation of FDA Label for ponatinib and ABL1, BCR	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		ponatinib	ABL1; BCR	rs121913459	2024-10-04
PA166177509	Annotation of FDA Label for formoterol and CYP2C19, CYP2D6	FDA	On FDA Biomarker List								formoterol	CYP2C19; CYP2D6		2024-11-06
PA166115365	Annotation of FDA Label for trametinib and BRAF	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		trametinib	BRAF	rs113488022	2025-01-21
PA166163422	Annotation of FDA Label for dronabinol and CYP2C9	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	dronabinol	CYP2C9		2025-01-30
PA166114928	Annotation of FDA Label for mipomersen and LDLR	FDA	Formerly on FDA Biomarker List								mipomersen	LDLR		2024-08-20
PA166182751	Annotation of FDA Label for mepivacaine and G6PD	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	mepivacaine	G6PD		2023-10-03
PA166179855	Annotation of FDA Label for avatrombopag and F2, F5, PROC, PROS1, SERPINC1	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	avatrombopag	F2; F5; PROC; PROS1; SERPINC1	rs1799963; rs6025	2024-07-17
PA166169878	Annotation of FDA Label for brigatinib and ALK	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		brigatinib	ALK		2024-08-02
PA166160009	Annotation of FDA Label for pembrolizumab and ALK, CD274, EGFR, ERBB2	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		pembrolizumab	ALK; CD274; EGFR; ERBB2		2023-11-30
PA166177475	Annotation of FDA Label for abemaciclib and ERBB2, ESR1, ESR2, PGR	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		abemaciclib	ERBB2; ESR1; ESR2; PGR		2024-08-26
PA166170936	Annotation of FDA Label for tamoxifen and F2, F5	FDA	On FDA Biomarker List	No Clinical PGx							tamoxifen	F2; F5		
PA166153432	Annotation of FDA Label for flibanserin and CYP2C9, CYP2D6	FDA	On FDA Biomarker List	Informative PGx							flibanserin	CYP2C9; CYP2D6		2024-07-22
PA166182765	Annotation of FDA Label for flutamide and G6PD	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	flutamide	G6PD		2024-07-22
PA166180000	Annotation of FDA Label for meclizine and CYP2D6	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	meclizine	CYP2D6		2019-10-21
PA166181925	Annotation of FDA Label for tamoxifen and CYP2D6	FDA	On FDA Biomarker List	Informative PGx							tamoxifen	CYP2D6		2019-10-09
PA166129553	Annotation of FDA Label for belinostat and UGT1A1	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info	Dosing Info				Prescribing	belinostat	UGT1A1		2019-05-09
PA166127663	Annotation of FDA Label for divalproex sodium and POLG	FDA	Formerly on FDA Biomarker List	Testing Required	Prescribing Info		Alternate Drug			Prescribing	divalproex sodium	POLG		2023-08-22
PA166182739	Annotation of FDA Label for tafenoquine and G6PD	FDA	On FDA Biomarker List	Testing Required	Prescribing Info		Alternate Drug			Prescribing	tafenoquine	G6PD		
PA166160021	Annotation of FDA Label for cabozantinib and RET	FDA	On FDA Biomarker List						Cancer Genome		cabozantinib	RET		2023-08-15
PA166177512	Annotation of FDA Label for inotuzumab ozogamicin and ABL1, BCR	FDA	On FDA Biomarker List						Cancer Genome		inotuzumab ozogamicin	ABL1; BCR		2023-08-18
PA166182729	Annotation of FDA Label for amoxapine and CYP2D6	FDA	On FDA Biomarker List	Informative PGx							amoxapine	CYP2D6		
PA166170957	Annotation of FDA Label for vemurafenib and HRAS, KRAS, NRAS	FDA	On FDA Biomarker List						Cancer Genome		vemurafenib	HRAS; KRAS; NRAS		2023-08-29
PA166170048	Annotation of FDA Label for ribociclib and ERBB2, ESR1, ESR2, PGR	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		ribociclib	ERBB2; ESR1; ESR2; PGR		2023-08-31
PA166170932	Annotation of FDA Label for pembrolizumab and BRAF	FDA	On FDA Biomarker List						Cancer Genome		pembrolizumab	BRAF	rs113488022	2023-11-30
PA166153492	Annotation of FDA Label for brivaracetam and CYP2C19	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info	Dosing Info				Prescribing	brivaracetam	CYP2C19		2024-07-15
PA166160061	Annotation of FDA Label for dinutuximab and MYCN	FDA	On FDA Biomarker List						Cancer Genome		dinutuximab	MYCN		2023-08-15
PA166182760	Annotation of FDA Label for docetaxel and ESR1, ESR2, PGR	FDA	On FDA Biomarker List						Cancer Genome		docetaxel	ESR1; ESR2; PGR		2023-08-15
PA166115363	Annotation of FDA Label for succimer and G6PD	FDA	On FDA Biomarker List								succimer	G6PD		2023-08-24
PA166182768	Annotation of FDA Label for gilteritinib and FLT3	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		gilteritinib	FLT3		2023-08-31
PA166163430	Annotation of FDA Label for isosorbide dinitrate and CYB5R1, CYB5R2, CYB5R3, CYB5R4	FDA	On FDA Biomarker List	Informative PGx							isosorbide dinitrate	CYB5R1; CYB5R2; CYB5R3; CYB5R4		2024-07-30
PA166114941	Annotation of FDA Label for pravastatin and LDLR	FDA	Formerly on FDA Biomarker List								pravastatin	LDLR		2023-09-28
PA166182724	Annotation of FDA Label for ixabepilone and ERBB2, ESR1, ESR2, PGR	FDA	On FDA Biomarker List						Cancer Genome		ixabepilone	ERBB2; ESR1; ESR2; PGR		2023-08-18
PA166163417	Annotation of FDA Label for sofosbuvir / velpatasvir and IFNL3	FDA	On FDA Biomarker List								sofosbuvir / velpatasvir	IFNL3	rs12979860	2023-08-24
PA166163420	Annotation of FDA Label for venetoclax and FLT3, IDH1, IDH2, NPM1, TP53	FDA	On FDA Biomarker List						Cancer Genome		venetoclax	FLT3; IDH1; IDH2; NPM1; TP53		2023-08-29
PA166182734	Annotation of FDA Label for larotrectinib and NTRK1, NTRK2, NTRK3	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		larotrectinib	NTRK1; NTRK2; NTRK3		2024-05-24
PA166170931	Annotation of FDA Label for midostaurin and KIT, NPM1	FDA	On FDA Biomarker List						Cancer Genome		midostaurin	KIT; NPM1		2023-08-15
PA166163429	Annotation of FDA Label for atezolizumab and ALK, BRAF, CD274, EGFR	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		atezolizumab	ALK; BRAF; CD274; EGFR	rs113488022	2023-08-31
PA166182757	Annotation of FDA Label for inotersen and TTR	FDA	On FDA Biomarker List								inotersen	TTR		2023-08-18
PA166160046	Annotation of FDA Label for cobimetinib and BRAF	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		cobimetinib	BRAF	rs113488022	2023-09-01
PA166163428	Annotation of FDA Label for ledipasvir / sofosbuvir and IFNL3	FDA	On FDA Biomarker List								ledipasvir / sofosbuvir	IFNL3		2023-09-06
PA166169920	Annotation of FDA Label for niraparib and BRCA1, BRCA2	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		niraparib	BRCA1; BRCA2		2024-08-09
PA166114944	Annotation of FDA Label for regorafenib and KRAS	FDA	On FDA Biomarker List						Cancer Genome		regorafenib	KRAS		2024-08-26
PA166163421	Annotation of FDA Label for daclatasvir and IFNL3	FDA	On FDA Biomarker List	No Clinical PGx							daclatasvir	IFNL3		2023-08-15
PA166269301	Annotation of FDA Label for maralixibat and JAG1	FDA	On FDA Biomarker List								maralixibat	JAG1		2024-10-04
PA166238981	Annotation of FDA Label for synthetic conjugated estrogens, A and PROC, PROS1, SERPINC1	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	synthetic conjugated estrogens, A	PROC; PROS1; SERPINC1		
PA166293421	Annotation of FDA Label for pemigatinib and FGFR1, FGFR2	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		pemigatinib	FGFR1; FGFR2		
PA166190141	Annotation of FDA Label for enfortumab vedotin and NECTIN4	FDA	Formerly on FDA Biomarker List						Cancer Genome		enfortumab vedotin	NECTIN4		2023-08-17
PA166185180	Annotation of FDA Label for nusinersen and SMN2	FDA	On FDA Biomarker List								nusinersen	SMN2		2023-08-17
PA166190701	Annotation of FDA Label for givosiran and CPOX, HMBS, PPOX	FDA	On FDA Biomarker List								givosiran	CPOX; HMBS; PPOX		2024-12-13
PA166190101	Annotation of FDA Label for elexacaftor / tezacaftor / ivacaftor and CFTR	FDA	On FDA Biomarker List	Testing Required							elexacaftor / tezacaftor / ivacaftor	CFTR	rs113993958; rs113993960; rs115545701; rs11971167; rs121908751; rs121908752; rs121908753; rs121908755; rs121908757; rs121909005; rs121909013; rs121909020; rs121909041; rs141033578; rs150212784; rs186045772; rs193922525; rs200321110; rs202179988; rs267606723; rs368505753; rs397508256; rs397508288; rs397508442; rs397508513; rs397508537; rs397508759; rs74503330; rs74551128; rs75527207; rs75541969; rs77834169; rs77932196; rs78655421; rs78769542; rs80282562	2025-04-22
PA166182769	Annotation of FDA Label for hydroxychloroquine and G6PD	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	hydroxychloroquine	G6PD		2023-09-27
PA166235601	Annotation of FDA Label for lonafarnib and LMNA, ZMPSTE24	FDA	On FDA Biomarker List	Testing Required							lonafarnib	LMNA; ZMPSTE24		2024-08-08
PA166278281	Annotation of FDA Label for estradiol valerate	FDA	On FDA Biomarker List								estradiol valerate			2023-08-17
PA166235441	Annotation of FDA Label for bupivacaine and CYB5R3, G6PD	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	bupivacaine	CYB5R3; G6PD		2024-07-18
PA166182886	Annotation of FDA Label for migalastat and GLA	FDA	On FDA Biomarker List	Testing Required							migalastat	GLA		2024-08-09
PA166225101	Annotation of FDA Label for sacituzumab govitecan and UGT1A1	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	sacituzumab govitecan	UGT1A1	UGT1A1*28	2023-10-24
PA166182890	Annotation of FDA Label for olaparib and ESR1, ESR2, PGR, PPP2R2A	FDA	On FDA Biomarker List						Cancer Genome		olaparib	ESR1; ESR2; PGR; PPP2R2A		2023-08-17
PA166190761	Annotation of FDA Label for upadacitinib and CYP2D6	FDA	On FDA Biomarker List	No Clinical PGx							upadacitinib	CYP2D6		
PA166190023	Annotation of FDA Label for luspatercept and HBB	FDA	On FDA Biomarker List								luspatercept	HBB		2024-03-31
PA166225121	Annotation of FDA Label for selpercatinib and RET	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		selpercatinib	RET		2024-08-13
PA166185168	Annotation of FDA Label for pitolisant and CYP2D6	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info	Dosing Info				Prescribing	pitolisant	CYP2D6		2020-02-11
PA166225142	Annotation of FDA Label for tucatinib and ERBB2, HRAS, KRAS, NRAS	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		tucatinib	ERBB2; HRAS; KRAS; NRAS		2023-10-24
PA166224202	Annotation of FDA Label for capmatinib and MET	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		capmatinib	MET		2023-08-31
PA166191501	Annotation of FDA Label for lenvatinib	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		lenvatinib			2023-08-31
PA166127644	Annotation of HCSC Label for capecitabine and DPYD	HCSC		Testing Recommended	Prescribing Info		Alternate Drug			Prescribing	capecitabine	DPYD	DPYD c.1905+1G>A (*2A)	2024-09-18
PA166236521	Annotation of FDA Label for viltolarsen and DMD	FDA	On FDA Biomarker List	Testing Required							viltolarsen	DMD		2023-08-21
PA166236001	Annotation of FDA Label for sodium oxybate and ALDH5A1	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	sodium oxybate	ALDH5A1		2022-04-22
PA166121327	Annotation of EMA Label for pegloticase and G6PD	EMA		Testing Required	Prescribing Info		Alternate Drug			Prescribing	pegloticase	G6PD		2023-03-31
PA166169884	Annotation of FDA Label for durvalumab and ALK, CD274, EGFR, PDCD1	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		durvalumab	ALK; CD274; EGFR; PDCD1		2024-10-03
PA166278321	Annotation of FDA Label for ganaxolone and CDKL5	FDA	On FDA Biomarker List	Testing Required							ganaxolone	CDKL5		2023-08-21
PA166191581	Annotation of FDA Label for ipilimumab and ALK, CD274, EGFR	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		ipilimumab	ALK; CD274; EGFR		2025-02-12
PA166123390	Annotation of EMA Label for fampridine and SLC22A2	EMA									fampridine	SLC22A2		2023-08-17
PA166123412	Annotation of EMA Label for sunitinib and CYP3A4	EMA									sunitinib	CYP3A4		2023-08-24
PA166123421	Annotation of EMA Label for atazanavir and CYP2C19	EMA		Informative PGx							atazanavir	CYP2C19		2024-07-25
PA166123528	Annotation of PMDA Label for atomoxetine and CYP2D6	PMDA		Actionable PGx							atomoxetine	CYP2D6		
PA166123530	Annotation of PMDA Label for azathioprine and TPMT	PMDA		Actionable PGx							azathioprine	TPMT		
PA166123531	Annotation of PMDA Label for capecitabine and DPYD	PMDA		Actionable PGx							capecitabine	DPYD		
PA166123535	Annotation of PMDA Label for clopidogrel and CYP2C19	PMDA		Actionable PGx							clopidogrel	CYP2C19		
PA166123536	Annotation of PMDA Label for crizotinib and ALK	PMDA		Testing Required							crizotinib	ALK		
PA166123538	Annotation of PMDA Label for eltrombopag and SERPINC1	PMDA		Actionable PGx							eltrombopag	SERPINC1		
PA166123539	Annotation of PMDA Label for fluorouracil and DPYD	PMDA		Actionable PGx							fluorouracil	DPYD		
PA166123543	Annotation of PMDA Label for indacaterol and UGT1A1	PMDA		Actionable PGx							indacaterol	UGT1A1		
PA166123526	Annotation of PMDA Label for irinotecan and UGT1A1	PMDA		Testing Recommended							irinotecan	UGT1A1		
PA166123546	Annotation of PMDA Label for mycophenolic acid and HPRT1	PMDA		Actionable PGx							mycophenolic acid	HPRT1		
PA166123547	Annotation of PMDA Label for panitumumab and KRAS	PMDA		Testing Required							panitumumab	KRAS		
PA166123548	Annotation of PMDA Label for rasburicase and G6PD	PMDA		Actionable PGx							rasburicase	G6PD		
PA166123550	Annotation of PMDA Label for trastuzumab and ERBB2	PMDA		Testing Required							trastuzumab	ERBB2		
PA166123537	Annotation of PMDA Label for dasatinib and ABL1, BCR	PMDA		Testing Required							dasatinib	ABL1; BCR		
PA166127724	Annotation of HCSC Label for trastuzumab and ERBB2	HCSC		Testing Required					Cancer Genome		trastuzumab	ERBB2		2024-09-17
PA166127721	Annotation of HCSC Label for tolterodine and CYP2D6	HCSC		Informative PGx							tolterodine	CYP2D6		2024-07-26
PA166127725	Annotation of HCSC Label for tretinoin and PML, RARA	HCSC							Cancer Genome		tretinoin	PML; RARA		2024-08-06
PA166123408	Annotation of EMA Label for vortioxetine and CYP2D6	EMA		Actionable PGx	Prescribing Info	Dosing Info				Prescribing	vortioxetine	CYP2D6		2014-09-15
PA166127730	Annotation of HCSC Label for voriconazole and CYP2C19	HCSC		Informative PGx							voriconazole	CYP2C19		2025-01-24
PA166127732	Annotation of HCSC Label for warfarin and CYP2C9, VKORC1	HCSC		Actionable PGx	Prescribing Info	Dosing Info				Prescribing	warfarin	CYP2C9; VKORC1	CYP2C9*2; CYP2C9*3; rs9923231	2024-11-21
PA166127723	Annotation of HCSC Label for trastuzumab emtansine and ERBB2	HCSC		Testing Required					Cancer Genome		trastuzumab emtansine	ERBB2		2024-09-18
PA166127727	Annotation of HCSC Label for velaglucerase alfa and GBA1	HCSC									velaglucerase alfa	GBA1		2024-08-06
PA166127729	Annotation of HCSC Label for moviprep and G6PD	HCSC		Informative PGx							moviprep	G6PD		2024-07-25
PA166127728	Annotation of HCSC Label for vemurafenib and BRAF	HCSC		Testing Required					Cancer Genome		vemurafenib	BRAF	rs113488022	2025-01-21
PA166129515	Annotation of FDA Label for desflurane and CACNA1S, RYR1	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	desflurane	CACNA1S; RYR1		2023-03-31
PA166129449	Annotation of EMA Label for ceritinib and ALK	EMA		Testing Required					Cancer Genome		ceritinib	ALK		2024-04-16
PA166129516	Annotation of HCSC Label for desflurane and CACNA1S, RYR1	HCSC		Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	desflurane	CACNA1S; RYR1		2024-09-19
PA166129448	Annotation of EMA Label for ibrutinib	EMA							Cancer Genome		ibrutinib			2024-08-07
PA166127631	Annotation of HCSC Label for aripiprazole and CYP2D6	HCSC		Actionable PGx	Prescribing Info	Dosing Info	Alternate Drug			Prescribing	aripiprazole	CYP2D6		2025-03-28
PA166127681	Annotation of HCSC Label for ibrutinib	HCSC							Cancer Genome		ibrutinib			2024-08-07
PA166123418	Annotation of EMA Label for posaconazole and CYP3A4	EMA									posaconazole	CYP3A4		2023-08-23
PA166123419	Annotation of EMA Label for indinavir and CYP3A4	EMA									indinavir	CYP3A4		2023-08-18
PA166127630	Annotation of HCSC Label for anastrozole and ESR1, ESR2, PGR	HCSC							Cancer Genome		anastrozole	ESR1; ESR2; PGR		2024-08-26
PA166127675	Annotation of HCSC Label for galantamine and CYP2D6	HCSC		No Clinical PGx							galantamine	CYP2D6		2024-12-03
PA166127657	Annotation of HCSC Label for dapsone and G6PD	HCSC		Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	dapsone	G6PD		2024-11-26
PA166127674	Annotation of HCSC Label for fluorouracil and DPYD	HCSC		Testing Recommended	Prescribing Info		Alternate Drug			Prescribing	fluorouracil	DPYD		2024-04-25
PA166127628	Annotation of HCSC Label for acetaminophen, tramadol and CYP2D6	HCSC		Informative PGx							acetaminophen; tramadol	CYP2D6		2024-07-18
PA166127627	Annotation of HCSC Label for abacavir and HLA-B	HCSC		Testing Required	Prescribing Info		Alternate Drug			Prescribing	abacavir	HLA-B	HLA-B*57:01	2024-02-07
PA166127659	Annotation of HCSC Label for darifenacin and CYP2D6	HCSC		No Clinical PGx							darifenacin	CYP2D6		2024-12-02
PA166127661	Annotation of HCSC Label for dexlansoprazole and CYP2C19	HCSC		Informative PGx							dexlansoprazole	CYP2C19		2024-12-02
PA166127653	Annotation of HCSC Label for clopidogrel and CYP2C19	HCSC		Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	clopidogrel	CYP2C19	CYP2C19*2; CYP2C19*3; CYP2C19*4; CYP2C19*5; CYP2C19*6; CYP2C19*7; CYP2C19*8	2024-07-17
PA166127667	Annotation of HCSC Label for efavirenz / emtricitabine / tenofovir disoproxil and CYP2B6	HCSC		Informative PGx							efavirenz / emtricitabine / tenofovir disoproxil	CYP2B6	CYP2B6*6; rs3745274	2024-12-02
PA166127654	Annotation of HCSC Label for codeine and CYP2D6	HCSC		Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	codeine	CYP2D6	CYP2D6*2x2	2024-07-19
PA166127673	Annotation of HCSC Label for fesoterodine and CYP2D6	HCSC		Informative PGx							fesoterodine	CYP2D6		2024-12-02
PA166127677	Annotation of HCSC Label for glyburide and G6PD	HCSC		Actionable PGx	Prescribing Info		Alternate Drug	Other Prescribing Guidance		Prescribing	glyburide	G6PD		2024-07-22
PA166127678	Annotation of HCSC Label for glimepiride and G6PD	HCSC		Actionable PGx	Prescribing Info		Alternate Drug	Other Prescribing Guidance		Prescribing	glimepiride	G6PD		2024-07-22
PA166127656	Annotation of HCSC Label for dabrafenib and BRAF	HCSC		Testing Required					Cancer Genome		dabrafenib	BRAF	rs113488022	2025-01-17
PA166127676	Annotation of HCSC Label for gefitinib and EGFR	HCSC		Testing Required					Cancer Genome		gefitinib	EGFR		2024-08-07
PA166127670	Annotation of HCSC Label for esomeprazole and CYP2C19	HCSC		No Clinical PGx							esomeprazole	CYP2C19		2024-07-26
PA166127629	Annotation of HCSC Label for afatinib and EGFR	HCSC		Testing Required					Cancer Genome		afatinib	EGFR	rs121434568	2024-09-10
PA166127655	Annotation of HCSC Label for crizotinib and ALK, ROS1	HCSC		Testing Required					Cancer Genome		crizotinib	ALK; ROS1		2024-09-10
PA166127665	Annotation of HCSC Label for divalproex sodium and POLG	HCSC		Testing Required	Prescribing Info		Alternate Drug			Prescribing	divalproex sodium	POLG		2024-09-10
PA166127669	Annotation of HCSC Label for erlotinib and EGFR	HCSC		Testing Required					Cancer Genome		erlotinib	EGFR		2024-09-10
PA166129518	Annotation of HCSC Label for isoflurane and CACNA1S, RYR1	HCSC		Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	isoflurane	CACNA1S; RYR1		2024-09-19
PA166123416	Annotation of EMA Label for ivabradine and CYP3A4	EMA									ivabradine	CYP3A4		2023-08-18
PA166129447	Annotation of EMA Label for eliglustat and CYP2D6	EMA		Testing Required	Prescribing Info	Dosing Info	Alternate Drug			Prescribing	eliglustat	CYP2D6		2025-04-23
PA166127714	Annotation of HCSC Label for sulfadiazine and G6PD	HCSC		Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	sulfadiazine	G6PD		2024-07-21
PA166127686	Annotation of HCSC Label for lenalidomide	HCSC		Testing Required					Cancer Genome		lenalidomide			2024-05-02
PA166127688	Annotation of HCSC Label for lomitapide and LDLR	HCSC									lomitapide	LDLR		2024-09-16
PA166127683	Annotation of HCSC Label for irinotecan and UGT1A1	HCSC		Testing Recommended	Prescribing Info	Dosing Info				Prescribing	irinotecan	UGT1A1	UGT1A1*28; UGT1A1*6	2024-05-30
PA166127696	Annotation of HCSC Label for norfloxacin and G6PD	HCSC		Informative PGx							norfloxacin	G6PD		2024-07-23
PA166127694	Annotation of HCSC Label for nitrofurantoin and G6PD	HCSC		Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	nitrofurantoin	G6PD		2024-07-23
PA166127684	Annotation of HCSC Label for ivacaftor and CFTR	HCSC		Testing Required							ivacaftor	CFTR	rs113993960; rs121908755; rs121908757; rs121909005; rs121909013; rs121909041; rs193922525; rs267606723; rs397508453; rs74503330; rs75527207; rs80282562	2024-09-12
PA166127715	Annotation of HCSC Label for sulfamethoxazole / trimethoprim and G6PD	HCSC		Informative PGx							sulfamethoxazole / trimethoprim	G6PD		2024-07-22
PA166127690	Annotation of HCSC Label for mercaptopurine and NUDT15, TPMT	HCSC		Testing Recommended	Prescribing Info	Dosing Info				Prescribing	mercaptopurine	NUDT15; TPMT	rs116855232; TPMT*2; TPMT*3A; TPMT*3C	2024-07-25
PA166127692	Annotation of HCSC Label for mycophenolic acid and HPRT1	HCSC		Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	mycophenolic acid	HPRT1		2024-07-25
PA166127718	Annotation of HCSC Label for tamoxifen and ESR1, ESR2, PGR	HCSC		Testing Required					Cancer Genome		tamoxifen	ESR1; ESR2; PGR		2024-08-14
PA166127716	Annotation of HCSC Label for sulfasalazine and G6PD	HCSC		Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	sulfasalazine	G6PD		2024-08-14
PA166127697	Annotation of HCSC Label for nortriptyline and CYP2D6	HCSC		Informative PGx							nortriptyline	CYP2D6		2024-07-24
PA166123423	Annotation of EMA Label for tipranavir and CYP3A4	EMA									tipranavir	CYP3A4		2023-08-27
PA166129450	Annotation of EMA Label for trametinib and BRAF	EMA		Testing Required					Cancer Genome		trametinib	BRAF	rs113488022	2025-01-21
PA166182753	Annotation of FDA Label for meloxicam and CYP2C9	FDA	On FDA Biomarker List	Informative PGx							meloxicam	CYP2C9		2024-11-12
PA166127719	Annotation of HCSC Label for tetrabenazine and CYP2D6	HCSC		Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	tetrabenazine	CYP2D6		2024-07-18
PA166127720	Annotation of HCSC Label for thioguanine and NUDT15, TPMT	HCSC		Testing Recommended	Prescribing Info	Dosing Info		Other Prescribing Guidance		Prescribing	thioguanine	NUDT15; TPMT	rs116855232; TPMT*2; TPMT*3A; TPMT*3B; TPMT*3C; TPMT*4	2024-07-19
PA166129520	Annotation of HCSC Label for sevoflurane and CACNA1S, RYR1	HCSC		Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	sevoflurane	CACNA1S; RYR1		2024-09-19
PA166359261	Annotation of HCSC Label for tobramycin and MT-RNR1	HCSC		Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	tobramycin	MT-RNR1	rs267606617	
PA166359281	Annotation of HCSC Label for trimipramine	HCSC									trimipramine			
PA166190201	Annotation of FDA Label for entrectinib and NTRK1, NTRK2, NTRK3, ROS1	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		entrectinib	NTRK1; NTRK2; NTRK3; ROS1		2024-04-16
PA166189821	Annotation of FDA Label for voxelotor and HBB	FDA	On FDA Biomarker List								voxelotor	HBB		2024-03-31
PA166190741	Annotation of FDA Label for golodirsen and DMD	FDA	On FDA Biomarker List	Testing Required							golodirsen	DMD		2023-08-21
PA166189982	Annotation of FDA Label for crizanlizumab-tmca and HBB	FDA	On FDA Biomarker List								crizanlizumab-tmca	HBB		2024-03-31
PA166359501	Annotation of HCSC Label for umeclidinium and CYP2D6	HCSC		No Clinical PGx							umeclidinium	CYP2D6		
PA166359521	Annotation of HCSC Label for valbenazine	HCSC									valbenazine			
PA166124617	Annotation of FDA Label for ceritinib and ALK	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		ceritinib	ALK		2023-09-01
PA166115367	Annotation of FDA Label for velaglucerase alfa and GBA1	FDA	Formerly on FDA Biomarker List								velaglucerase alfa	GBA1		2024-08-06
PA166114910	Annotation of FDA Label for chlorpropamide and G6PD	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug	Other Prescribing Guidance		Prescribing	chlorpropamide	G6PD		2023-08-25
PA166104787	Annotation of FDA Label for cevimeline and CYP2D6	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	cevimeline	CYP2D6		2013-10-25
PA166359641	Annotation of HCSC Label for venlafaxine and CYP2D6	HCSC		No Clinical PGx							venlafaxine	CYP2D6		
PA166127731	Annotation of HCSC Label for vortioxetine and CYP2D6	HCSC		Informative PGx							vortioxetine	CYP2D6		2024-11-21
PA166184423	Annotation of Swissmedic Label for antithrombotic agents and G6PD	Swissmedic		Actionable PGx							antithrombotic agents	G6PD		
PA166184111	Annotation of Swissmedic Label for atomoxetine and CYP2D6	Swissmedic		Actionable PGx							atomoxetine	CYP2D6		
PA166359681	Annotation of EMA Label for vutrisiran and TTR	EMA									vutrisiran	TTR		
PA166184456	Annotation of Swissmedic Label for glyburide and G6PD	Swissmedic		Actionable PGx							glyburide	G6PD		
PA166104776	Annotation of FDA Label for warfarin and CYP2C9, VKORC1	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info	Dosing Info				Prescribing	warfarin	CYP2C9; VKORC1	CYP2C9*1; CYP2C9*2; CYP2C9*3; rs9923231	2024-11-21
PA166184223	Annotation of Swissmedic Label for Paracetamol, combinations excl. Psycholeptics (Vicks MediNait Sirup) and CYP2D6, G6PD	Swissmedic		Actionable PGx	Prescribing Info					Prescribing	Paracetamol, combinations excl. Psycholeptics (Vicks MediNait Sirup)	CYP2D6; G6PD		2023-02-28
PA166359701	Annotation of FDA Label for warfarin and PROC, PROS1	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	warfarin	PROC; PROS1		
PA166184428	Annotation of Swissmedic Label for sertindole and CYP2D6	Swissmedic		Actionable PGx							sertindole	CYP2D6		
PA166184231	Annotation of Swissmedic Label for umeclidinium and CYP2D6	Swissmedic		Informative PGx							umeclidinium	CYP2D6		
PA166184237	Annotation of Swissmedic Label for Vitamin B-complex with vitamin C and G6PD	Swissmedic		Actionable PGx							Vitamin B-complex with vitamin C	G6PD		
PA166359741	Annotation of HCSC Label for amikacin	HCSC									amikacin			
PA166184490	Annotation of Swissmedic Label for zuclopenthixol and CYP2D6	Swissmedic									zuclopenthixol	CYP2D6		2023-08-29
PA166184499	Annotation of Swissmedic Label for rosuvastatin and ABCG2, SLCO1B1	Swissmedic		Actionable PGx	Prescribing Info	Dosing Info				Prescribing	rosuvastatin	ABCG2; SLCO1B1	rs2231142; rs4149056	2024-08-13
PA166359761	Annotation of HCSC Label for amitriptyline and CYP2C19, CYP2D6	HCSC		Actionable PGx	Prescribing Info	Dosing Info				Prescribing	amitriptyline	CYP2C19; CYP2D6		
PA166184434	Annotation of Swissmedic Label for sofosbuvir and IFNL3, IFNL4	Swissmedic		Actionable PGx	Prescribing Info					Prescribing	sofosbuvir	IFNL3; IFNL4	rs12979860	
PA166223861	Annotation of FDA Label for bupropion and CYP2D6	FDA	On FDA Biomarker List								bupropion	CYP2D6		2023-08-14
PA166223902	Annotation of FDA Label for alglucosidase alfa and GAA	FDA	On FDA Biomarker List	Testing Required							alglucosidase alfa	GAA		2023-08-21
PA166223941	Annotation of FDA Label for avapritinib and PDGFRA	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		avapritinib	PDGFRA	rs121908585	2023-08-31
PA166224061	Annotation of HCSC Label for oxcarbazepine and HLA-B	HCSC		Testing Recommended	Prescribing Info		Alternate Drug			Prescribing	oxcarbazepine	HLA-B	HLA-B*15:02	2024-07-26
PA166359721	Annotation of HCSC Label for warfarin and PROC, PROS1	HCSC		Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	warfarin	PROC; PROS1		
PA166224121	Annotation of FDA Label for escitalopram and CYP2D6	FDA	On FDA Biomarker List								escitalopram	CYP2D6		2025-01-23
PA166127664	Annotation of FDA Label for ibrutinib	FDA	On FDA Biomarker List						Cancer Genome		ibrutinib			2024-08-07
PA166224361	Annotation of FDA Label for gemtuzumab ozogamicin and CD33	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		gemtuzumab ozogamicin	CD33		2023-08-31
PA166224101	Annotation of FDA Label for citalopram and CYP2D6	FDA	On FDA Biomarker List	No Clinical PGx							citalopram	CYP2D6		2023-08-15
PA166224962	Annotation of FDA Label for isatuximab	FDA	On FDA Biomarker List						Cancer Genome		isatuximab			2023-08-18
PA166224961	Annotation of FDA Label for inebilizumab and AQP4	FDA	On FDA Biomarker List								inebilizumab	AQP4		2023-09-28
PA166225161	Annotation of FDA Label for oliceridine and CYP2D6	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info	Dosing Info		Other Prescribing Guidance		Prescribing	oliceridine	CYP2D6		2024-09-09
PA166224441	Annotation of FDA Label for ibrutinib and MYD88	FDA	On FDA Biomarker List						Cancer Genome		ibrutinib	MYD88	rs387907272	2023-08-18
PA166224221	Annotation of FDA Label for eculizumab and AQP4, CHRNA1, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNB1, CHRNE	FDA	On FDA Biomarker List								eculizumab	AQP4; CHRNA1; CHRNA3; CHRNA4; CHRNA5; CHRNA6; CHRNA7; CHRNB1; CHRNE		2023-09-28
PA166185145	Annotation of FDA Label for brentuximab vedotin and TNFRSF8	FDA	On FDA Biomarker List						Cancer Genome		brentuximab vedotin	TNFRSF8		2024-08-05
PA166227321	Annotation of HCSC Label for amifampridine phosphate and NAT2	HCSC		Actionable PGx	Prescribing Info	Dosing Info				Prescribing	amifampridine phosphate	NAT2		
PA166227161	Annotation of EMA Label for ramucirumab and KRAS	EMA							Cancer Genome		ramucirumab	KRAS		2023-08-23
PA166227221	Annotation of EMA Label for amifampridine phosphate and NAT2	EMA		Informative PGx							amifampridine phosphate	NAT2		
PA166160054	Annotation of FDA Label for brexpiprazole and CYP2D6	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info	Dosing Info				Prescribing	brexpiprazole	CYP2D6		2019-05-01
PA166227101	Annotation of EMA Label for alglucosidase alfa and GAA	EMA		Testing Required							alglucosidase alfa	GAA		2024-04-15
PA166227121	Annotation of HCSC Label for alglucosidase alfa and GAA	HCSC		Testing Required							alglucosidase alfa	GAA		2024-04-15
PA166227141	Annotation of EMA Label for ramucirumab and EGFR	EMA		Testing Required					Cancer Genome		ramucirumab	EGFR		2024-04-21
PA166227181	Annotation of EMA Label for alpelisib and ERBB2, ESR1, ESR2, PIK3CA	EMA		Testing Required					Cancer Genome		alpelisib	ERBB2; ESR1; ESR2; PIK3CA		2024-04-15
PA166227201	Annotation of HCSC Label for alpelisib and ERBB2, ESR1, ESR2, PIK3CA	HCSC		Testing Required					Cancer Genome		alpelisib	ERBB2; ESR1; ESR2; PIK3CA		2024-04-15
PA166234761	Annotation of FDA Label for simvastatin and SLCO1B1	FDA									simvastatin	SLCO1B1		2023-08-24
PA166235981	Annotation of FDA Label for pralsetinib and RET	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		pralsetinib	RET	rs74799832; rs77709286	2024-08-13
PA166235921	Annotation of FDA Label for metreleptin and AGPAT2, BSCL2, LEP	FDA	On FDA Biomarker List	Testing Required							metreleptin	AGPAT2; BSCL2; LEP		2024-08-09
PA166235361	Annotation of FDA Label for lumasiran and AGXT	FDA	On FDA Biomarker List								lumasiran	AGXT		2024-08-08
PA166184430	Annotation of Swissmedic Label for fenofibrate, simvastatin and SLCO1B1	Swissmedic		Actionable PGx							fenofibrate; simvastatin	SLCO1B1	rs4149056	
PA166184158	Annotation of Swissmedic Label for ombitasvir / paritaprevir / ritonavir and IFNL3, IFNL4	Swissmedic		Actionable PGx							ombitasvir / paritaprevir / ritonavir	IFNL3; IFNL4	rs12979860	
PA166184394	Annotation of Swissmedic Label for prasugrel and CYP2B6, CYP2C19, CYP2C9, CYP3A5	Swissmedic		Informative PGx							prasugrel	CYP2B6; CYP2C19; CYP2C9; CYP3A5		
PA166160718	Annotation of PMDA Label for methylene blue and BLVRB, G6PD	PMDA		Actionable PGx							methylene blue	BLVRB; G6PD		
PA166160274	Annotation of PMDA Label for cetuximab and EGFR, KRAS	PMDA		Testing Required							cetuximab	EGFR; KRAS		
PA166160711	Annotation of PMDA Label for everolimus and ERBB2, ESR1, ESR2	PMDA		Testing Required							everolimus	ERBB2; ESR1; ESR2		
PA166184426	Annotation of Swissmedic Label for tolterodine and CYP2D6, CYP3A4	Swissmedic		Actionable PGx							tolterodine	CYP2D6; CYP3A4		
PA166120287	Annotation of EMA Label for ethinyl estradiol / norelgestromin and F5, PROC, PROS1, SERPINC1	EMA		Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	ethinyl estradiol / norelgestromin	F5; PROC; PROS1; SERPINC1		2023-02-16
PA166163419	Annotation of FDA Label for rucaparib and BRCA1, BRCA2	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		rucaparib	BRCA1; BRCA2		2023-08-31
PA166104915	Annotation of EMA Label for olanzapine and CYP1A2, CYP2D6	EMA									olanzapine	CYP1A2; CYP2D6		2023-08-17
PA166104817	Annotation of FDA Label for tretinoin and PML, RARA	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		tretinoin	PML; RARA		2023-09-11
PA166104819	Annotation of FDA Label for tamoxifen and ESR1, ESR2, PGR	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		tamoxifen	ESR1; ESR2; PGR		2023-09-01
PA166104907	Annotation of EMA Label for eltrombopag and F5, SERPINC1	EMA		Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	eltrombopag	F5; SERPINC1		2024-08-14
PA166184560	Annotation of FDA Label for ramucirumab and ALK, EGFR	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		ramucirumab	ALK; EGFR		2023-12-05
PA166104909	Annotation of EMA Label for crizotinib and ALK, ROS1	EMA		Testing Required					Cancer Genome		crizotinib	ALK; ROS1		2024-04-16
PA166127632	Annotation of HCSC Label for arsenic trioxide and PML, RARA	HCSC		Testing Required					Cancer Genome		arsenic trioxide	PML; RARA		2024-12-02
PA166104821	Annotation of EMA Label for arsenic trioxide and PML, RARA	EMA		Testing Required					Cancer Genome		arsenic trioxide	PML; RARA		2024-04-15
PA166127699	Annotation of HCSC Label for panitumumab and KRAS, NRAS	HCSC		Testing Required					Cancer Genome		panitumumab	KRAS; NRAS		2024-08-12
PA166104911	Annotation of EMA Label for everolimus and ERBB2, ESR1, ESR2	EMA		Testing Required					Cancer Genome		everolimus	ERBB2; ESR1; ESR2		2024-04-16
PA166104919	Annotation of EMA Label for fulvestrant and ERBB2, ESR1, ESR2, PGR	EMA		Testing Required					Cancer Genome		fulvestrant	ERBB2; ESR1; ESR2; PGR		2024-04-16
PA166104809	Annotation of FDA Label for panitumumab and KRAS, NRAS	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		panitumumab	KRAS; NRAS		2024-08-12
PA166120370	Annotation of EMA Label for glimepiride, pioglitazone and G6PD	EMA		Actionable PGx	Prescribing Info		Alternate Drug	Other Prescribing Guidance		Prescribing	glimepiride; pioglitazone	G6PD		2024-07-22
PA166104914	Annotation of EMA Label for dasatinib and ABL1, BCR	EMA		Testing Required					Cancer Genome		dasatinib	ABL1; BCR		2024-08-26
PA166182923	Annotation of EMA Label for abemaciclib and ERBB2, ESR1, ESR2, PGR	EMA		Testing Required					Cancer Genome		abemaciclib	ERBB2; ESR1; ESR2; PGR		2024-08-26
PA166127645	Annotation of HCSC Label for carbamazepine and HLA-A, HLA-B	HCSC		Testing Recommended	Prescribing Info		Alternate Drug			Prescribing	carbamazepine	HLA-A; HLA-B	HLA-A*31:01; HLA-B*15:02	2024-09-18
PA166127648	Annotation of HCSC Label for cetuximab and EGFR, KRAS, NRAS	HCSC		Testing Required					Cancer Genome		cetuximab	EGFR; KRAS; NRAS		2025-01-16
PA166170938	Annotation of FDA Label for trametinib and HRAS, KRAS, NRAS	FDA	On FDA Biomarker List						Cancer Genome		trametinib	HRAS; KRAS; NRAS		2025-01-21
PA166104926	Annotation of EMA Label for imatinib and ABL1, BCR, FIP1L1, KIT, PDGFRA, PDGFRB	EMA		Testing Required					Cancer Genome		imatinib	ABL1; BCR; FIP1L1; KIT; PDGFRA; PDGFRB		2025-02-05
PA166184224	Annotation of Swissmedic Label for acetaminophen, acetaminophen / tramadol and G6PD	Swissmedic		Actionable PGx	Prescribing Info					Prescribing	acetaminophen; acetaminophen / tramadol	G6PD		2023-02-28
PA166105232	Annotation of FDA Label for quinine and CYP2D6	FDA	On FDA Biomarker List								quinine	CYP2D6		2024-10-04
PA166123527	Annotation of PMDA Label for arsenic trioxide and PML, RARA	PMDA		Testing Required							arsenic trioxide	PML; RARA		
PA166123532	Annotation of PMDA Label for carbamazepine and HLA-A, HLA-B	PMDA		Actionable PGx							carbamazepine	HLA-A; HLA-B		
PA166123540	Annotation of PMDA Label for fulvestrant and ESR1, ESR2	PMDA		Testing Required							fulvestrant	ESR1; ESR2		
PA166123541	Annotation of PMDA Label for gefitinib and CYP2D6, EGFR	PMDA		Testing Required							gefitinib	CYP2D6; EGFR		
PA166123542	Annotation of PMDA Label for imatinib and ABL1, BCR	PMDA		Testing Required							imatinib	ABL1; BCR		
PA166123544	Annotation of PMDA Label for lapatinib and ERBB2, HLA-DQA1, HLA-DRB1	PMDA		Testing Required							lapatinib	ERBB2; HLA-DQA1; HLA-DRB1		
PA166123552	Annotation of PMDA Label for valproic acid and CPS1, OTC	PMDA		Actionable PGx							valproic acid	CPS1; OTC		
PA166104823	Annotation of EMA Label for methylene blue and BLVRB, G6PD	EMA		Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	methylene blue	BLVRB; G6PD		2024-11-12
PA166105334	Annotation of EMA Label for nilotinib and ABL1, BCR	EMA		Testing Required					Cancer Genome		nilotinib	ABL1; BCR		2025-01-15
PA166127682	Annotation of HCSC Label for imatinib and ABL1, BCR, FIP1L1, KIT, PDGFRA, PDGFRB	HCSC		Testing Required					Cancer Genome		imatinib	ABL1; BCR; FIP1L1; KIT; PDGFRA; PDGFRB		2025-02-11
PA166183781	Annotation of Swissmedic Label for mercaptopurine and NUDT15, TPMT	Swissmedic		Actionable PGx	Prescribing Info					Prescribing	mercaptopurine	NUDT15; TPMT	TPMT*2; TPMT*3A; TPMT*3C	
PA166127668	Annotation of HCSC Label for eltrombopag and F5, SERPINC1	HCSC		Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	eltrombopag	F5; SERPINC1	rs6025	2024-07-19
PA166185190	Annotation of FDA Label for ospemifene and CYP2B6, CYP2C9	FDA	On FDA Biomarker List								ospemifene	CYP2B6; CYP2C9		2023-08-23
PA166127666	Annotation of HCSC Label for drospirenone / ethinyl estradiol and F5, PROC, PROS1, SERPINC1	HCSC		Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	drospirenone / ethinyl estradiol	F5; PROC; PROS1; SERPINC1	rs6025	2024-07-18
PA166127726	Annotation of HCSC Label for valproic acid and OTC, POLG	HCSC		Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	valproic acid	OTC; POLG		2024-07-19
PA166127685	Annotation of HCSC Label for lapatinib and ERBB2	HCSC		Testing Required					Cancer Genome		lapatinib	ERBB2		2024-07-23
PA166236241	Annotation of FDA Label for satralizumab and AQP4, IL6R	FDA	On FDA Biomarker List								satralizumab	AQP4; IL6R		2023-09-28
PA166182759	Annotation of FDA Label for chloroprocaine and CYB5R3, G6PD	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	chloroprocaine	CYB5R3; G6PD		2024-07-23
PA166129517	Annotation of FDA Label for isoflurane and CACNA1S, RYR1	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	isoflurane	CACNA1S; RYR1		2023-04-01
PA166235941	Annotation of FDA Label for setmelanotide and LEPR, PCSK1, POMC	FDA	On FDA Biomarker List	Testing Required							setmelanotide	LEPR; PCSK1; POMC		2023-08-22
PA166123410	Annotation of EMA Label for ritonavir and CYP2D6, CYP3A4	EMA									ritonavir	CYP2D6; CYP3A4		2023-08-22
PA166123551	Annotation of PMDA Label for tretinoin and PML, RARA	PMDA							Cancer Genome		tretinoin	PML; RARA		2023-09-26
PA166104840	Annotation of EMA Label for lapatinib and ERBB2, ESR1, ESR2	EMA		Testing Required					Cancer Genome		lapatinib	ERBB2; ESR1; ESR2		2024-04-21
PA166183421	Annotation of EMA Label for ribociclib and ERBB2, ESR1, ESR2, PGR	EMA		Testing Required					Cancer Genome		ribociclib	ERBB2; ESR1; ESR2; PGR		2024-04-21
PA166183425	Annotation of EMA Label for talazoparib and BRCA1, BRCA2, ERBB2	EMA		Testing Required					Cancer Genome		talazoparib	BRCA1; BRCA2; ERBB2		2024-04-21
PA166127695	Annotation of HCSC Label for ethinyl estradiol / norelgestromin and F2, F5, MTHFR, PROC, PROS1, SERPINC1	HCSC		Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	ethinyl estradiol / norelgestromin	F2; F5; MTHFR; PROC; PROS1; SERPINC1	rs1799963; rs1801131; rs1801133	2024-07-25
PA166127687	Annotation of HCSC Label for letrozole and ESR1, ESR2, PGR	HCSC		Testing Required					Cancer Genome		letrozole	ESR1; ESR2; PGR		2024-08-08
PA166127693	Annotation of HCSC Label for nilotinib and ABL1, BCR	HCSC		Testing Required					Cancer Genome		nilotinib	ABL1; BCR		2024-08-09
PA166127712	Annotation of HCSC Label for sodium phenylbutyrate and ASS1, CPS1, OTC	HCSC									sodium phenylbutyrate	ASS1; CPS1; OTC		2024-08-13
PA166114381	Annotation of EMA Label for sodium phenylbutyrate and ASS1, CPS1, OTC	EMA									sodium phenylbutyrate	ASS1; CPS1; OTC		2024-08-13
PA166182789	Annotation of EMA Label for toremifene and ESR1, ESR2	EMA							Cancer Genome		toremifene	ESR1; ESR2		2024-08-16
PA166127660	Annotation of HCSC Label for dasatinib and ABL1, BCR	HCSC		Testing Required					Cancer Genome		dasatinib	ABL1; BCR		2024-08-26
PA166127671	Annotation of HCSC Label for everolimus and ERBB2, ESR1, ESR2	HCSC		Testing Required					Cancer Genome		everolimus	ERBB2; ESR1; ESR2		2024-09-10
PA166127672	Annotation of HCSC Label for exemestane and ESR1, ESR2	HCSC		Testing Required					Cancer Genome		exemestane	ESR1; ESR2		2024-09-10
PA166123422	Annotation of EMA Label for efavirenz / emtricitabine / tenofovir disoproxil and CYP2B6	EMA		Informative PGx							efavirenz / emtricitabine / tenofovir disoproxil	CYP2B6	CYP2B6*6; rs3745274	2024-12-02
PA166240301	Annotation of EMA Label for avatrombopag and CYP2C9, F2, F5, PROC, PROS1, SERPINC1	EMA		Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	avatrombopag	CYP2C9; F2; F5; PROC; PROS1; SERPINC1	CYP2C9*2; CYP2C9*3; rs1799963; rs6025	2024-07-17
PA166246485	Annotation of FDA Label for sotorasib and KRAS	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		sotorasib	KRAS	rs121913530	2023-09-01
PA166248801	Annotation of FDA Label for anakinra and IL1RN	FDA									anakinra	IL1RN		2024-08-07
PA166252901	Annotation of FDA Label for tepotinib and ALK, EGFR	FDA	On FDA Biomarker List						Cancer Genome		tepotinib	ALK; EGFR		2023-08-24
PA166251482	Annotation of FDA Label for dostarlimab	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		dostarlimab			2023-08-31
PA166252881	Annotation of FDA Label for tepotinib and MET	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		tepotinib	MET		2023-08-31
PA166251821	Annotation of FDA Label for evinacumab and LDLR	FDA	On FDA Biomarker List								evinacumab	LDLR		2024-08-20
PA166127698	Annotation of HCSC Label for omeprazole and CYP2C19	HCSC		No Clinical PGx							omeprazole	CYP2C19		2024-12-03
PA166225042	Annotation of FDA Label for rimegepant and CYP2C9	FDA	On FDA Biomarker List	No Clinical PGx							rimegepant	CYP2C9		2024-12-04
PA166269081	Annotation of FDA Label for glycerol phenylbutyrate and NAGS	FDA	On FDA Biomarker List								glycerol phenylbutyrate	NAGS		2023-08-17
PA166269121	Annotation of FDA Label for nateglinide and CYP2C9	FDA	On FDA Biomarker List	Informative PGx							nateglinide	CYP2C9		2024-08-28
PA166268901	Annotation of FDA Label for efgartigimod alfa and CHRNA1, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNB1, CHRNE	FDA	On FDA Biomarker List								efgartigimod alfa	CHRNA1; CHRNA3; CHRNA4; CHRNA5; CHRNA6; CHRNA7; CHRNB1; CHRNE		2023-09-28
PA166268923	Annotation of FDA Label for ropeginterferon alfa-2b and JAK2	FDA	On FDA Biomarker List	No Clinical PGx					Cancer Genome		ropeginterferon alfa-2b	JAK2	rs77375493	2022-07-06
PA166170052	Annotation of FDA Label for valbenazine and CYP2D6	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info	Dosing Info				Prescribing	valbenazine	CYP2D6		2022-04-12
PA166269101	Annotation of FDA Label for glycerol phenylbutyrate and ASS1, CPS1, OTC	FDA	On FDA Biomarker List	Testing Required							glycerol phenylbutyrate	ASS1; CPS1; OTC		2023-08-21
PA166179878	Annotation of FDA Label for encorafenib and BRAF	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		encorafenib	BRAF	rs113488022	2023-10-25
PA166268902	Annotation of FDA Label for odevixibat and ABCB11, ATP8B1	FDA	On FDA Biomarker List								odevixibat	ABCB11; ATP8B1	rs11568372; rs72549402	2024-08-16
PA166234701	Annotation of FDA Label for allopurinol and HLA-B	FDA	On FDA Biomarker List	Testing Recommended	Prescribing Info		Alternate Drug			Prescribing	allopurinol	HLA-B	HLA-B*58:01	2024-05-23
PA166122592	Annotation of FDA Label for simeprevir and IFNL3	FDA	On FDA Biomarker List	Informative PGx							simeprevir	IFNL3	rs12979860	2024-07-26
PA166127710	Annotation of HCSC Label for simeprevir and IFNL3	HCSC		Informative PGx							simeprevir	IFNL3	rs12979860	2024-07-26
PA166122607	Annotation of FDA Label for vortioxetine and CYP2D6	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info	Dosing Info				Prescribing	vortioxetine	CYP2D6		2023-08-10
PA166278361	Annotation of FDA Label for dextromethorphan hydrobromide / bupropion hydrochloride and CYP2D6	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info	Dosing Info				Prescribing	dextromethorphan hydrobromide / bupropion hydrochloride	CYP2D6		2024-10-02
PA166104807	Annotation of FDA Label for fluorouracil and DPYD	FDA	On FDA Biomarker List	Testing Recommended	Prescribing Info		Alternate Drug			Prescribing	fluorouracil	DPYD		2024-04-19
PA166293341	Annotation of FDA Label for tremelimumab and ALK, EGFR	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		tremelimumab	ALK; EGFR		2025-01-09
PA166182741	Annotation of FDA Label for articaine / epinephrine and CYB5R3, G6PD	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	articaine / epinephrine	CYB5R3; G6PD		2019-10-24
PA166170929	Annotation of FDA Label for gefitinib and CYP2D6	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	gefitinib	CYP2D6		
PA166104780	Annotation of FDA Label for carbamazepine and HLA-B	FDA	On FDA Biomarker List	Testing Required	Prescribing Info		Alternate Drug			Prescribing	carbamazepine	HLA-B	HLA-B*15:02	2024-04-26
PA166104839	Annotation of FDA Label for aripiprazole and CYP2D6	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info	Dosing Info		Other Prescribing Guidance		Prescribing	aripiprazole	CYP2D6		2025-03-28
PA166246301	Annotation of FDA Label for acetaminophen / caffeine / dihydrocodeine and CYP2D6	FDA		Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	acetaminophen / caffeine / dihydrocodeine	CYP2D6		
PA166104838	Annotation of FDA Label for thioguanine and NUDT15, TPMT	FDA	On FDA Biomarker List	Testing Recommended	Prescribing Info	Dosing Info				Prescribing	thioguanine	NUDT15; TPMT		2013-10-25
PA166104801	Annotation of FDA Label for peginterferon alfa-2b and IFNL3	FDA	On FDA Biomarker List	Informative PGx							peginterferon alfa-2b	IFNL3	rs12979860	2019-04-19
PA166170935	Annotation of FDA Label for rucaparib and CYP1A2, CYP2D6	FDA	On FDA Biomarker List	No Clinical PGx							rucaparib	CYP1A2; CYP2D6		2020-10-28
PA166178750	Annotation of FDA Label for metoclopramide and CYP2D6	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info	Dosing Info				Prescribing	metoclopramide	CYP2D6		
PA166179887	Annotation of FDA Label for raltegravir and UGT1A1	FDA	On FDA Biomarker List	No Clinical PGx							raltegravir	UGT1A1	UGT1A1*28	2019-04-23
PA166129519	Annotation of FDA Label for sevoflurane and CACNA1S, RYR1	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	sevoflurane	CACNA1S; RYR1		2023-04-01
PA166104829	Annotation of FDA Label for tetrabenazine and CYP2D6	FDA	On FDA Biomarker List	Testing Required	Prescribing Info	Dosing Info				Prescribing	tetrabenazine	CYP2D6		2013-10-25
PA166104827	Annotation of FDA Label for atomoxetine and CYP2D6	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info	Dosing Info				Prescribing	atomoxetine	CYP2D6		2019-05-09
PA166104856	Annotation of FDA Label for amitriptyline and CYP2D6	FDA	On FDA Biomarker List	Informative PGx							amitriptyline	CYP2D6		2024-07-18
PA166104874	Annotation of FDA Label for sulfamethoxazole / trimethoprim and G6PD, NAT2	FDA	On FDA Biomarker List	Informative PGx							sulfamethoxazole / trimethoprim	G6PD; NAT2		2019-10-10
PA166268861	Annotation of FDA Label for asciminib and ABL1, BCR	FDA	On FDA Biomarker List	Testing Required	Prescribing Info	Dosing Info			Cancer Genome	Prescribing	asciminib	ABL1; BCR	rs121913459	2023-10-11
PA166273021	Annotation of FDA Label for mavacamten and CYP2C19	FDA	On FDA Biomarker List	Informative PGx							mavacamten	CYP2C19	CYP2C19*2; CYP2C19*3	2023-12-20
PA166104879	Annotation of FDA Label for imipramine and CYP2D6	FDA	On FDA Biomarker List	Informative PGx							imipramine	CYP2D6		2024-07-23
PA166104885	Annotation of FDA Label for norfloxacin and G6PD	FDA		Informative PGx							norfloxacin	G6PD		2019-04-14
PA166104895	Annotation of FDA Label for erythromycin ethylsuccinate / sulfisoxazole acetyl and G6PD	FDA	On FDA Biomarker List	Informative PGx							erythromycin ethylsuccinate / sulfisoxazole acetyl	G6PD		2024-07-24
PA166104795	Annotation of FDA Label for busulfan and ABL1, BCR	FDA	On FDA Biomarker List	Informative PGx					Cancer Genome		busulfan	ABL1; BCR		2024-02-03
PA166114926	Annotation of FDA Label for mafenide and G6PD	FDA	On FDA Biomarker List	Informative PGx							mafenide	G6PD		2024-07-24
PA166104878	Annotation of FDA Label for methylene blue and G6PD	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	methylene blue	G6PD		2013-12-17
PA166182728	Annotation of FDA Label for ropivacaine and CYB5R3, G6PD	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	ropivacaine	CYB5R3; G6PD		2024-11-15
PA166105058	Annotation of FDA Label for pazopanib and HLA-B, UGT1A1	FDA	On FDA Biomarker List	Informative PGx							pazopanib	HLA-B; UGT1A1	HLA-B*57:01; UGT1A1*28	2019-04-19
PA166122971	Annotation of FDA Label for darifenacin and CYP2D6	FDA	On FDA Biomarker List	Informative PGx							darifenacin	CYP2D6		2024-07-19
PA166160052	Annotation of FDA Label for palonosetron and CYP2D6	FDA	On FDA Biomarker List	No Clinical PGx							palonosetron	CYP2D6		
PA166185151	Annotation of FDA Label for amifampridine and NAT2	FDA	Formerly on FDA Biomarker List	Actionable PGx	Prescribing Info	Dosing Info				Prescribing	amifampridine	NAT2		2024-10-02
PA166105195	Annotation of FDA Label for metoclopramide and CYB5R1, CYB5R2, CYB5R3, CYB5R4, G6PD	FDA	On FDA Biomarker List	Informative PGx							metoclopramide	CYB5R1; CYB5R2; CYB5R3; CYB5R4; G6PD		2019-10-17
PA166170933	Annotation of FDA Label for pertuzumab and ESR1, ESR2, PGR	FDA	On FDA Biomarker List	Informative PGx					Cancer Genome		pertuzumab	ESR1; ESR2; PGR		2019-04-19
PA166182749	Annotation of FDA Label for lusutrombopag and F2, F5, PROC, PROS1, SERPINC1	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	lusutrombopag	F2; F5; PROC; PROS1; SERPINC1	rs1799963; rs6025	2024-07-24
PA166182737	Annotation of FDA Label for lidocaine and tetracaine and G6PD	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	lidocaine and tetracaine	G6PD		2023-10-05
PA166161219	Annotation of FDA Label for aripiprazole lauroxil and CYP2D6	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info	Dosing Info	Alternate Drug			Prescribing	aripiprazole lauroxil	CYP2D6		
PA166182746	Annotation of FDA Label for ceftriaxone and CYB5R3, G6PD	FDA	On FDA Biomarker List								ceftriaxone	CYB5R3; G6PD		2024-10-15
PA166104837	Annotation of FDA Label for propafenone and CYP2D6	FDA	On FDA Biomarker List	No Clinical PGx							propafenone	CYP2D6		2024-07-30
PA166177514	Annotation of FDA Label for mirabegron and CYP2D6	FDA	On FDA Biomarker List	Informative PGx							mirabegron	CYP2D6		
PA166104903	Annotation of FDA Label for nitrofurantoin and G6PD	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	nitrofurantoin	G6PD		2024-07-23
PA166160672	Annotation of FDA Label for tamsulosin and CYP2D6	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	tamsulosin	CYP2D6		
PA166105117	Annotation of FDA Label for efavirenz and CYP2B6	FDA	On FDA Biomarker List	Informative PGx							efavirenz	CYP2B6	CYP2B6*6	2024-07-18
PA166177521	Annotation of FDA Label for umeclidinium and CYP2D6	FDA	On FDA Biomarker List	No Clinical PGx							umeclidinium	CYP2D6		
PA166182747	Annotation of FDA Label for lorlatinib and ROS1	FDA	On FDA Biomarker List	No Clinical PGx					Cancer Genome		lorlatinib	ROS1		2024-07-30
PA166104847	Annotation of FDA Label for venlafaxine and CYP2D6	FDA	On FDA Biomarker List	Informative PGx							venlafaxine	CYP2D6		2013-10-25
PA166160007	Annotation of FDA Label for lesinurad and CYP2C9	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	lesinurad	CYP2C9		2024-11-08
PA166185156	Annotation of FDA Label for mivacurium and BCHE	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug	Other Prescribing Guidance		Prescribing	mivacurium	BCHE		2024-08-14
PA166104897	Annotation of FDA Label for moviprep and G6PD	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	moviprep	G6PD		2024-09-09
PA166224341	Annotation of FDA Label for encorafenib and HRAS, KRAS, NRAS	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug	Other Prescribing Guidance	Cancer Genome	Prescribing	encorafenib	HRAS; KRAS; NRAS		2025-01-17
PA166160049	Annotation of FDA Label for lacosamide and CYP2C19	FDA	On FDA Biomarker List	No Clinical PGx							lacosamide	CYP2C19		2025-01-24
PA166151882	Annotation of FDA Label for carbamazepine and HLA-A	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	carbamazepine	HLA-A	HLA-A*31:01	2023-10-05
PA166170934	Annotation of FDA Label for primaquine and CYB5R1, CYB5R2, CYB5R3, CYB5R4	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	primaquine	CYB5R1; CYB5R2; CYB5R3; CYB5R4		2024-07-24
PA166122970	Annotation of FDA Label for succinylcholine and BCHE, CACNA1S, RYR1	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug	Other Prescribing Guidance		Prescribing	succinylcholine	BCHE; CACNA1S; RYR1		2023-04-01
PA166105211	Annotation of FDA Label for ondansetron and CYP2D6	FDA	On FDA Biomarker List	No Clinical PGx							ondansetron	CYP2D6		
PA166115362	Annotation of FDA Label for sodium nitrite and CYB5R3, G6PD	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug	Other Prescribing Guidance		Prescribing	sodium nitrite	CYB5R3; G6PD		2019-10-16
PA166179848	Annotation of FDA Label for lofexidine and CYP2D6	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	lofexidine	CYP2D6		
PA166105147	Annotation of FDA Label for glimepiride and G6PD	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug	Other Prescribing Guidance		Prescribing	glimepiride	G6PD		2023-08-25
PA166184637	Annotation of FDA Label for oxymetazoline and tetracaine and BCHE, CYB5R3, G6PD	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	oxymetazoline and tetracaine	BCHE; CYB5R3; G6PD		2019-10-24
PA166278161	Annotation of FDA Label for lutetium (177Lu) vipivotide tetraxetan and FOLH1	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		lutetium (177Lu) vipivotide tetraxetan	FOLH1		2023-09-01
PA166104852	Annotation of FDA Label for citalopram and CYP2C19	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info	Dosing Info				Prescribing	citalopram	CYP2C19		2020-09-22
PA166278181	Annotation of FDA Label for azacitidine and CBL, KRAS, NRAS, PTPN11	FDA	On FDA Biomarker List						Cancer Genome		azacitidine	CBL; KRAS; NRAS; PTPN11		2024-08-05
PA166293201	Annotation of FDA Label for capecitabine and ERBB2	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		capecitabine	ERBB2		2023-08-31
PA166277661	Annotation of FDA Label for vutrisiran and TTR	FDA	On FDA Biomarker List								vutrisiran	TTR		2023-09-28
PA166273561	Annotation of FDA Label for inclisiran and APOB, LDLR, PCSK9	FDA	On FDA Biomarker List								inclisiran	APOB; LDLR; PCSK9		2024-07-23
PA166278121	Annotation of FDA Label for nivolumab / relatlimab and BRAF, CD274, LAG3	FDA	On FDA Biomarker List						Cancer Genome		nivolumab / relatlimab	BRAF; CD274; LAG3	rs113488022	2025-01-09
PA166278081	Annotation of FDA Label for mitapivat and PKLR	FDA	On FDA Biomarker List								mitapivat	PKLR		2024-08-09
PA166296341	Annotation of FDA Label for pemetrexed and ALK, EGFR	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		pemetrexed	ALK; EGFR		2023-08-31
PA166104790	Annotation of FDA Label for imatinib and ABL1, BCR, FIP1L1, KIT, PDGFRA, PDGFRB	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		imatinib	ABL1; BCR; FIP1L1; KIT; PDGFRA; PDGFRB		2025-02-05
PA166251421	Annotation of FDA Label for cemiplimab-rwlc and ALK, CD274, EGFR, ROS1	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		cemiplimab-rwlc	ALK; CD274; EGFR; ROS1		2023-08-31
PA166296361	Annotation of FDA Label for pemetrexed and CD274	FDA	On FDA Biomarker List						Cancer Genome		pemetrexed	CD274		2023-09-07
PA166277841	Annotation of FDA Label for sacrosidase and SI	FDA	On FDA Biomarker List	Testing Required							sacrosidase	SI		2023-08-21
PA166104846	Annotation of FDA Label for arsenic trioxide and PML, RARA	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		arsenic trioxide	PML; RARA		2023-09-01
PA166234723	Annotation of FDA Label for atorvastatin and SLCO1B1	FDA									atorvastatin	SLCO1B1		2023-12-04
PA166234801	Annotation of FDA Label for tacrolimus and CYP3A4, CYP3A5	FDA									tacrolimus	CYP3A4; CYP3A5		2024-08-29
PA166272961	Annotation of FDA Label for abrocitinib and CYP2C19	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info	Dosing Info				Prescribing	abrocitinib	CYP2C19		2023-08-21
PA166179871	Annotation of FDA Label for binimetinib and UGT1A1	FDA	On FDA Biomarker List	No Clinical PGx							binimetinib	UGT1A1		2023-10-25
PA166277681	Annotation of FDA Label for anifrolumab and IFNAR1	FDA	On FDA Biomarker List								anifrolumab	IFNAR1		2023-08-14
PA166293262	Annotation of FDA Label for adagrasib and KRAS	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		adagrasib	KRAS	rs121913530	2023-09-01
PA166252781	Annotation of FDA Label for fosdenopterin and MOCS1	FDA	On FDA Biomarker List	Testing Required							fosdenopterin	MOCS1		2023-08-22
PA166293401	Annotation of FDA Label for futibatinib and FGFR2	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		futibatinib	FGFR2		2023-10-11
PA166104860	Annotation of FDA Label for phenytoin and CYP2C9, HLA-B	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info	Dosing Info	Alternate Drug			Prescribing	phenytoin	CYP2C9; HLA-B	CYP2C9*2; CYP2C9*3; HLA-B*15:02	2024-09-18
PA166184561	Annotation of FDA Label for ramucirumab and KRAS	FDA	On FDA Biomarker List						Cancer Genome		ramucirumab	KRAS		2023-12-05
PA166268881	Annotation of FDA Label for belzutifan and VHL	FDA	On FDA Biomarker List								belzutifan	VHL		2024-08-05
PA166170958	Annotation of FDA Label for valproic acid and POLG	FDA	On FDA Biomarker List	Testing Required	Prescribing Info		Alternate Drug			Prescribing	valproic acid	POLG		2023-08-22
PA166169880	Annotation of FDA Label for cerliponase alfa and TPP1	FDA	On FDA Biomarker List								cerliponase alfa	TPP1		2024-08-05
PA166236221	Annotation of FDA Label for risdiplam and SMN1, SMN2	FDA	On FDA Biomarker List	Testing Required							risdiplam	SMN1; SMN2		2023-08-21
PA166104792	Annotation of FDA Label for fulvestrant and ERBB2, ESR1, ESR2, PGR	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		fulvestrant	ERBB2; ESR1; ESR2; PGR		2024-11-07
PA166184565	Annotation of FDA Label for tafamidis and TTR	FDA	On FDA Biomarker List								tafamidis	TTR		2023-08-24
PA166104923	Annotation of FDA Label for exemestane and ESR1, ESR2, PGR	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		exemestane	ESR1; ESR2; PGR		2023-09-01
PA166268941	Annotation of FDA Label for mobocertinib and EGFR	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		mobocertinib	EGFR		2023-09-01
PA166182786	Annotation of FDA Label for tolazamide and G6PD	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug	Other Prescribing Guidance		Prescribing	tolazamide	G6PD		2024-10-14
PA166268961	Annotation of FDA Label for zanubrutinib and MYD88, TP53	FDA	On FDA Biomarker List						Cancer Genome		zanubrutinib	MYD88; TP53	rs387907272	2024-09-08
PA166127662	Annotation of FDA Label for arformoterol and CYP2D6, UGT1A1	FDA	On FDA Biomarker List	No Clinical PGx							arformoterol	CYP2D6; UGT1A1		
PA166105010	Annotation of FDA Label for duloxetine and CYP2D6	FDA	On FDA Biomarker List	Informative PGx							duloxetine	CYP2D6		
PA166122589	Annotation of FDA Label for obinutuzumab and MS4A1	FDA	On FDA Biomarker List						Cancer Genome		obinutuzumab	MS4A1		2024-12-12
PA166182755	Annotation of FDA Label for vincristine and ABL1, BCR	FDA	On FDA Biomarker List						Cancer Genome		vincristine	ABL1; BCR		2024-11-21
PA166159963	Annotation of FDA Label for blinatumomab and ABL1, BCR	FDA	On FDA Biomarker List						Cancer Genome		blinatumomab	ABL1; BCR		2024-10-02
PA166177518	Annotation of FDA Label for sofosbuvir / velpatasvir / voxilaprevir and IFNL3	FDA	On FDA Biomarker List								sofosbuvir / velpatasvir / voxilaprevir	IFNL3		2023-08-24
PA166190643	Annotation of FDA Label for trastuzumab deruxtecan and ERBB2	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		trastuzumab deruxtecan	ERBB2		2023-08-31
PA166182762	Annotation of FDA Label for elagolix and SLCO1B1	FDA	On FDA Biomarker List	Informative PGx							elagolix	SLCO1B1	rs4149056	2024-07-19
PA166163439	Annotation of FDA Label for elbasvir / grazoprevir and IFNL3	FDA	On FDA Biomarker List								elbasvir / grazoprevir	IFNL3		2023-09-06
PA166160005	Annotation of FDA Label for dasabuvir / ombitasvir / paritaprevir / ritonavir and IFNL3	FDA	On FDA Biomarker List								dasabuvir / ombitasvir / paritaprevir / ritonavir	IFNL3		2023-09-06
PA166251501	Annotation of FDA Label for cabotegravir / rilpivirine and UGT1A1	FDA	On FDA Biomarker List	No Clinical PGx							cabotegravir / rilpivirine	UGT1A1		2023-12-05
PA166114923	Annotation of FDA Label for lomitapide	FDA	On FDA Biomarker List								lomitapide			2024-09-16
PA166182738	Annotation of FDA Label for siponimod and CYP2C9	FDA	On FDA Biomarker List	Testing Required	Prescribing Info	Dosing Info	Alternate Drug			Prescribing	siponimod	CYP2C9	CYP2C9*2; CYP2C9*3	2024-03-07
PA166178724	Annotation of FDA Label for neratinib and ESR1, ESR2, PGR	FDA	On FDA Biomarker List						Cancer Genome		neratinib	ESR1; ESR2; PGR		2023-08-15
PA166182764	Annotation of FDA Label for emapalumab and PRF1, RAB27A, SH2D1A, STX11, STXBP2, UNC13D, XIAP	FDA	On FDA Biomarker List								emapalumab	PRF1; RAB27A; SH2D1A; STX11; STXBP2; UNC13D; XIAP		2023-08-17
PA166105070	Annotation of FDA Label for anastrozole and ESR1, ESR2, PGR	FDA	On FDA Biomarker List						Cancer Genome		anastrozole	ESR1; ESR2; PGR		2024-08-06
PA166163431	Annotation of FDA Label for isosorbide mononitrate and CYB5R1, CYB5R2, CYB5R3, CYB5R4	FDA	On FDA Biomarker List	Informative PGx							isosorbide mononitrate	CYB5R1; CYB5R2; CYB5R3; CYB5R4		2024-07-30
PA166182742	Annotation of FDA Label for talazoparib and ATM, ATR, BRCA1, BRCA2, CDK12, CHEK2, FANCA, MLH1, MRE11, NBN, PALB2, RAD51C	FDA	On FDA Biomarker List	Testing Required							talazoparib	ATM; ATR; BRCA1; BRCA2; CDK12; CHEK2; FANCA; MLH1; MRE11; NBN; PALB2; RAD51C		2024-08-13
PA166160056	Annotation of FDA Label for cholic acid and AKR1D1, AMACR, CYP27A1, CYP7A1, DHCR7, HSD3B2	FDA	On FDA Biomarker List								cholic acid	AKR1D1; AMACR; CYP27A1; CYP7A1; DHCR7; HSD3B2		2024-08-05
PA166182730	Annotation of FDA Label for amphetamine and CYP2D6	FDA	On FDA Biomarker List	Informative PGx							amphetamine	CYP2D6		2024-07-26
PA166184539	Annotation of FDA Label for paliperidone and CYP2D6	FDA	On FDA Biomarker List	No Clinical PGx							paliperidone	CYP2D6		
PA166104778	Annotation of FDA Label for brentuximab vedotin and ALK	FDA	On FDA Biomarker List						Cancer Genome		brentuximab vedotin	ALK		2023-09-07
PA166225001	Annotation of FDA Label for lutetium (177Lu) dotatate and SSTR1, SSTR2, SSTR3, SSTR4, SSTR5	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		lutetium (177Lu) dotatate	SSTR1; SSTR2; SSTR3; SSTR4; SSTR5		2024-08-08
PA166105012	Annotation of FDA Label for escitalopram and CYP2C19	FDA	On FDA Biomarker List	Informative PGx							escitalopram	CYP2C19		2025-01-23
PA166114317	Annotation of FDA Label for sodium phenylbutyrate and ASS1, CPS1, OTC	FDA	On FDA Biomarker List								sodium phenylbutyrate	ASS1; CPS1; OTC		2024-08-13
PA166293701	Annotation of FDA Label for levothyroxine and IRS4, NKX2-5, PAX8, TBL1X, TSHB	FDA	On FDA Biomarker List								levothyroxine	IRS4; NKX2-5; PAX8; TBL1X; TSHB		2024-08-08
PA166169882	Annotation of FDA Label for deutetrabenazine and CYP2D6	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info	Dosing Info				Prescribing	deutetrabenazine	CYP2D6		2023-09-07
PA166169918	Annotation of FDA Label for midostaurin and FLT3	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		midostaurin	FLT3		2023-08-31
PA166104900	Annotation of FDA Label for pegloticase and G6PD	FDA	On FDA Biomarker List	Testing Required	Prescribing Info		Alternate Drug			Prescribing	pegloticase	G6PD		2023-03-31
PA166182961	Annotation of FDA Label for duvelisib	FDA	On FDA Biomarker List						Cancer Genome		duvelisib			2023-08-15
PA166184636	Annotation of FDA Label for tipiracil / trifluridine and ERBB2, KRAS	FDA	On FDA Biomarker List						Cancer Genome		tipiracil / trifluridine	ERBB2; KRAS		2023-08-27
PA166163414	Annotation of FDA Label for ustekinumab and IL12A, IL12B, IL23A	FDA	On FDA Biomarker List								ustekinumab	IL12A; IL12B; IL23A		2023-08-29
PA166177486	Annotation of FDA Label for enasidenib and IDH2	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		enasidenib	IDH2		2023-08-31
PA166123487	Annotation of FDA Label for eliglustat and CYP2D6	FDA	On FDA Biomarker List	Testing Required	Prescribing Info	Dosing Info		Other Prescribing Guidance		Prescribing	eliglustat	CYP2D6		2023-08-28
PA166177483	Annotation of FDA Label for desvenlafaxine and CYP2D6	FDA	On FDA Biomarker List	No Clinical PGx							desvenlafaxine	CYP2D6		2023-08-15
PA166151878	Annotation of FDA Label for lapatinib and HLA-DQA1, HLA-DRB1	FDA	On FDA Biomarker List	Informative PGx							lapatinib	HLA-DQA1; HLA-DRB1	HLA-DQA1*02:01; HLA-DRB1*07:01	2020-08-24
PA166160040	Annotation of FDA Label for Parathyroid Hormones And Analogues and CASR	FDA	On FDA Biomarker List								Parathyroid Hormones And Analogues	CASR		2023-08-23
PA166122594	Annotation of FDA Label for sofosbuvir and IFNL3	FDA	On FDA Biomarker List								sofosbuvir	IFNL3	rs12979860	2023-08-24
PA166182280	Annotation of FDA Label for dacomitinib and EGFR	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		dacomitinib	EGFR	rs121434568	2023-08-31
PA166105148	Annotation of FDA Label for glipizide and G6PD	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug	Other Prescribing Guidance		Prescribing	glipizide	G6PD		2023-08-25
PA166105113	Annotation of FDA Label for donepezil and CYP2D6	FDA	On FDA Biomarker List	Informative PGx							donepezil	CYP2D6		
PA166182021	Annotation of FDA Label for amifampridine phosphate and NAT2	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info	Dosing Info				Prescribing	amifampridine phosphate	NAT2		2019-10-04
PA166170939	Annotation of FDA Label for trastuzumab and ESR1, ESR2, PGR	FDA	On FDA Biomarker List						Cancer Genome		trastuzumab	ESR1; ESR2; PGR		2023-08-29
PA166191561	Annotation of FDA Label for nivolumab and ALK, CD274, EGFR	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		nivolumab	ALK; CD274; EGFR		2024-08-09
PA166160133	Annotation of FDA Label for palbociclib and ERBB2, ESR1, ESR2	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		palbociclib	ERBB2; ESR1; ESR2		2023-09-01
PA166313381	Annotation of FDA Label for polatuzumab vedotin and BCL2, BCL6, MYC	FDA	On FDA Biomarker List						Cancer Genome		polatuzumab vedotin	BCL2; BCL6; MYC		
PA166114930	Annotation of FDA Label for omacetaxine and ABL1, BCR	FDA	On FDA Biomarker List						Cancer Genome		omacetaxine	ABL1; BCR		2024-08-12
PA166314003	Annotation of FDA Label for odevixibat and JAG1, NOTCH2	FDA	On FDA Biomarker List								odevixibat	JAG1; NOTCH2		
PA166313361	Annotation of FDA Label for elacestrant and ERBB2, ESR1	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		elacestrant	ERBB2; ESR1		2023-09-27
PA166159962	Annotation of FDA Label for alirocumab and LDLR	FDA	Formerly on FDA Biomarker List								alirocumab	LDLR		2024-02-08
PA166274001	Annotation of EMA Label for blinatumomab and ABL1, BCR	EMA							Cancer Genome		blinatumomab	ABL1; BCR		2024-10-02
PA166277881	Annotation of FDA Label for ravulizumab and AQP4, CHRNA1, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNB1, CHRNE	FDA	On FDA Biomarker List								ravulizumab	AQP4; CHRNA1; CHRNA3; CHRNA4; CHRNA5; CHRNA6; CHRNA7; CHRNB1; CHRNE		2024-10-04
PA166278621	Annotation of HCSC Label for satralizumab and AQP4	HCSC									satralizumab	AQP4		2024-12-13
PA166114921	Annotation of FDA Label for ibritumomab and MS4A1	FDA	Formerly on FDA Biomarker List						Cancer Genome		ibritumomab	MS4A1		2023-09-28
PA166281101	Annotation of HCSC Label for eculizumab and AQP4, CHRNA1, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNB1, CHRNE	HCSC									eculizumab	AQP4; CHRNA1; CHRNA3; CHRNA4; CHRNA5; CHRNA6; CHRNA7; CHRNB1; CHRNE		2023-09-28
PA166281121	Annotation of EMA Label for efgartigimod alfa and CHRNA1, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNB1, CHRNE	EMA									efgartigimod alfa	CHRNA1; CHRNA3; CHRNA4; CHRNA5; CHRNA6; CHRNA7; CHRNB1; CHRNE		2023-09-28
PA166273541	Annotation of EMA Label for inebilizumab and AQP4	EMA									inebilizumab	AQP4		2023-09-28
PA166272761	Annotation of EMA Label for satralizumab and AQP4	EMA									satralizumab	AQP4		2023-09-28
PA166272123	Annotation of EMA Label for zanubrutinib and MYD88	EMA							Cancer Genome		zanubrutinib	MYD88		2023-09-28
PA166273081	Annotation of HCSC Label for zanubrutinib and MYD88	HCSC							Cancer Genome		zanubrutinib	MYD88		2023-09-28
PA166182758	Annotation of FDA Label for goserelin and ESR1, ESR2, PGR	FDA	On FDA Biomarker List						Cancer Genome		goserelin	ESR1; ESR2; PGR		2023-09-28
PA166272141	Annotation of EMA Label for voxelotor and HBB	EMA									voxelotor	HBB		2023-12-11
PA166182721	Annotation of FDA Label for erdafitinib and FGFR3	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		erdafitinib	FGFR3		2024-10-03
PA166182722	Annotation of FDA Label for erdafitinib and CYP2C9	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	erdafitinib	CYP2C9	CYP2C9*3	2024-10-03
PA166316281	Annotation of FDA Label for trofinetide and MECP2	FDA	On FDA Biomarker List								trofinetide	MECP2		
PA166316301	Annotation of FDA Label for plazomicin and MT-RNR1	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	plazomicin	MT-RNR1	rs267606617	
PA166316321	Annotation of FDA Label for amikacin and MT-RNR1	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	amikacin	MT-RNR1	rs267606617	
PA166316341	Annotation of FDA Label for tobramycin and MT-RNR1	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	tobramycin	MT-RNR1	rs267606617	
PA166317742	Annotation of EMA Label for margetuximab	EMA									margetuximab			
PA166184524	Annotation of FDA Label for alpelisib and ERBB2, ESR1, ESR2, PIK3CA	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		alpelisib	ERBB2; ESR1; ESR2; PIK3CA		2023-08-31
PA166190261	Annotation of FDA Label for estradiol / progesterone and PROC, PROS1, SERPINC1	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	estradiol / progesterone	PROC; PROS1; SERPINC1		
PA166251561	Annotation of FDA Label for casimersen and DMD	FDA	On FDA Biomarker List	Testing Required							casimersen	DMD		2023-08-21
PA166251621	Annotation of FDA Label for viloxazine and SLCO1B1	FDA	On FDA Biomarker List								viloxazine	SLCO1B1		2023-08-29
PA166159964	Annotation of FDA Label for olaparib and BRCA1, BRCA2, ERBB2	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		olaparib	BRCA1; BRCA2; ERBB2		2023-09-01
PA166251522	Annotation of FDA Label for cabotegravir / rilpivirine and HLA-B	FDA	On FDA Biomarker List								cabotegravir / rilpivirine	HLA-B		2023-12-05
PA166268882	Annotation of FDA Label for belzutifan and CYP2C19, UGT2B17	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	belzutifan	CYP2C19; UGT2B17	CYP2C19*2; CYP2C19*3	2023-09-28
PA166316381	Annotation of FDA Label for gentamicin and MT-RNR1	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	gentamicin	MT-RNR1	rs267606617	
PA166316361	Annotation of FDA Label for streptomycin and MT-RNR1	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	streptomycin	MT-RNR1	rs267606617	
PA166317641	Annotation of EMA Label for mavacamten and CYP2C19	EMA		Testing Required	Prescribing Info	Dosing Info				Prescribing	mavacamten	CYP2C19	CYP2C19*1; CYP2C19*2; CYP2C19*3	2024-07-24
PA166313401	Annotation of FDA Label for lecanemab and APOE	FDA	On FDA Biomarker List	Testing Required							lecanemab	APOE	rs429358; rs7412	2024-08-16
PA166317521	Annotation of EMA Label for asciminib and ABL1, BCR	EMA		Testing Required					Cancer Genome		asciminib	ABL1; BCR		2024-08-26
PA166251601	Annotation of FDA Label for viloxazine and CYP2D6	FDA	On FDA Biomarker List	Informative PGx							viloxazine	CYP2D6		
PA166184754	Annotation of FDA Label for procainamide and NAT2	FDA	On FDA Biomarker List	Informative PGx							procainamide	NAT2		2023-09-07
PA166235901	Annotation of FDA Label for margetuximab and FCGR2A, FCGR2B, FCGR3A	FDA	On FDA Biomarker List	No Clinical PGx							margetuximab	FCGR2A; FCGR2B; FCGR3A		
PA166317601	Annotation of EMA Label for futibatinib and FGFR2	EMA		Testing Required					Cancer Genome		futibatinib	FGFR2	rs1057519045; rs1057519797	2024-09-10
PA166317541	Annotation of EMA Label for ganaxolone and CDKL5	EMA		Testing Required							ganaxolone	CDKL5		2024-09-10
PA166317441	Annotation of EMA Label for adagrasib and KRAS	EMA		Testing Required					Cancer Genome		adagrasib	KRAS	rs121913530	2024-12-05
PA166317741	Annotation of EMA Label for infigratinib	EMA									infigratinib			2024-12-05
PA166317461	Annotation of EMA Label for mirvetuximab soravtansine and FOLR1	EMA		Testing Required					Cancer Genome		mirvetuximab soravtansine	FOLR1		2024-12-11
PA166317442	Annotation of EMA Label for Ascorbic acid (vitamin C), plain	EMA									Ascorbic acid (vitamin C), plain			
PA166317443	Annotation of EMA Label for desmopressin	EMA									desmopressin			
PA166317444	Annotation of EMA Label for levothyroxine	EMA									levothyroxine			
PA166317445	Annotation of EMA Label for olutasidenib	EMA									olutasidenib			
PA166317481	Annotation of EMA Label for desflurane	EMA									desflurane			
PA166317482	Annotation of EMA Label for isoflurane	EMA									isoflurane			
PA166317483	Annotation of EMA Label for belzutifan	EMA									belzutifan			
PA166317501	Annotation of EMA Label for sevoflurane	EMA									sevoflurane			
PA166317502	Annotation of EMA Label for succinylcholine	EMA									succinylcholine			
PA166317503	Annotation of EMA Label for escitalopram	EMA									escitalopram			
PA166317504	Annotation of EMA Label for estradiol valerate	EMA									estradiol valerate			
PA166317721	Annotation of EMA Label for casimersen	EMA									casimersen			
PA166317701	Annotation of EMA Label for golodirsen	EMA									golodirsen			
PA166317663	Annotation of EMA Label for fosphenytoin	EMA									fosphenytoin			
PA166317662	Annotation of EMA Label for enflurane	EMA									enflurane			
PA166317761	Annotation of EMA Label for metoclopramide	EMA									metoclopramide			
PA166317762	Annotation of EMA Label for mivacurium	EMA									mivacurium			
PA166317782	Annotation of EMA Label for oliceridine	EMA									oliceridine			
PA166317783	Annotation of EMA Label for oxymetazoline and tetracaine	EMA									oxymetazoline and tetracaine			
PA166317681	Annotation of EMA Label for mitapivat and PKLR	EMA									mitapivat	PKLR	rs118204085	2024-08-09
PA166317581	Annotation of EMA Label for capmatinib and MET	EMA		Testing Required					Cancer Genome		capmatinib	MET		2024-09-10
PA166317781	Annotation of EMA Label for mobocertinib	EMA									mobocertinib			
PA166317784	Annotation of EMA Label for phenytoin	EMA									phenytoin			
PA166317801	Annotation of EMA Label for procainamide	EMA									procainamide			
PA166317821	Annotation of EMA Label for tretinoin	EMA									tretinoin			
PA166317841	Annotation of EMA Label for valproic acid	EMA									valproic acid			
PA166317822	Annotation of EMA Label for viloxazine	EMA									viloxazine			
PA166317842	Annotation of EMA Label for viltolarsen	EMA									viltolarsen			
PA166317901	Annotation of HCSC Label for adagrasib	HCSC									adagrasib			
PA166317882	Annotation of HCSC Label for futibatinib	HCSC									futibatinib			
PA166317903	Annotation of HCSC Label for mirvetuximab soravtansine	HCSC									mirvetuximab soravtansine			
PA166317904	Annotation of HCSC Label for olutasidenib	HCSC									olutasidenib			
PA166317905	Annotation of HCSC Label for pegloticase	HCSC									pegloticase			
PA166317906	Annotation of HCSC Label for ganaxolone	HCSC									ganaxolone			
PA166317883	Annotation of HCSC Label for mitapivat	HCSC									mitapivat			
PA166317884	Annotation of HCSC Label for casimersen	HCSC									casimersen			
PA166317908	Annotation of HCSC Label for crizanlizumab-tmca	HCSC									crizanlizumab-tmca			
PA166317941	Annotation of HCSC Label for lonafarnib	HCSC									lonafarnib			
PA166317942	Annotation of HCSC Label for margetuximab	HCSC									margetuximab			
PA166317961	Annotation of HCSC Label for mobocertinib	HCSC									mobocertinib			
PA166317947	Annotation of HCSC Label for procainamide	HCSC									procainamide			
PA166317962	Annotation of HCSC Label for ropeginterferon alfa-2b	HCSC									ropeginterferon alfa-2b			
PA166317963	Annotation of HCSC Label for rucaparib	HCSC									rucaparib			
PA166317949	Annotation of HCSC Label for viloxazine	HCSC									viloxazine			
PA166317964	Annotation of HCSC Label for viltolarsen	HCSC									viltolarsen			
PA166317950	Annotation of HCSC Label for voxelotor	HCSC									voxelotor			
PA166319021	Annotation of FDA Label for mepolizumab and FIP1L1, PDGFRA	FDA	On FDA Biomarker List								mepolizumab	FIP1L1; PDGFRA		
PA166317907	Annotation of HCSC Label for vutrisiran and TTR	HCSC									vutrisiran	TTR		2024-11-21
PA166317948	Annotation of HCSC Label for rimegepant and CYP2C9	HCSC		No Clinical PGx							rimegepant	CYP2C9	CYP2C9*2; CYP2C9*3	2024-12-04
PA166294083	Annotation of HCSC Label for durvalumab and CD274	HCSC							Cancer Genome		durvalumab	CD274		2023-08-15
PA166317221	Annotation of FDA Label for rozanolixizumab and CHRNA1, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNB1, CHRNE, MUSK	FDA	On FDA Biomarker List								rozanolixizumab	CHRNA1; CHRNA3; CHRNA4; CHRNA5; CHRNA6; CHRNA7; CHRNB1; CHRNE; MUSK		
PA166317281	Annotation of FDA Label for leniolisib and PIK3CD, PIK3R1	FDA	On FDA Biomarker List								leniolisib	PIK3CD; PIK3R1		
PA166317902	Annotation of HCSC Label for Ascorbic acid (vitamin C), plain	HCSC									Ascorbic acid (vitamin C), plain			2025-01-10
PA166319001	Annotation of FDA Label for sacituzumab govitecan and BRCA1, BRCA2	FDA	On FDA Biomarker List								sacituzumab govitecan	BRCA1; BRCA2		
PA166319101	Annotation of FDA Label for tofersen and SOD1	FDA	On FDA Biomarker List								tofersen	SOD1		2024-08-06
PA166317881	Annotation of EMA Label for lonafarnib and LMNA, ZMPSTE24	EMA		Testing Required							lonafarnib	LMNA; ZMPSTE24		2023-11-21
PA166293282	Annotation of FDA Label for Ascorbic acid (vitamin C), combinations, Ascorbic acid (vitamin C), plain, sodium ascorbate and G6PD	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info	Dosing Info		Other Prescribing Guidance		Prescribing	Ascorbic acid (vitamin C), combinations; Ascorbic acid (vitamin C), plain; sodium ascorbate	G6PD		2023-05-23
PA166317943	Annotation of HCSC Label for metreleptin and AGPAT2, BSCL2, LEP, LMNB2	HCSC		Testing Required							metreleptin	AGPAT2; BSCL2; LEP; LMNB2		2024-08-09
PA166318021	Annotation of HCSC Label for tremelimumab	HCSC									tremelimumab			
PA166317981	Annotation of HCSC Label for mavacamten and CYP2C19	HCSC		Informative PGx							mavacamten	CYP2C19		2023-12-20
PA166318001	Annotation of HCSC Label for setmelanotide and LEPR, PCSK1, POMC	HCSC		Testing Required							setmelanotide	LEPR; PCSK1; POMC		2024-09-17
PA166318981	Annotation of FDA Label for sacituzumab govitecan and ERBB2, ESR1, ESR2	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		sacituzumab govitecan	ERBB2; ESR1; ESR2		
PA166283781	Annotation of EMA Label for givosiran and CPOX, HMBS, PPOX	EMA									givosiran	CPOX; HMBS; PPOX		2024-12-13
PA166284042	Annotation of EMA Label for entrectinib and NTRK1, NTRK2, NTRK3, ROS1	EMA		Testing Required					Cancer Genome		entrectinib	NTRK1; NTRK2; NTRK3; ROS1		2024-04-16
PA166283922	Annotation of EMA Label for gemtuzumab ozogamicin and CD33	EMA		Testing Required					Cancer Genome		gemtuzumab ozogamicin	CD33		2024-04-16
PA166294381	Annotation of EMA Label for evolocumab	EMA									evolocumab			2024-08-14
PA166184454	Annotation of Swissmedic Label for galantamine and CYP2D6	Swissmedic		Informative PGx							galantamine	CYP2D6		2023-11-13
PA166122907	Annotation of EMA Label for vandetanib and RET	EMA		Testing Required							vandetanib	RET		2023-12-05
PA166294041	Annotation of EMA Label for durvalumab and ALK, CD274, EGFR	EMA		Testing Required					Cancer Genome		durvalumab	ALK; CD274; EGFR		2025-01-09
PA166182719	Annotation of FDA Label for ipilimumab and HLA-A	FDA	On FDA Biomarker List	No Clinical PGx							ipilimumab	HLA-A	HLA-A*02:01	2025-01-09
PA166362201	Annotation of EMA Label for pemetrexed	EMA									pemetrexed			
PA166362221	Annotation of EMA Label for tremelimumab and ALK, EGFR	EMA		Testing Required					Cancer Genome		tremelimumab	ALK; EGFR		
PA166362241	Annotation of HCSC Label for rituximab and MS4A1	HCSC							Cancer Genome		rituximab	MS4A1		
PA166362261	Annotation of HCSC Label for ofatumumab and MS4A1	HCSC									ofatumumab	MS4A1		
PA166105059	Annotation of FDA Label for ofatumumab and MS4A1	FDA	Formerly on FDA Biomarker List						Cancer Genome		ofatumumab	MS4A1		2025-01-10
PA166121250	Annotation of EMA Label for lomitapide and APOB, LDLR, PCSK9	EMA		Testing Required							lomitapide	APOB; LDLR; PCSK9		2024-08-08
PA166122968	Annotation of EMA Label for sildenafil	EMA									sildenafil			2023-08-24
PA166123388	Annotation of EMA Label for ruxolitinib and CYP3A4	EMA									ruxolitinib	CYP3A4		2023-08-24
PA166123411	Annotation of EMA Label for sirolimus and CYP3A4	EMA									sirolimus	CYP3A4		2023-08-24
PA166123413	Annotation of EMA Label for zonisamide and CYP3A4	EMA									zonisamide	CYP3A4		2023-08-29
PA166123417	Annotation of EMA Label for telithromycin and CYP3A4	EMA									telithromycin	CYP3A4		2023-08-24
PA166123420	Annotation of EMA Label for fosamprenavir and CYP3A4	EMA									fosamprenavir	CYP3A4		2023-08-17
PA166121252	Annotation of EMA Label for ofatumumab and MS4A1	EMA									ofatumumab	MS4A1		2025-01-10
PA166123424	Annotation of EMA Label for darunavir and CYP3A4	EMA									darunavir	CYP3A4		2023-08-15
PA166317885	Annotation of HCSC Label for fosdenopterin	HCSC									fosdenopterin			
PA166317945	Annotation of HCSC Label for oliceridine	HCSC									oliceridine			
PA166317921	Annotation of HCSC Label for golodirsen	HCSC									golodirsen			
PA166317946	Annotation of HCSC Label for oxymetazoline and tetracaine	HCSC									oxymetazoline and tetracaine			
PA166104882	Annotation of EMA Label for desloratadine	EMA									desloratadine			2023-09-06
PA166105315	Annotation of EMA Label for nelfinavir and CYP3A4	EMA									nelfinavir	CYP3A4		2023-08-15
PA166123529	Annotation of PMDA Label for atorvastatin and LDLR	PMDA									atorvastatin	LDLR		2023-09-25
PA166123545	Annotation of PMDA Label for lenalidomide	PMDA							Cancer Genome		lenalidomide			2023-09-26
PA166123549	Annotation of PMDA Label for tolterodine and CYP2D6	PMDA		Informative PGx							tolterodine	CYP2D6		2023-08-14
PA166123553	Annotation of PMDA Label for abacavir and HLA-B	PMDA		Informative PGx							abacavir	HLA-B		2023-08-14
PA166120286	Annotation of EMA Label for esomeprazole and CYP2C19	EMA		No Clinical PGx							esomeprazole	CYP2C19		2023-08-17
PA166317944	Annotation of HCSC Label for odevixibat and ABCB11	HCSC									odevixibat	ABCB11		2024-08-16
PA166127640	Annotation of HCSC Label for boceprevir and IFNL3	HCSC		No Clinical PGx							boceprevir	IFNL3		2024-07-26
PA166123414	Annotation of EMA Label for dronedarone and CYP2D6, CYP3A4	EMA		No Clinical PGx							dronedarone	CYP2D6; CYP3A4		2023-08-15
PA166123387	Annotation of EMA Label for axitinib and CYP2C19, UGT1A1	EMA		No Clinical PGx							axitinib	CYP2C19; UGT1A1		2023-08-14
PA166127691	Annotation of HCSC Label for metoprolol and CYP2D6	HCSC		Informative PGx							metoprolol	CYP2D6		2024-07-25
PA166160720	Annotation of PMDA Label for omeprazole and CYP2C19	PMDA		Informative PGx							omeprazole	CYP2C19		2023-08-14
PA166161087	Annotation of PMDA Label for isoniazid and NAT2	PMDA		Informative PGx							isoniazid	NAT2		2023-08-14
PA166183789	Annotation of Swissmedic Label for metabutethamine and G6PD	Swissmedic		Actionable PGx	Prescribing Info					Prescribing	metabutethamine	G6PD		2023-02-28
PA166184129	Annotation of Swissmedic Label for daclatasvir and IFNL3	Swissmedic		Informative PGx							daclatasvir	IFNL3		2023-08-15
PA166184380	Annotation of Swissmedic Label for brivaracetam and CYP2C19, CYP2C9	Swissmedic		Informative PGx							brivaracetam	CYP2C19; CYP2C9		
PA166272161	Annotation of EMA Label for venetoclax and FLT3, IDH1, IDH2, NPM1, TP53	EMA							Cancer Genome		venetoclax	FLT3; IDH1; IDH2; NPM1; TP53		2023-08-29
PA166272181	Annotation of EMA Label for upadacitinib and CYP2D6	EMA									upadacitinib	CYP2D6		2023-08-29
PA166272261	Annotation of HCSC Label for venetoclax and FLT3, IDH1, IDH2, NPM1, TP53	HCSC							Cancer Genome		venetoclax	FLT3; IDH1; IDH2; NPM1; TP53		2023-08-29
PA166272621	Annotation of EMA Label for tafamidis and TTR	EMA									tafamidis	TTR		2023-08-24
PA166272681	Annotation of EMA Label for tipiracil / trifluridine and ERBB2, KRAS	EMA							Cancer Genome		tipiracil / trifluridine	ERBB2; KRAS		2023-08-27
PA166272741	Annotation of EMA Label for ropeginterferon alfa-2b and JAK2	EMA							Cancer Genome		ropeginterferon alfa-2b	JAK2	rs77375493	2023-08-24
PA166283001	Annotation of EMA Label for elexacaftor / tezacaftor / ivacaftor and CFTR	EMA		Testing Required							elexacaftor / tezacaftor / ivacaftor	CFTR	rs113993960	2025-04-22
PA166283021	Annotation of HCSC Label for elexacaftor / tezacaftor / ivacaftor and CFTR	HCSC		Testing Required							elexacaftor / tezacaftor / ivacaftor	CFTR	rs113993960	2025-04-22
PA166278461	Annotation of EMA Label for crizanlizumab-tmca and HBB, SELP	EMA									crizanlizumab-tmca	HBB; SELP		2023-09-26
PA166278501	Annotation of EMA Label for duvelisib	EMA							Cancer Genome		duvelisib			2023-08-15
PA166282861	Annotation of HCSC Label for nusinersen and SMN2	HCSC									nusinersen	SMN2		2023-08-17
PA166283261	Annotation of HCSC Label for isatuximab	HCSC							Cancer Genome		isatuximab			2024-12-13
PA166277721	Annotation of HCSC Label for anifrolumab and IFNAR1	HCSC									anifrolumab	IFNAR1		2023-08-14
PA166284661	Annotation of HCSC Label for pembrolizumab and BRAF	HCSC							Cancer Genome		pembrolizumab	BRAF	rs113488022	2023-08-23
PA166284701	Annotation of HCSC Label for regorafenib and KRAS	HCSC							Cancer Genome		regorafenib	KRAS		2024-08-26
PA166272981	Annotation of EMA Label for abrocitinib and CYP2C19, CYP2C9	EMA		No Clinical PGx							abrocitinib	CYP2C19; CYP2C9		2023-08-11
PA166273001	Annotation of HCSC Label for abrocitinib and CYP2C19, CYP2C9	HCSC		No Clinical PGx							abrocitinib	CYP2C19; CYP2C9		2023-08-11
PA166273321	Annotation of EMA Label for niraparib and BRCA1, BRCA2	EMA		Informative PGx					Cancer Genome		niraparib	BRCA1; BRCA2		2023-09-08
PA166183424	Annotation of EMA Label for rucaparib and CYP1A2, CYP2D6	EMA		No Clinical PGx							rucaparib	CYP1A2; CYP2D6		2023-12-05
PA166127713	Annotation of HCSC Label for succinylcholine and BCHE, CACNA1S, RYR1	HCSC		Actionable PGx	Prescribing Info		Alternate Drug	Other Prescribing Guidance		Prescribing	succinylcholine	BCHE; CACNA1S; RYR1		2024-09-19
PA166283181	Annotation of HCSC Label for meloxicam and CYP2C9	HCSC									meloxicam	CYP2C9		2024-12-13
PA166281781	Annotation of HCSC Label for ospemifene and CYP2B6, CYP2C9	HCSC									ospemifene	CYP2B6; CYP2C9		2024-12-13
PA166284741	Annotation of HCSC Label for nivolumab and BRAF	HCSC							Cancer Genome		nivolumab	BRAF	rs113488022	2023-09-07
PA166273981	Annotation of HCSC Label for asciminib and ABL1, BCR	HCSC		Testing Required					Cancer Genome		asciminib	ABL1; BCR		2024-08-26
PA166362721	Annotation of EMA Label for busulfan	EMA									busulfan			
PA166362741	Annotation of HCSC Label for busulfan	HCSC									busulfan			
PA166151853	Annotation of FDA Label for nilotinib and UGT1A1	FDA	On FDA Biomarker List	Informative PGx							nilotinib	UGT1A1	rs8175347	2025-01-15
PA166104908	Annotation of EMA Label for cetuximab and EGFR, KRAS, NRAS	EMA		Testing Required					Cancer Genome		cetuximab	EGFR; KRAS; NRAS		2025-01-16
PA166329481	Annotation of EMA Label for fruquintinib and KRAS	EMA							Cancer Genome		fruquintinib	KRAS		
PA166329322	Annotation of FDA Label for repotrectinib and NTRK1, NTRK2, NTRK3, ROS1	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		repotrectinib	NTRK1; NTRK2; NTRK3; ROS1		2024-10-04
PA166329281	Annotation of EMA Label for repotrectinib	EMA									repotrectinib			2025-01-10
PA166329121	Annotation of EMA Label for eplontersen and TTR	EMA									eplontersen	TTR		2024-11-06
PA166329501	Annotation of HCSC Label for fruquintinib and KRAS	HCSC							Cancer Genome		fruquintinib	KRAS		2025-01-07
PA166328941	Annotation of EMA Label for capivasertib and AKT1, ERBB2, ESR1, ESR2, PIK3CD, PTEN	EMA		Testing Required					Cancer Genome		capivasertib	AKT1; ERBB2; ESR1; ESR2; PIK3CD; PTEN		2025-01-10
PA166328921	Annotation of FDA Label for capivasertib and AKT1, ERBB2, ESR1, ESR2, PIK3CA, PTEN	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		capivasertib	AKT1; ERBB2; ESR1; ESR2; PIK3CA; PTEN		
PA166328961	Annotation of HCSC Label for capivasertib and AKT1, ERBB2, ESR1, ESR2, PIK3CA, PTEN	HCSC		Testing Required					Cancer Genome		capivasertib	AKT1; ERBB2; ESR1; ESR2; PIK3CA; PTEN		
PA166329001	Annotation of EMA Label for eflornithine	EMA									eflornithine			
PA166329021	Annotation of HCSC Label for eflornithine	HCSC									eflornithine			
PA166329061	Annotation of EMA Label for elranatamab	EMA									elranatamab			
PA166329043	Annotation of HCSC Label for elranatamab	HCSC							Cancer Genome		elranatamab			
PA166329041	Annotation of FDA Label for elranatamab	FDA	On FDA Biomarker List						Cancer Genome		elranatamab			
PA166329101	Annotation of FDA Label for eplontersen and TTR	FDA	On FDA Biomarker List	Testing Required							eplontersen	TTR	rs28933979	
PA166329141	Annotation of HCSC Label for quizartinib	HCSC									quizartinib			
PA166329221	Annotation of FDA Label for quizartinib and FLT3	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		quizartinib	FLT3		
PA166329241	Annotation of EMA Label for quizartinib and FLT3	EMA		Testing Required					Cancer Genome		quizartinib	FLT3		
PA166329301	Annotation of HCSC Label for repotrectinib	HCSC									repotrectinib			
PA166329341	Annotation of FDA Label for pirtobrutinib and BTK, IGH, TP53	FDA	On FDA Biomarker List						Cancer Genome		pirtobrutinib	BTK; IGH; TP53		
PA166329122	Annotation of HCSC Label for eplontersen and TTR	HCSC									eplontersen	TTR		2024-07-05
PA166329441	Annotation of EMA Label for pirtobrutinib and BTK	EMA							Cancer Genome		pirtobrutinib	BTK		
PA166329525	Annotation of FDA Label for fruquintinib and KRAS	FDA	On FDA Biomarker List						Cancer Genome		fruquintinib	KRAS		
PA166328981	Annotation of FDA Label for eflornithine and MYCN	FDA	On FDA Biomarker List	No Clinical PGx					Cancer Genome		eflornithine	MYCN		
PA166127722	Annotation of HCSC Label for trametinib and BRAF	HCSC		Testing Required					Cancer Genome		trametinib	BRAF	rs113488022	2025-01-17
PA166329782	Annotation of EMA Label for zilucoplan and CHRNA1, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNB1, CHRNE	EMA									zilucoplan	CHRNA1; CHRNA3; CHRNA4; CHRNA5; CHRNA6; CHRNA7; CHRNB1; CHRNE		
PA166329781	Annotation of FDA Label for zilucoplan and CHRNA1, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNB1, CHRNE	FDA	On FDA Biomarker List								zilucoplan	CHRNA1; CHRNA3; CHRNA4; CHRNA5; CHRNA6; CHRNA7; CHRNB1; CHRNE		
PA166330081	Annotation of EMA Label for nirogacestat	EMA									nirogacestat			2025-01-10
PA166277981	Annotation of HCSC Label for belzutifan and VHL	HCSC									belzutifan	VHL		2025-01-21
PA166278001	Annotation of HCSC Label for belzutifan and CYP2C19, UGT2B17	HCSC		Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	belzutifan	CYP2C19; UGT2B17		2025-01-21
PA166330041	Annotation of EMA Label for nedosiran and AGXT	EMA									nedosiran	AGXT		
PA166330042	Annotation of HCSC Label for nedosiran and AGXT	HCSC									nedosiran	AGXT		
PA166330082	Annotation of HCSC Label for nirogacestat and APC, CTNNB1	HCSC									nirogacestat	APC; CTNNB1		
PA166330101	Annotation of FDA Label for nirogacestat and APC, CTNNB1	FDA	On FDA Biomarker List								nirogacestat	APC; CTNNB1		
PA166277701	Annotation of EMA Label for anifrolumab and IFNAR1	EMA									anifrolumab	IFNAR1		2023-08-14
PA166329261	Annotation of EMA Label for etrasimod and CYP2C9	EMA		Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	etrasimod	CYP2C9		2024-07-25
PA166329181	Annotation of HCSC Label for etrasimod and CYP2C9	HCSC		Informative PGx							etrasimod	CYP2C9		2024-08-28
PA166330061	Annotation of FDA Label for nedosiran and AGXT	FDA	On FDA Biomarker List								nedosiran	AGXT		2024-08-09
PA166277801	Annotation of HCSC Label for tebentafusp and HLA-A	HCSC		Testing Required							tebentafusp	HLA-A	HLA-A*02:01	2024-08-14
PA166269742	Annotation of EMA Label for odevixibat and ABCB11	EMA									odevixibat	ABCB11		2024-08-16
PA166329161	Annotation of FDA Label for etrasimod and CYP2C9	FDA	On FDA Biomarker List	Informative PGx							etrasimod	CYP2C9	CYP2C9*2; CYP2C9*3	2024-09-09
PA166278581	Annotation of HCSC Label for siponimod and CYP2C9	HCSC		Testing Required	Prescribing Info	Dosing Info	Alternate Drug			Prescribing	siponimod	CYP2C9	CYP2C9*1; CYP2C9*2; CYP2C9*3	2024-09-17
PA166284542	Annotation of HCSC Label for encorafenib and BRAF	HCSC		Testing Required					Cancer Genome		encorafenib	BRAF	rs113488022	2024-12-02
PA166286181	Annotation of HCSC Label for alectinib and ALK	HCSC		Testing Required					Cancer Genome		alectinib	ALK		2024-04-15
PA166230001	Annotation of EMA Label for avapritinib and PDGFRA	EMA		Testing Required					Cancer Genome		avapritinib	PDGFRA	rs121908585	2024-04-15
PA166278421	Annotation of EMA Label for cemiplimab-rwlc and ALK, CD274, EGFR, ROS1	EMA		Testing Required					Cancer Genome		cemiplimab-rwlc	ALK; CD274; EGFR; ROS1		2024-04-16
PA166334981	Annotation of EMA Label for fluorouracil	EMA									fluorouracil			
PA166183209	Annotation of EMA Label for migalastat and GLA	EMA		Testing Required							migalastat	GLA		2024-04-21
PA166183243	Annotation of EMA Label for olaparib and BRCA1, BRCA2, ERBB2	EMA		Testing Required					Cancer Genome		olaparib	BRCA1; BRCA2; ERBB2		2024-04-21
PA166335921	Annotation of HCSC Label for vincristine	HCSC									vincristine			
PA166335941	Annotation of EMA Label for vincristine	EMA									vincristine			
PA166336642	Annotation of HCSC Label for eliglustat and CYP2D6	HCSC		Testing Required	Prescribing Info	Dosing Info	Alternate Drug			Prescribing	eliglustat	CYP2D6		
PA166336761	Annotation of EMA Label for tafenoquine	EMA									tafenoquine			
PA166284282	Annotation of HCSC Label for gemtuzumab ozogamicin and CD33	HCSC		Testing Required					Cancer Genome		gemtuzumab ozogamicin	CD33		2024-09-10
PA166335081	Annotation of HCSC Label for lapatinib and HLA-DQA1, HLA-DRB1	HCSC		Informative PGx							lapatinib	HLA-DQA1; HLA-DRB1	HLA-DQA1*02:01; HLA-DRB1*07:01	
PA166122548	Annotation of EMA Label for velaglucerase alfa and GBA1	EMA									velaglucerase alfa	GBA1		2024-08-06
PA166273301	Annotation of EMA Label for nivolumab and ALK, CD274, EGFR, ERBB2	EMA		Testing Required					Cancer Genome		nivolumab	ALK; CD274; EGFR; ERBB2		2024-08-09
PA166127641	Annotation of HCSC Label for bosutinib and ABL1, BCR	HCSC		Testing Required					Cancer Genome		bosutinib	ABL1; BCR		2024-08-26
PA166282882	Annotation of HCSC Label for olaparib and BRCA1, BRCA2, ERBB2	HCSC		Testing Required					Cancer Genome		olaparib	BRCA1; BRCA2; ERBB2		2024-09-12
PA166284121	Annotation of HCSC Label for trastuzumab deruxtecan and ERBB2	HCSC		Testing Required					Cancer Genome		trastuzumab deruxtecan	ERBB2		2024-09-17
PA166336762	Annotation of HCSC Label for tafenoquine	HCSC									tafenoquine			
PA166336801	Annotation of EMA Label for allopurinol	EMA									allopurinol			
PA166339221	Annotation of EMA Label for erdafitinib and FGFR3	EMA		Testing Required					Cancer Genome		erdafitinib	FGFR3		2024-10-03
PA166337881	Annotation of HCSC Label for avapritinib and KIT, PDGFRA	HCSC							Cancer Genome		avapritinib	KIT; PDGFRA		2024-10-15
PA166339061	Annotation of HCSC Label for binimetinib and UGT1A1	HCSC		No Clinical PGx							binimetinib	UGT1A1		2024-12-02
PA166336781	Annotation of EMA Label for obinutuzumab and MS4A1	EMA							Cancer Genome		obinutuzumab	MS4A1		2024-12-12
PA166337902	Annotation of EMA Label for avelumab and CD274	EMA							Cancer Genome		avelumab	CD274		2025-01-09
PA166337801	Annotation of HCSC Label for efgartigimod alfa and CHRNA1, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNB1, CHRNE	HCSC									efgartigimod alfa	CHRNA1; CHRNA3; CHRNA4; CHRNA5; CHRNA6; CHRNA7; CHRNB1; CHRNE		
PA166337901	Annotation of HCSC Label for avelumab and CD274	HCSC							Cancer Genome		avelumab	CD274		2025-01-09
PA166339241	Annotation of HCSC Label for ibritumomab and MS4A1	HCSC							Cancer Genome		ibritumomab	MS4A1		2025-01-10
PA166337821	Annotation of HCSC Label for duvelisib	HCSC									duvelisib			
PA166337841	Annotation of HCSC Label for anakinra and NLRP3	HCSC									anakinra	NLRP3		
PA166337941	Annotation of EMA Label for amifampridine	EMA									amifampridine			
PA166339262	Annotation of HCSC Label for cobimetinib and BRAF	HCSC		Testing Required					Cancer Genome		cobimetinib	BRAF	rs113488022	2024-09-10
PA166339181	Annotation of HCSC Label for brigatinib and ALK	HCSC		Testing Required					Cancer Genome		brigatinib	ALK		
PA166339301	Annotation of HCSC Label for elacestrant	HCSC									elacestrant			
PA166339321	Annotation of EMA Label for elacestrant and ESR1	EMA		Testing Required					Cancer Genome		elacestrant	ESR1		
PA166339442	Annotation of EMA Label for gilteritinib and FLT3	EMA		Testing Required					Cancer Genome		gilteritinib	FLT3		
PA166339443	Annotation of HCSC Label for gilteritinib and FLT3	HCSC		Testing Required					Cancer Genome		gilteritinib	FLT3		
PA166339461	Annotation of HCSC Label for larotrectinib and NTRK1, NTRK2, NTRK3	HCSC		Testing Required					Cancer Genome		larotrectinib	NTRK1; NTRK2; NTRK3		
PA166339462	Annotation of EMA Label for larotrectinib and NTRK1, NTRK2, NTRK3	EMA		Testing Required					Cancer Genome		larotrectinib	NTRK1; NTRK2; NTRK3		
PA166339481	Annotation of HCSC Label for lorlatinib and ALK	HCSC		Testing Required					Cancer Genome		lorlatinib	ALK		
PA166337861	Annotation of EMA Label for anakinra and NLRP3	EMA									anakinra	NLRP3		
PA166337961	Annotation of FDA Label for atazanavir and CYP2C19	FDA		Informative PGx							atazanavir	CYP2C19		
PA166339041	Annotation of HCSC Label for binimetinib and BRAF	HCSC		Testing Required					Cancer Genome		binimetinib	BRAF	rs113488022	2024-09-10
PA166284642	Annotation of HCSC Label for pembrolizumab and ALK, CD274, EGFR, ERBB2	HCSC		Testing Required					Cancer Genome		pembrolizumab	ALK; CD274; EGFR; ERBB2		2024-04-21
PA166340121	Annotation of EMA Label for amphetamine	EMA									amphetamine			
PA166341882	Annotation of EMA Label for dostarlimab	EMA		Testing Required					Cancer Genome		dostarlimab			
PA166336561	Annotation of EMA Label for teclistamab	EMA									teclistamab			
PA166336562	Annotation of HCSC Label for teclistamab	HCSC									teclistamab			
PA166341881	Annotation of HCSC Label for dostarlimab	HCSC		Testing Required					Cancer Genome		dostarlimab			
PA166340161	Annotation of FDA Label for axitinib and CYP2C19, UGT1A1	FDA		No Clinical PGx							axitinib	CYP2C19; UGT1A1		
PA166340181	Annotation of HCSC Label for axitinib and CYP2C19, UGT1A1	HCSC		No Clinical PGx							axitinib	CYP2C19; UGT1A1		
PA166344801	Annotation of FDA Label for dapsone and G6PD	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	dapsone	G6PD		2024-11-26
PA166343901	Annotation of HCSC Label for avatrombopag and CYP2C9, F2, F5, PROC, PROS1, SERPINC1	HCSC		Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	avatrombopag	CYP2C9; F2; F5; PROC; PROS1; SERPINC1	CYP2C9*2; CYP2C9*3; rs1799963; rs6025	2024-07-17
PA166344821	Annotation of HCSC Label for dapsone and CYB5R3	HCSC		Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	dapsone	CYB5R3		
PA166344841	Annotation of HCSC Label for dolutegravir and UGT1A1	HCSC		Informative PGx							dolutegravir	UGT1A1		
PA166344641	Annotation of HCSC Label for azathioprine and NUDT15	HCSC		Testing Required	Prescribing Info	Dosing Info				Prescribing	azathioprine	NUDT15	rs116855232	
PA166278381	Annotation of EMA Label for bupivacaine and CYB5R3, G6PD	EMA		Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	bupivacaine	CYB5R3; G6PD		2024-07-18
PA166344721	Annotation of HCSC Label for bupivacaine	HCSC									bupivacaine			
PA166345022	Annotation of FDA Label for flibanserin and CYP2C19	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	flibanserin	CYP2C19		
PA166345321	Annotation of HCSC Label for glyburide and CYP2C9	HCSC		Actionable PGx	Prescribing Info	Dosing Info				Prescribing	glyburide	CYP2C9	CYP2C9*2; CYP2C9*3	
PA166345341	Annotation of HCSC Label for glimepiride and CYP2C9	HCSC		Actionable PGx	Prescribing Info	Dosing Info				Prescribing	glimepiride	CYP2C9	CYP2C9*2; CYP2C9*3	
PA166122947	Annotation of EMA Label for ranolazine and CYP2D6	EMA		Actionable PGx	Prescribing Info	Dosing Info	Alternate Drug	Other Prescribing Guidance		Prescribing	ranolazine	CYP2D6		2024-07-22
PA166345301	Annotation of HCSC Label for rosuvastatin and ABCG2, SLCO1B1	HCSC		Actionable PGx	Prescribing Info	Dosing Info				Prescribing	rosuvastatin	ABCG2; SLCO1B1	rs2231142; rs4149056	
PA166344521	Annotation of HCSC Label for tramadol and CYP2D6	HCSC		Informative PGx							tramadol	CYP2D6		
PA166273581	Annotation of EMA Label for inclisiran and APOB, LDLR, PCSK9	EMA									inclisiran	APOB; LDLR; PCSK9		2024-07-23
PA166345781	Annotation of HCSC Label for metoclopramide and CYP2D6	HCSC		Actionable PGx	Prescribing Info	Dosing Info				Prescribing	metoclopramide	CYP2D6		
PA166345921	Annotation of HCSC Label for primaquine and G6PD	HCSC		Testing Required	Prescribing Info	Dosing Info	Alternate Drug	Other Prescribing Guidance		Prescribing	primaquine	G6PD		
PA166346941	Annotation of HCSC Label for dabrafenib and HRAS, KRAS, NRAS	HCSC		Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	dabrafenib	HRAS; KRAS; NRAS		2025-01-17
PA166346641	Annotation of EMA Label for letrozole	EMA									letrozole			
PA166346802	Annotation of HCSC Label for azacitidine	HCSC									azacitidine			
PA166346841	Annotation of HCSC Label for cerliponase alfa and TPP1	HCSC									cerliponase alfa	TPP1		
PA166338381	Annotation of EMA Label for dabrafenib and HRAS, KRAS, NRAS	EMA		Actionable PGx	Prescribing Info			Other Prescribing Guidance	Cancer Genome	Prescribing	dabrafenib	HRAS; KRAS; NRAS		
PA166346981	Annotation of EMA Label for denileukin diftitox	EMA									denileukin diftitox			
PA166347001	Annotation of HCSC Label for denileukin diftitox	HCSC									denileukin diftitox			
PA166347081	Annotation of HCSC Label for elosulfase alfa and GALNS	HCSC									elosulfase alfa	GALNS		
PA166347101	Annotation of EMA Label for eteplirsen	EMA									eteplirsen			
PA166347121	Annotation of HCSC Label for eteplirsen	HCSC									eteplirsen			
PA166347141	Annotation of FDA Label for abemaciclib and MKI67	FDA	On FDA Biomarker List						Cancer Genome		abemaciclib	MKI67		
PA166347181	Annotation of FDA Label for tremelimumab and CD274	FDA	On FDA Biomarker List						Cancer Genome		tremelimumab	CD274		
PA166283881	Annotation of HCSC Label for glycerol phenylbutyrate and ARG1, ASL, ASS1, CPS1, OTC	HCSC		Testing Required							glycerol phenylbutyrate	ARG1; ASL; ASS1; CPS1; OTC		2024-08-07
PA166272221	Annotation of HCSC Label for tucatinib and ERBB2	HCSC							Cancer Genome		tucatinib	ERBB2		2024-08-16
PA166272201	Annotation of EMA Label for tucatinib and ERBB2	EMA							Cancer Genome		tucatinib	ERBB2		2024-08-16
PA166345821	Annotation of HCSC Label for metoclopramide and CYB5R1, CYB5R2, CYB5R3, CYB5R4, G6PD	HCSC		Informative PGx							metoclopramide	CYB5R1; CYB5R2; CYB5R3; CYB5R4; G6PD		
PA166347161	Annotation of FDA Label for anakinra and NLRP3	FDA	On FDA Biomarker List								anakinra	NLRP3		2024-08-26
PA166345861	Annotation of HCSC Label for mirabegron and CYP2D6	HCSC		No Clinical PGx							mirabegron	CYP2D6		
PA166347361	Annotation of HCSC Label for gefitinib and CYP2D6	HCSC		Informative PGx							gefitinib	CYP2D6		
PA166273441	Annotation of EMA Label for lumasiran and AGXT	EMA									lumasiran	AGXT		2024-08-08
PA166278481	Annotation of HCSC Label for lutetium (177Lu) dotatate and SSTR1, SSTR2, SSTR3, SSTR4, SSTR5	HCSC		Testing Required					Cancer Genome		lutetium (177Lu) dotatate	SSTR1; SSTR2; SSTR3; SSTR4; SSTR5		2024-08-08
PA166273381	Annotation of EMA Label for metreleptin and AGPAT2, BSCL2, LEP, LMNB2	EMA		Testing Required							metreleptin	AGPAT2; BSCL2; LEP; LMNB2		2024-08-09
PA166347601	Annotation of HCSC Label for midostaurin and FLT3	HCSC		Testing Required					Cancer Genome		midostaurin	FLT3		
PA166347622	Annotation of HCSC Label for migalastat and GLA	HCSC		Testing Required							migalastat	GLA		
PA166347641	Annotation of HCSC Label for neratinib and ERBB2	HCSC		Testing Required					Cancer Genome		neratinib	ERBB2		
PA166347741	Annotation of HCSC Label for osimertinib and EGFR	HCSC		Testing Required					Cancer Genome		osimertinib	EGFR	rs121434568; rs121434569	
PA166347901	Annotation of FDA Label for panitumumab and EGFR	FDA	On FDA Biomarker List								panitumumab	EGFR		
PA166273121	Annotation of EMA Label for pralsetinib and RET	EMA		Testing Required					Cancer Genome		pralsetinib	RET		2024-08-13
PA166278701	Annotation of HCSC Label for risdiplam and SMN1, SMN2	HCSC		Testing Required							risdiplam	SMN1; SMN2		2024-08-13
PA166347941	Annotation of HCSC Label for toremifene	HCSC									toremifene			
PA166273241	Annotation of EMA Label for paliperidone and CYP2D6	EMA		No Clinical PGx							paliperidone	CYP2D6		
PA166122966	Annotation of EMA Label for darifenacin and CYP2D6	EMA		Informative PGx							darifenacin	CYP2D6		2014-08-07
PA166121326	Annotation of EMA Label for pazopanib and HLA-B	EMA		Informative PGx							pazopanib	HLA-B	HLA-B*57:01	2014-06-05
PA166347921	Annotation of HCSC Label for tamoxifen and CYP2D6	HCSC		Informative PGx							tamoxifen	CYP2D6		
PA166347961	Annotation of FDA Label for sulfasalazine and NAT2	FDA	On FDA Biomarker List	Informative PGx							sulfasalazine	NAT2		
PA166347981	Annotation of HCSC Label for sulfasalazine and NAT2	HCSC		Informative PGx							sulfasalazine	NAT2		
PA166350541	Annotation of HCSC Label for triheptanoin and ACADVL, CPT2, HADHA, HADHB	HCSC									triheptanoin	ACADVL; CPT2; HADHA; HADHB		
PA166350561	Annotation of EMA Label for triheptanoin	EMA									triheptanoin			
PA166350521	Annotation of FDA Label for triheptanoin and ACADVL, CPT2, HADHA, HADHB	FDA	On FDA Biomarker List	Testing Required							triheptanoin	ACADVL; CPT2; HADHA; HADHB		
PA166350601	Annotation of HCSC Label for patisiran and TTR	HCSC		Testing Required							patisiran	TTR		
PA166350581	Annotation of FDA Label for patisiran and TTR	FDA	On FDA Biomarker List	Testing Required							patisiran	TTR		
PA166350641	Annotation of FDA Label for neomycin and MT-RNR1	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	neomycin	MT-RNR1	rs267606617	
PA166350682	Annotation of FDA Label for amivantamab and EGFR	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		amivantamab	EGFR		
PA166350661	Annotation of HCSC Label for amivantamab and EGFR	HCSC		Testing Required					Cancer Genome		amivantamab	EGFR		
PA166350681	Annotation of EMA Label for amivantamab and EGFR	EMA		Testing Required					Cancer Genome		amivantamab	EGFR		
PA166350721	Annotation of FDA Label for aducanumab and APOE	FDA	On FDA Biomarker List	Testing Required							aducanumab	APOE	rs429358; rs7412	
PA166350741	Annotation of HCSC Label for aducanumab	HCSC									aducanumab			
PA166350722	Annotation of EMA Label for aducanumab	EMA									aducanumab			
PA166350602	Annotation of EMA Label for patisiran and TTR	EMA		Testing Required							patisiran	TTR		
PA166351741	Annotation of FDA Label for phenytoin and CYP2C19	FDA	On FDA Biomarker List	Informative PGx							phenytoin	CYP2C19		2024-09-18
PA166114482	Annotation of EMA Label for vemurafenib and BRAF	EMA		Testing Required					Cancer Genome		vemurafenib	BRAF	rs113488022	2025-01-21
